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The calcium-activated chloride channel regulator (CLCA) proteins are key signaling 
molecules, which are implicated in various diseases through their tissue-specific expression. 
Human CLCA1 protein, overexpressed in airway epithelia under pathophysiological conditions, 
is centrally involved in the manifestation of IL-13-driven mucus cell metaplasia (MCM), a 
hallmark feature of asthma and chronic obstructive pulmonary disease (COPD), for which there 
are currently no available therapeutics. Elucidating the poorly understood molecular basis of 
CLCA1 function is thus required to design specific inhibitors of CLCA1 activity to treat MCM 
in asthma and COPD.   
Originally misannotated as ion channels, CLCA proteins are secreted soluble proteins 
that act as regulators of unknown calcium-activated chloride channels (CaCC) in the airways. 
Additionally, these proteins undergo proteolytic cleavage, adding yet another level of complexity 
to the mystery of how a secreted protein can regulate chloride currents.   
! 
 
x 
This study focuses on the proteolytic cleavage of CLCA1 and provides mechanistic detail 
into how secreted CLCA1 protein modulates currents from a CaCC in mammalian cells, which is 
identified as TMEM16A. For this unique interaction to occur, secreted full-length CLCA1 
undergoes a self-cleavage reaction using an N-terminal zincin metalloprotease with a novel fold, 
which releases the functionally active N-terminal fragment. This cleavage exposes the von 
Willebrand factor type A (vWA) domain to directly interact with membrane-associated 
TMEM16A at the C-terminal extracellular loop (loop 9-10). The direct interaction increases 
TMEM16A surface density by stabilizing the channel on the cell surface and blocking its rapid 
recycling, thus resulting in increased chloride currents. 
! 
 
1 
 
 
 
 
 
 
 
CHAPTER 1: CLCA in Airway Disease 
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1. CLCA in Airway Disease 
 
1.1 Mucus cell metaplasia in airway disease 
 
Asthma and chronic obstructive pulmonary disease (COPD) are leading causes of death, 
with millions of people afflicted worldwide each year (1, 2). These deadly pulmonary diseases 
are characterized by inflammation, airway hyperreactivity (AHR) and mucus cell metaplasia 
(MCM) (3-6). Currently available treatments for these diseases fall under two categories: beta-2 
adrenergic receptor (β2AR) agonists, used as bronchodilators, to treat AHR and corticosteroids 
to induce an anti-inflammatory response (7, 8). However, 30-40% of asthmatics do not respond 
to steroids (9, 10), the “gold-standard asthma treatment”, due to heterogeneity of disease on a 
molecular level (11). For this particular reason, identification of new drug targets in the airways 
has become crucial.  
 
Under physiological conditions, the airway epithelium maintains an absorptive phenotype 
and contains various cell types, including ciliated cells, secretory club cells (previously known as 
Clara cells) and a small amount of secretory goblet cells (12, 13). Under inflammatory 
conditions, IL-13 and similar cytokines can convert the epithelium to a secretory phenotype (4, 
12). This process, when unregulated, can lead to abnormal airway remodeling, which is observed 
in hypersecretory diseases such as cystic fibrosis (CF), chronic bronchitis and asthma (14-16). 
The hypersecretion is maintained mostly by the increased abundance of goblet cells in the 
surface airway epithelium (16), which is mainly a result of the IL-13-driven cell 
transdifferentiation process and not of goblet cell division (17, 18) (Figure 1a).  
! 
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Figure 1. Scheme of IL-13 stimulated MCM in the lung. A. IL-13 signaling results in transdifferentiation 
of lung epithelial cells into goblet cells. The significant increase in goblet cell count results in mucus 
overproduction and subsequent hypersecretion into the small airways, which leads to a thick mucus layer. 
B. IL-13 binding to receptor activates STAT6 signaling and induces CLCA1 overexpression. After 
getting secreted and cleaved, CLCA1 acts on a target channel, CaCC, and also signals for the activation of 
MAPK13 pathway, which induces MUC5AC expression and drives mucus production. Circle encloses 
the pathways focused on in this thesis. Figure modified from Sala-Rabanal et al.(19). 
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Recognition of IL-13 by its receptor (IL-13Rα1+IL-4Rα) (7) activates signaling 
pathways, resulting in phosphorylation of signal transducer and activator of transcription-6 
(STAT6) (20). The phosphorylation event is followed by STAT6 translocation to the nucleus, 
where it regulates expression of an array of genes by directly binding specific promoters.  IL-13-
induced STAT6 signaling was shown to be essential for the reprogramming of basal airway cells, 
resulting in MCM and AHR (21, 22)(Figure 1b).  
 
Normal mucus in the airways is made up largely of water, with a small percentage of 
solids (23). The major solid component of mucus is mucins, which are large glycoproteins with 
water-absorbing properties (24).  While there are at least eleven mucin genes that are expressed 
in the lung, MUC5AC and MUC5B are the predominant mucins in airway secretion (25). 
MUC5B is largely secreted from the submucosal glands and MUC5AC is found secreted from 
goblet cells that line the epithelial surface (5, 17).  The latter is considered the main mucin 
overproduced in hypersecretory diseases, as it is the only one inducible by IL-13 (18, 23). 
Hypersecretion of MUC5AC increases the viscosity of the mucus significantly, because the 
mucin monomers polymerize and occlude water molecules through their glycan chains (23). 
Although this mucus can be cleared under normal conditions by the motion of ciliated cells, IL-
13 signaling also reduces the number of ciliated cells and the ciliary beat frequency (CBF) of 
remaining cells (18, 26). Thus, MCM is characterized by the abundance of viscous, dehydrated 
mucus and impaired mucociliary clearance. 
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1.2 CLCA in mucus cell metaplasia 
The first members of what we now call the CLCA family were initially characterized as 
lung endothelial cell adhesion molecules (27, 28) or ECAMs. A few years later, a new name was 
given to the family: “CLCA”, which stood for ChLoride channel Calcium-Activated, based on 
the predicted multiple transmembrane domains and the observed increase in calcium-activated 
chloride currents, ICaCC, as a result of heterologous expression of various family members, such 
as hCLCA1, hCLCA2 and mCLCA4 (29-32).  
 
hCLCA1 was described as the main family member expressed in the intestine under 
normal conditions and could not be detected in other human tissues (30). However, stimulation 
of primary epithelial cells with IL-4, IL-9 and IL-13 induced overexpression of this gene (18, 33, 
34).  Similarly, human tracheal epithelial cells (hTECs) treated with IL-13 significantly 
overexpressed CLCA1, whereas other family members were not induced by IL-13 (35). These 
hTECs present a good system to reconstitute “MCM in a dish”, since they produce MUC5AC in 
response to the IL-13-stimulated STAT6 signaling cascade (Figure 1b). In this system, CLCA1 
mRNA levels correlated directly with MUC5AC levels and shRNA knockdown of CLCA1 
suppressed mucin induction, suggesting CLCA1 signaling lies upstream of and is required for 
MUC5AC expression (35). 
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The homologue of hCLCA1 in mice, mCLCA3, has been the focus of researchers in 
developing a mouse model of asthma. Researchers were able to induce MCM in mice by 
intratrachaeal instillation of IL-13 (33, 36). The direct introduction of IL-13 resulted in the same 
disease attributes as in immunocompromised mice following ovalbumin challenge (37, 38) or 
viral infection in the airways (39). Following all three treatments, mCLCA3 levels were elevated 
in the bronchoalveolar lavage fluid (BALF) (37, 40). Similar to hCLCA1, no mCLCA3 
expression could be detected in the lungs of naïve mice prior to induction with IL-4/IL-9/IL-13.  
This overexpression was also somewhat selective, since mCLCA1 was not induced under the 
same conditions (33).  
 
Gene transfer of mCLCA3 alone was sufficient to induce MCM in mice (39), further 
strengthening the role of CLCAs in driving mucus overproduction in the lung. Based on the 
homology to hCLCA1, mCLCA3-/- was the first knockout mouse generated to study IL-13-
stimulated MCM. Surprisingly, these knockout mice were also susceptible to MCM; disease 
progression and severity in these mice were comparable to wild-type (WT) mice. Further 
experiments showed an IL-13-dependent increase in mCLCA3, mCLCA5 and mCLCA7 (35), 
which had not been investigated by Zhou et al. (33) The mCLCA3-/- mice also had increased 
mCLCA5 levels after IL-13 stimulation (39). These observations suggested a functional 
redundancy between mouse CLCA proteins, where lack of a family member was compensated 
for by the activity of other family members, ultimately preventing a distinct lung disease 
phenotype with a single knockout mouse model.  
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Similar to mCLCA3, hCLCA1 was abundantly found in the BALF from asthmatic 
patients, whereas non-asthmatic samples were negative for CLCA1 (37). It is only expressed in 
the airways under pathophysiological conditions (41) and it is one the most highly induced genes 
in asthmatics (11), demonstrating the potential utility of CLCA1 as a biomarker of chronic 
airway diseases (42) and a viable drug target to treat MCM.  
 
1.3 CLCA in Cystic Fibrosis 
Mucociliary clearance in the airways is not dictated just by the mucin concentration, but 
also by hydration (18, 43). Since osmosis follows the salt gradient (mainly NaCl in this case), 
active ion transport becomes an important mechanism for airway surface liquid (ASL) 
maintenance. In lung epithelia, cystic fibrosis transmembrane regulator (CFTR) maintains ASL 
by secreting chloride/bicarbonate ions (44-47) and regulating sodium absorption through 
inhibition of epithelial sodium channel (ENaC) (48-50).  
 
Cystic fibrosis (CF) is a hypersecretory disease characterized by MCM and decreased 
mucus clearance in the airways, both of which lead to inflammation and bacterial colonization 
(51, 52), similar to asthma and COPD. The driving force behind CF is inherited mutations in the 
CFTR gene, which result in decreased/diminished CFTR activity. As a result of the subsequent 
reduction in chloride secretion and the rapid increase in sodium absorption, ASL volume is 
significantly reduced (23, 49, 50). 
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CFTR currents are regulated by cyclic AMP (cAMP) and cannot be blocked by DIDS 
(4,4’-diisothiocyano-2,2’-stilbenedisulfonic acid) (53). In the airways, a second type of chloride 
current was observed, which was sensitive to (local) calcium concentration, but insensitive to 
cAMP. Furthermore, these currents could be blocked by DIDS. Since the molecular identity was 
unknown at the time, the channel was named calcium-activated chloride channel (CaCC) (54). 
These types of currents were found upregulated in CFTR-/- mice, suggesting CaCC currents 
could be protective under CF conditions (48, 49, 54). 
 
CLCAs were a good candidate for the unidentified CaCC, as their heterologous 
expression in HEK293 cells resulted in increased CaCC currents, similar to the ones observed in 
the airways. These currents had the kinetic properties of native CaCC activity and were blocked 
by non-specific chloride channel blockers, such as DIDS and niflumic acid (NFA) (29-32, 55). 
However, as will be discussed later, CLCAs are soluble, secreted proteins that can act as ion 
channel regulators, as opposed to being bonafide ion channels.  
 
Although they are not channels themselves, CLCAs are still implicated in CF. While both 
CLCA proteins and CFTR have similar tissue expression patterns under normal conditions (29), 
CLCA proteins are found downregulated in CF (56). Aside from downregulation, there are also 
CLCA single nucleotide polymorphisms (SNPs) associated with worse CF disease in clinical 
investigations (55, 57, 58).  Thus, if diminished CLCA activity accompanies worse CF 
symptoms, CLCAs might carry out a function beneficial under specific pathophysiological 
conditions. Indeed, heterologous expression of CLCAs has been shown to rescue chloride 
currents in CF patients (59) and ameliorate CF symptoms (57, 60). These results suggest that 
! 
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CLCA can modulate chloride/bicarbonate currents in CF airways and help restore the ion 
gradient. The amelioration of CF symptoms is likely due to compensation of decreased/abolished 
CFTR activity, which is a result of the interaction between CLCA and its target CaCC, expressed 
alongside CFTR in the small airways (Figure 2). 
 
 
 
!
!
Figure 2. Ion channels in the small airways. IL4/13 signaling induces a (hyper)secretory phenotype, 
which activates CFTR and CaCC activity. CFTR can, in turn, block ENaC activity. Ion concentrations 
due to channel activity dictate airway surface liquid (ASL) volume. CLCA1 as a secreted protein is found 
in the extracellular medium under pathophysiological conditions and interacts with CaCC. Figure 
modified from Sala-Rabanal et al. (19). 
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2.  Structural Organization of CLCA1 
 
2.1 Misannotation 
 
The first insight into the structural organization/topology was made by hydropathy 
analysis of the primary sequence of CLCA proteins. The analysis was based on the Kyte-
Doolittle scale, which calculates the hydropathy of a group of residues (n=19) to predict whether 
the segment is membrane-spanning (hydropathy score > 1.6) (1). Data analysis of CLCA family 
members predicted multiple transmembrane domains. (2-5).  
 
While most CLCAs are actually soluble proteins with no integral membrane domains (6-
9), a few select members of the family are predicted to have different structural features, such as 
a single transmembrane domain in the C-terminus (like hCLCA2) or a glycophosphatidylinositol 
(GPI) anchor (hCLCA4) as predicted by PredGPI (10). Although both hCLCA2 and hCLCA4 
undergo self-cleavage (8), the C-terminal cleavage fragment might remain anchored to cells. The 
fate of the N-terminal cleavage fragment is uncertain. Recent experiments conducted in our lab 
suggest the N-terminal fragment of hCLCA4 remains associated with the cell membrane; while it 
was not freely detectable in the supernatant by Western blot, this cleavage fragment could be 
recovered in the supernatant of HEK293T cells following phospholipase C treatment, which 
releases GPI-anchored proteins from cell surface (11), such as the C-terminal fragment of 
hCLCA4.   
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Figure 3. Domain organization of the human CLCA proteins. CAT, catalytic domain, Cys, Cys-rich 
domain, vWA, von Willebrand domain type A, FnIII, fibronectin type III, TM, transmembrane domain, 
GPI, glycophosphatidylinositol anchor.  Scissors denote experimentally determined cleavage site.  Figure 
modified from Sala-Rabanal et al. (12). 
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2.2 Structure predictions 
2.2.1 Signal peptide 
The full-length human CLCA1 is a 120 kDa protein comprised of 914 residues (Figure 
3). The first 21 residues constitute a signal peptide, as identified by Phobius 
(http://phobius.sbc.su.se/) (13) and Signalp4 (http://www.cbs.dtu.dk/services/SignalP/) (14). 
Signal peptides allow proteins to enter the endoplasmic reticulum (ER) for post-translational 
modifications (15, 16), which can regulate protein localization, structure and function. 
2.2.2 N-linked glycosylations 
N-linked glycosylation is an important component of quaternary protein structure, as 
these glycans can grossly affect protein function and interaction partners (17).  Potential N-
linked glycosylation sites in a given protein sequence can be predicted using NetNGlyc 1.0 
server (http://www.cbs.dtu.dk/services/NetNGlyc/) (18), whose algorithm analyzes the sequence 
for N-X-S/T motifs (where X can be any residue except Proline) (19). For CLCA1, the server 
predicts a total of 9 N-linked glycosylation sites (Figure 4), however the first motif (around 
residue 270) is likely not glycosylated, due to the Proline residue in the second position, which 
creates conformational restraints that prevents glycosylation. Thus, there are 2 sites within the N-
terminal fragment and 6 within the C-terminal fragment. 
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Figure 4. N-linked glycosylation predictions for full-length WT CLCA1. The signal sequence was 
omitted for the analysis by NetNGlyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc/). Green 
vertical lines indicate predicted N-linked glycosylation sites. Red horizontal line indicates confidence 
threshold for the prediction. Blue vertical line indicates cleavage site.  
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2.2.3 Distinct domains 
Phyre2 is a protein structure prediction server (20), which can be used to analyze a new 
protein sequence for potential homology to known domains. For full-length CLCA1, the server 
identified three domains as homologues of previously determined structures. A 180-residue 
stretch in the middle was modeled as a von Willebrand factor type A domain (vWA), which is 
involved in mediating protein-protein interactions, especially in the extracellular matrix (ECM), 
where they play a role in cell adhesion (21). A 130-residue stretch at the C-terminus was 
identified as a fibronectin type III domain (FnIII), which mediates fibronectin-integrin 
interactions in the ECM (22). It is interesting to note that the vWA domain, homologous to the 
inserted (I) domain of integrins (23), could potentially interact with the FnIII domain. However, 
the CLCA vWA domain does not have the RGD peptide, which is the main recognition motif for 
fibronectin binding (22, 24).  The third fold detected within CLCA1 was in the N-terminal 
region, which was predicted to assume a zincin metalloprotease-like fold (Figure 5). Although 
percent identity within the query (CLCA1) and template sequence in the region was low (<15%), 
the confidence of prediction was moderate to high (65-90%), as the HEXXH motif was 
identified in the CLCA1 N-terminal sequence, which is the zinc-binding region of 
metalloproteases (25). There were no predicted folds for the region spanning between the vWA 
and the FnIII domains, its secondary structure is predicted to mainly consist of beta sheets. 
Hence we coined the term beta-sheet-rich (BSR) for this region. 
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Figure 5. Domain organization of hCLCA1. CAT, catalytic domain, vWA, von Willebrand domain type 
A, BSR, beta sheet-rich domain, FnIII, fibronectin type III. The purple box preceding the CAT domain 
indicates secretion signal. The pink star denotes the zincin metalloprotease active site. Dashed vertical 
line at 695 denotes experimentally determined cleavage site.  
 
2.2.4 Novel CLCA1 metalloprotease is unlike MMPs 
 
In order to determine how much CLCA1 enzyme resembled MMPs, we carried out 
sequence analysis, looking for certain features and conducted biochemical experiments, where 
applicable, to test the existence of said features. Based on the sequence analysis of the CLCA 
family, there is no conserved Met residue at the C-terminal end of the predicted catalytic site of 
the metalloprotease, which means this family of proteins lack the Met turn, a characteristic of 
metzincins (26). 
The prodomain is also a characteristic of metalloproteases, as it is involved in the first 
step of regulating enzymatic activity. This is usually an 80-residue stretch in the N-terminus of 
the protein, which blocks the active site (27, 28) and has to be cleaved for the enzyme to be 
active. Phyre2 predicts the catalytic fold of CLCA1 would begin around residue 50. Almost half 
of the first 50 residues corresponds to the signal peptide, which would make the putative 
prodomain of CLCA1 only about 25 amino acids long. Although that would be a significantly 
shorter prodomain, which is unlikely, we wanted to experimentally determine whether it was 
intact following secretion and cleavage.  
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2.2.4.1.Experimental design 
To analyze the potential prodomain, we inserted a FLAG-tag directly after the signal 
sequence and expressed the full-length WT protein in HEK293T cells via transient transfection 
(Figure 6). Proteins were detected in the supernatant by Western blotting with an anti-FLAG 
antibody, an anti-NCLCA1 antibody (8D3) and an anti-His6 antibody.  
2.2.4.2. Results 
The antibodies detected a total of three species, the full-length uncleaved protein around 
120 kDa and the two cleavage fragments, N-terminal and C-terminal at 70 and 50 kDa, 
respectively.  If the prodomain had been cleaved, the anti-FLAG antibody would not have 
recognized the N-terminal cleavage fragment and there would have been a protein band at very 
low molecular weight corresponding to the FLAG-tagged prodomain (8) (Figure 6). These 
results indicate that there is no prodomain preceding the catalytic fold of CLCA1.  
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Figure 6. CLCA1 metalloprotease does not have a prodomain. A, Full-length CLCA1 with an N-terminal 
FLAG tag and a C-terminal 6His tag. Epitope of the 8D3 antibody is between residues 500-695, after the 
vWA domain, as shown. B, Western blot against FLAG tag and N-terminal CLCA1 (8D3). C, Western 
blot against the C-terminal 6His-tag. Figure modified from Yurtsever et al. (8). 
 
2.3 Crystallization Trials 
2.3.1 Rationale 
 The lack of known metalloprotease regulatory elements, such as the Met turn and the 
prodomain, in CLCA structure suggests that the CLCA enzyme likely has a novel fold and that 
enzymatic activity is regulated by previously undefined structural features. Determination of 
such potential features requires structural information, especially on an atomic resolution, which 
can be obtained by protein X-ray crystallography. 
 
A 
B C 
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2.3.2 Experimental design 
2.3.2.1 Cloning 
 
hCLCA1 constructs were cloned into pHLsec backbone (29) using AgeI- KpnI restriction 
site cloning. There is a C-terminal 6-His tag in the backbone, which allows for detection of 
protein expression via Western blotting and purification from the cell supernatant.  
 
Mutations in hCLCA1 vWA domain (297-478) were introduced using Quikchange 
Lightning Mutagenesis Kit (#210513 Agilent Genomics) according to manufacturer’s 
instructions. Primers were designed using neb website (http://nebasechanger.neb.com/) and 
ordered through IDTDNA (https://www.idtdna.com/site/order/oligoentry) (standard desalting). 
Amplification products were digested with Dpn I provided with the kit and then transformed 
onto XL10 Gold ultra-competent cells. After incubation of the cell culture in SOC media shaking 
for 1 hour at 37°C, the cells were plated onto an agar plate with carbenicillin (100 ug/ml) 
selection. The plate was incubated overnight at 37°C, then single colonies were cultured in 4 ml 
LB media supplemented with carbenicillin. The cells were pelleted using centrifugation at 2000 
rpm and the DNA template was prepared using QIAprep Spin Miniprep kit (#27104 QIAGEN) 
according to manufacturer’s instructions. Briefly, cell pellets were lysed, the plasmid DNA was 
isolated and precipitated with ethanol, then eluted in 30 µl of elution buffer (10 mM tris-Cl pH 
8.5) (Qiagen). The presence of target plasmid DNA was verified by analytical PCR reaction (10 
µl 2x Phusion High Fidelity PCR Master Mix (m0531s NEB), 7 µl H2O, 1 µl mini-prep + (x2) 1 
µl 10 µM primer). DNA bands were visualized on FlashGel DNA system (Lonza). The mutations 
were verified by sequencing (10 µl H2O, 4 µl 5x sequencing buffer (400 mM tris-HCl pH 9.0, 10 
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mM MgCl2), 4 µl Big Dye3.1 (Applied Biosystems), 1 µl mini-prep, 1 µl 10 µM sequencing 
primer). Sequencing was done by PNACL at WUSM and sequences were analyzed by 
MacVector (Apex, NC). 
 
The mutations K398A and K398A+K399A were introduced into the full-length WT 
CLCA1 protein in pHLsec vector. To clone the vWA domain separately, primers were made 
with 5’ AgeI and 3’ KpnI restriction sites starting at residues 297 and 478, respectively. vWA 
construct was amplified with these primers from the full-length CLCA1 template. The insert was 
PCR purified with QIAquick PCR Purification Kit (28104, Qiagen) according to manufacturer’s 
instructions and eluted in 30 µl EB. The insert and uncut pHLsec vector were double digested 
using AgeI-HF (R3552S, NEB) and KpnI-HF (R3142S, NEB) in 1x CutSmart Buffer (B7204S, 
NEB) at 37°C for 1 hour. 1 µl of alkaline phosphatase (M0290S, NEB) was added into the vector 
digestion reaction and incubated for 1 hour for removal of the 5’ phosphate groups. Digested 
samples were purified over a 1% agarose gel at 135 V for 40 minutes. DNA bands were cut out 
of the gel, the plasmids were extracted using QIAquick Gel Extraction Kit (28704, Qiagen) 
according to manufacturer’s instructions and eluted in 30 µl EB. The concentration of DNA was 
quantified on a NanoDrop 2000 instrument (Thermo Scientific). For the ligation, 50 ng of vector 
was used at a 1:3 mole ratio of vector-to-insert. The required volume of insert plasmid in the 
reaction was calculated based on the size of vector and insert using Ligation Calculator 
(http://www.insilico.uni-duesseldorf.de/Lig_Input.html). For the ligation reaction, the insert and 
the vector were mixed with 2x Quick Ligase buffer and 0.75 µl Quick Ligase (M2200S NEB). 
After incubating at RT for 15 minutes, 5 µl of the ligation reaction was transformed onto 20 µl of 
competent cells (either GC10, G2794 Sigma, or 10-beta, C3019I NEB) according to 
! 
 
24 
manufacturer’s instructions. Following the 37°C incubation in 500 µl SOC, the reactions were 
plated onto carbenicillin (100 µg/ml) plates and placed in a 37°C incubator overnight. Colonies 
were picked and grown in 4 ml Luria broth (LB) + 1x carb overnight at 37°C. The plasmid was 
purified using QIAprep Spin Miniprep Kit (27104 Qiagen) and eluted in 30 µl EB. After the 
constructs were verified by sequencing as described above, colonies were streaked into 250 ml 
LB + 1x carb and the plasmid was purified using HiSpeed Plasmid Maxi Kit (12662 Qiagen) and 
eluted in 1ml EB. 
 
For refolding, hCLCA1 vWA (297-478) K398A and K398A+K399A constructs were 
amplified with 5’ NheI and 3’ XhoI primers and ligated into pet23b vector. Inclusion bodies 
were prepared as described in Section 2.3.1.5.  Solubilized inclusion bodies were refolded in 
arginine refolding buffer with 1 mM MgCl2 or 1 mM MnCl2 overnight at 4°C. The refoldings 
were concentrated to ~4 ml volume and purified over S75 in 1x sizing buffer. The protein 
refolded in MgCl2 eluted off the column at a monomeric size.  
 
2.3.2.2 HEK293T Cell culture and transient transfection 
 
Adherent HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM), supplemented with 10% fetal bovine serum (FBS), 1% pen/strep (50 U/ml), 1% non-
essential amino acids (11140050 Thermo Fisher) and 1% GlutaMAX (35050061 Thermo Fisher) 
at 37°C and 5% CO2. 
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Maxi-prep DNA concentration was measured by absorbance at 260 nm using NanoDrop 
instrument. On the day of transfection, 1 µg DNA per 106 cells was diluted in low-serum OPTI-
MEM (31985070 Thermo Fisher). The transfection reagent (Table 1) was diluted in OPTI-MEM, 
separately from the DNA solution. After incubating for 5 minutes at room temperature (RT), 
diluted transfection reagent was added onto the DNA solution and incubated for 20 minutes at 
RT for complexation. Then, the solution was added onto the cells dropwise and the cells were 
returned to the incubator for 24-48 hours. 
 
Small-scale expression tests were carried out with adherent HEK293T cells, usually on a 
6-well plate (Vtotal= 2 ml) at 1x106 cells/ml density, via transient transfection of the constructs. 
For large-scale expression, 293F cells grown in FreeStyle 293F Expression Medium (12338018 
ThermoFisher) (Vtotal= 300 or 600 ml) were transiently transfected as  we reported (30). 
Table 1. Transfection reagent ratios for transient transfection 
Transfection Reagent Vreagent / 1 µg DNA  (µl) 
293Fectin 2 
Lipofectamine 2000 2 
FuGENE 6 3 
Polyethlyeneimine (PEI) 1.5 
PEI-TMC-25 (31) 1.5 
 
!
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2.3.2.3 Recombinant Protein Purification 
 
Proteins with a C-terminal 6His-tag were purified by nickel affinity chromatography as 
described by us (30). Briefly, the supernatant was collected from transfected 293F cells 
following centrifugation, pH-adjusted by adding 10% volume of 10x lysis buffer (500 mM 
K2HPO4 pH 8.0, 3 M NaCl, 100 mM imidazole) and poured over Ni-NTA superflow resin 
(Qiagen), which had been equilibrated in 1x lysis buffer. Once the flow-through was cleared, the 
column was washed with 2 column volumes (CV) of wash buffer containing 50 mM imidazole. 
The protein was eluted in 1 CV of elution buffer with 250 mM imidazole. The eluate fraction 
was concentrated to a final volume of 2 ml and buffer exchanged using a centrifugation filter. 
For structural studies, proteins were exchanged into 1x sizing buffer (20 mM HEPES pH 7.5 + 
150 mM NaCl ± 10% glycerol) and purified over Superdex 75 (S75) or 200 (S200) columns on 
the ÄKTA FLPC instrument. If further purification was necessary, the protein peak was pooled 
and dialyzed into buffer A (20 mM tris pH 8.0, 10 mM NaCl and 10% glycerol) overnight at 
4°C. The dialyzed protein sample was then injected onto the MonoQ column (GE Lifesciences) 
using buffer A and eluted off using a gradient from 0-100% of buffer B (20 mM tris pH 8.0, 1 M 
NaCl and 10% glycerol) over 40 CV. The protein peak was pooled and concentrated using a 
centrifugation filter.  
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2.3.2.4 Western blotting 
 
HEK293T cells were lifted in phosphate buffered saline (PBS). Cells were lysed in 1% 
v/v triton x-100 in PBS with stirring at 4°C for 1 hour.  Lysates were lightly spun and 10 µl of 
the clear supernatant was mixed with 10 µl 2x sodium dodecyl sulfate (SDS) loading buffer. The 
sample was boiled for a five minutes, loaded onto a 4-12% bis-tris polyacrylamide gel and run at 
200 V for 35 minutes. The proteins were transferred onto a nitrocellulose membrane using gel 
transfer device (iBlot2). In the meantime, 50 mL of blocking buffer with 0.2 g milk powder 
dissolved in 0.1% Tween-20 in 10% PBS (PBST) was prepared. After blocking the membrane 
with 10 ml blocking buffer for 5 minutes, 10 ml of primary antibody in blocking buffer (Table 2) 
was incubated with the membrane for 15 minutes. Following three PBST washes, 10 ml of the 
appropriate HRP-conjugated secondary antibody in blocking buffer was placed on the membrane 
and incubated for 15 minutes. The membrane was then washed three times with PBST and 
proteins were detected using a western blotting substrate (Pierce ECL, Thermo Fisher 32106) at 
4-ml/membrane volume. 
Table 2. Antibodies used for Western blotting. 
Antibody Species Epitope/Target Dilution 
Anti 6His-HRP Rabbit 6His-tag 1:5000 
8D3 Mouse NTF of CLCA1 1:500 
Anti-mouse IgG-HRP Goat Mouse IgG 1:5000 
Anti-actin mouse Actin protein 1:2000 
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2.3.2.5 Inclusion body refolding and purification 
 
hCLCA1 constructs were cloned into pet23b backbone using NheI- KpnI restriction site 
cloning. Constructs were transformed into Rosetta 2 (DE3) competent cells (Millipore) and 
expression was carried out under chloramphenicol and carbenicillin selection. A 100 ml starter 
culture was used to inoculate 6-8 L of Luria Broth (LB). After culture optical density reached 
1.0, protein expression was induced using 2.0 mM isopropyl-β-D-1-thiogalactopyranoside 
(IPTG) at 25°C overnight (or 30°C for 4-5 hours). Cells were lysed in buffer (50 mM tris pH 8, 
1% v/v triton x-100, 100 mM NaCl, 0.01% w/w NaN3 and 10 mM dithiothreitol) and 
supplemented with lysozyme and DNAse I. Following rigorous washing with wash buffer 
containing 0.5% v/v triton x-100, a final wash without triton x-100 was performed and inclusion 
bodies were solubilized in 20 ml buffer (6 M guanidine hydrochloride, 10 mM tris pH 8 and 20 
mM 2-mercaptoethanol). Inclusion bodies were diluted 1:4 in solubilization buffer and were 
added into oxidative arginine refolding buffer (100 mM tris, 400 mM arginine, 0.5 mM oxidized 
glutathione, 5 mM reduced glutathione, 0.1 mM ZnCl2 and 10 mM CaCl2) in small portions. 
Proteins were allowed to refold overnight at 4°C in 250-500 ml volume, then concentrated under 
pressure to a final volume of 5 ml and purified by gel filtration chromatography and ion 
exchange chromatography as described above. 
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2.3.3 Results 
2.3.3.1 Metalloprotease domain 
The first metalloprotease constructs I used for crystallization were 22-189, 22-199 and 
22-283. These boundaries were determined using the structure predictions; the first two 
constructs contain only the metalloprotease domain, while the last construct also includes the 
Cys-rich domain (Figure 6).  These constructs could be expressed in mammalian cells, but were 
not secreted (Table 3), which indicated problems with proper folding. 
I then tried different truncations within the metalloprotease domain and among those, 22-
293 was the construct that expressed and secreted the most robustly. Making the E157Q 
mutation, which has aided in the crystallization of other metalloproteases (32-35), did not affect 
expression or secretion of the protein. However, neither of these constructs could be purified to 
homogeneity via FPLC (Figure 7). With samples purified only by nickel affinity 
chromatography, crystal screens were set at 1-5 mg/ml using hanging-drop method with 
Mosquito. The commercial screens JCSG Core Suite I-IV, PEGS Suite I-II (Qiagen) were 
screened, but no crystal hits were obtained. With these samples, I also tried in situ proteolysis 
(36) with chymotrypsin to cut off flexible terminal residues, but the treatment did not improve 
the results. 
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Table 3. Metalloprotease constructs tested for structural studies. 
Construct expressed secreted refolded Purified notes 
22-189 x     
22-189 E157Q x     
22-199 x  x   
22-199 E157Q x  x   
22-283 x  x   
22-283 E157Q x  x   
22-293 x x x x heterogeneous 
22-293 E157Q x x x x heterogeneous 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Representative size exclusion and ion change (monoQ) chromatograms. A. Refolded 22-283 
E157Q purified over S75. Red star indicates the fraction collected for subsequent monoQ purification. B. 
Refolded 22-283 E157Q purified over monoQ after S75. C. Refolded 22-293 E157Q purified over S75. 
D. Refolded 22-293 purified over monoQ after S75. 
  
A 
B 
C 
D 
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2.3.3.2 vWA domain  
CLCA1 vWA (297-478) construct was expressed and secreted robustly. During size 
exclusion chromatography, it eluted at a volume corresponding to its monomeric weight and 
from the pooled fractions the protein could be purified to 99%, as assessed by SDS-PAGE 
(Figure 8).  Crystal screens were set at 10 mg/ml using hanging-drop method with Mosquito. The 
commercial screens JCSG Core Suite I-IV, PEGS Suite I-II (Qiagen) were screened, but no 
crystal hits were obtained.  
 
 
 
Figure 8. Purification of recombinant vWA (297-478) expressed in 293F cells. Left, Size exclusion 
chromatogram (analytical S200) of the affinity purified protein. Protein elutes at a volume corresponding 
to monomeric protein (~20 kDa). Red star indicates the protein peak. Right, Imperial stain of the 
concentrated peak off of S200 column for crystallization trials. Protein is 99% pure Arrow indicates the 
major protein band at 20 kDa, corresponding to monomeric vWA. Note: There is only one Trp and two 
Tyr residues within the construct, so absorption at 280 nm is weak, despite the high concentration of 
protein. 
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2.3.3.3. Surface entropy reduction for crystallization 
 
vWA domains are homologous to inserted (I) domains found in integrins (23). Both these 
domains adopt a Rossmann fold, also known as classic alpha/beta open, dinucleotide-binding or 
doubly wound fold (37). There is a closed conformation, which reverts to open conformation 
upon ligand binding (23, 38) and most structures determined so far have the vWA (or the I) 
domain in complex with a ligand (peptide) (38-40). Since the specific ligand of CLCA1 vWA is 
unknown, I tried other techniques to create stable and homogenous proteins amenable for 
crystallization.  
 
To improve the probability of crystallization, the free energy of the reaction needs to be 
minimized and is determined by the following equation: ΔGcrystallization= ΔHcrystallization – 
T.ΔScrystallization = ΔHcrystallization – T.(ΔSprotein  + ΔSsolvent)  (41). The enthalpy term of 
crystallization is minor, making the free energy directly correlated with the entropy term (42). 
Thus, the surface entropy of the protein becomes the major factor in determining the fate of 
crystallization. A high entropy term, in this case, translates as surface heterogeneity, which even 
at high sample purity, can be detrimental to protein crystallization. Residues with high side chain 
conformational entropy (Lys, Glu, Gln) introduce conformational flexibility on the surface and 
“interfere with the ability of the protein to form stable crystal contacts” (43).   
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There are two methods utilized that reduce surface entropy and create a conformationally 
homogeneous patch to help crystallization: lysine methylation (44) and surface mutagenesis (42). 
The latter method, in practice, requires a model of the protein to pick residues that would be 
surface exposed. Using the primary sequence of CLCA1 vWA, I built a high-confidence 
homology model using Phyre2 (Figure 9), which I used as my template. Surface entropy 
reduction prediction (SERp) server (http://services.mbi.ucla.edu/SER, UCLA, CA) (45) takes 
protein primary sequence as input to predict which charged residues would be clustered on the 
protein surface. For CLCA1 vWA domain, the server came up with three clusters, which are 
indeed surface exposed on the homology model built by Phyre2 (Figure 9). The first of the three 
clusters has the highest score, indicative of predicted success the mutagenesis would have in 
enabling crystallization.  
 
Figure 9. Homology model of vWA depicting the predicted residue clusters for surface entropy reduction. 
Residues targeted for mutation are colored in the model and typed in bold. Numbers in the boxes denote 
SERp score, which is an indicator of entropy reduction upon mutation of these floppy charged residues to 
Ala. Model is built by Phyre2 and the figure is made with Pymol. 
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2.4 Summary 
CLCAs are secreted soluble proteins, which are comprised of multiple distinct domains. 
Aside from the well-characterized vWA and FnIII domains, CLCAs also contain an N-terminal 
domain that is predicted to have an MMP-like fold. This metalloprotease domain is distinct from 
MMP and ADAM family members, because it lacks certain regulatory features such as the 
prodomain and the Met turn. For structural studies, I was able to determine domain boundaries, 
which would get expressed and secreted from cells, indicating proper folding. While I was able 
to get sufficient expression from mammalian cells, the metalloprotease constructs did not purify 
to homogeneity. The CLCA1 vWA domain, however, expresses robustly and can be purified to 
homogeneity. In order to improve probability of crystallization, I recently cloned a double 
surface Alanine mutant (K398A + K399A). These constructs express robustly and can be 
refolded for crystallization trials. 
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3 Proteolytic Processing 
3.1 Conserved Cleavage Sequence 
 In order to determine how CLCA proteins were getting cleaved, it was important to 
identify the location of the cleavage site within the primary sequence. We also wanted to 
investigate if the cleavage site was conserved within the entire CLCA family or if it was 
occurring at a different site for each protein. 
3.1.1 Determination of cleavage site by Edman degradation 
Full-length CLCA proteins (hCLCA1, hCLCA2, hCLCA4, mCLCA3, mCLCA4), 
without their endogenous signal peptide, were cloned into pHLsec vector, which contains an 
optimized signal sequence and a C-terminal 6His-tag (1). hCLCA2, hCLCA4 and mCLCA4 
were made into soluble constructs by the truncation of the C-terminal transmembrane domains or 
GPI-anchors. All proteins were expressed in 293F cells by transient transfection and the C-
terminal fragments were captured by nickel affinity chromatography. SDS-PAGE was used to 
separate the C-terminal cleavage fragment for Edman degradation analysis.  
3.1.2 Results 
By Edman degradation, the first 5 N-terminal residues of the fragments were identified, 
which determined the proteolytic cleavage site of the protein. All proteins tested were cleaved in 
a heavily conserved region (Figure 10), which starts with an Ala in the P1’ site for most family 
members and includes an invariant Tyr in the P3’ position, followed by an invariant Gly in the 
P6’ position. There is a Pro in the P5’ for most family members and the P4’ site is occupied by 
small hydrophobic residues, either an Ile or a Val. These results indicate that CLCAs have a 
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conserved cleavage sequence within the family that transcends species, which is likely 
recognized by a specific protease (family).  
 
 
Figure 10.  CLCA family members have a conserved cleavage sequence. Red arrow indicates site of 
cleavage. Underlined green residues have been experimentally determined by Edman degradation/ N-
terminal sequencing. Figure modified from Yurtsever et al. (2). 
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 3.2 N-terminal zincin metalloprotease 
3.2.1 Point mutations in the active site 
Based on the metalloprotease-like fold prediction, the active site of CLCA1 would 
consist of H156, E157, H160, D167 and E168. Residue E157 is the catalytically required Glu 
that initiates the nucleophilic attack on the substrate, i.e. the cleavage sequence of CLCA1. The 
other residues are required for coordinating the zinc ion (table 4). In order to test the hypothesis 
that there really was an N-terminal metalloprotease, I mutated each residue to Ala and tested the 
effect of the mutations on CLCA cleavage.!
3.2.1.1 Experimental design 
These residues were separately mutated to Ala using Phusion Site-directed mutagenesis 
kit (F541 Thermo Fisher), according to manufacturer’s instructions. Full-length CLCA1 
constructs were expressed in HEK293T cells via transient transfection. Supernatants were 
collected after 72 hours and analyzed by Western blot for cleavage product formation. 
Table 4. List of point mutations in the predicted active site. 
Constructs! Deficiency! Expressed! Cleaved!
WildStype! none! X! X!
Q150A! none! X! X!
H156A! Zinc!binding! X! !
E157Q! Nucleophilic!center! X! !
H160A! Zinc!binding! X! !
D167A! Zinc!binding! X! !
E168A! Zinc!binding! X! !
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3.2.1.2 Results 
The point mutations did not affect protein expression or secretion. However, each point 
mutation alone was sufficient to block cleavage product formation, as assayed by Western 
blotting for both the N-terminal cleavage fragment (8D3 mouse monoclonal antibody) and the C-
terminal fragment (C-terminal 6His tag was recognized by anti-6His antibody). Residue Q150 
was used as a control for this experiment, where the mutation to alanine had minimal effect on 
the amount of cleavage product formed. (Figure 11). These results suggest that CLCAs contain 
an N-terminal zincin metalloprotease and that they are capable of self-cleavage. 
 
Figure 11. Point mutations in the predicted active site of the metalloprotease block self-cleavage in cells.. 
Western blot monitoring cleavage product formation. Top panel, anti-6-His antibody that recognizes the 
full-length and the C-terminal cleavage fragment. Bottom panel, custom 8D3 antibody that recognizes the 
full-length and the N-terminal cleavage fragment. Figure modified from Yurtsever et al. (2). 
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3.2.2 In vitro digestion assay 
3.2.2.1 Rationale 
! While the effect of mutations in the predicted active site of CLCA1, i.e. complete 
abrogation of cleavage product formation, indicated that CLCA1 metalloprotease was 
responsible for the cleavage reaction, the experiment was carried out in a cellular environment, 
where the mutations could possible affect other regulators of enzymatic activity. In order to 
definitely show that CLCA1 metalloprotease is the only enzyme required for CLCA1 cleavage, I 
wanted to recapitulate the cleavage reaction in vitro using recombinant proteins. Chelators were 
used to test the divalent cation dependency of the enzymatic reaction. MMP inhibitors were used 
to determine whether the CLCA1 active site could accommodate known MMP inhibitors and 
whether the interaction would be sufficient to block all enzymatic activity. 
3.2.2.2 Experimental design 
CLCA1 full-length protein was separated into two parts for the reconstitution of the 
cleavage reaction in vitro: The enzyme construct (22-478) contained the metalloprotease domain 
and the vWA domain, the substrate construct (297-914) was only missing the catalytic domain 
(Figure 12a). The vWA domain was included in the enzyme construct to confer stability to the 
protein.  
 
The 50 µl reaction was set up in the digestion buffer (20 mM HEPES pH 7.5, 150 mM 
NaCl, 10 µM ZnCl2,10 mM CaCl2), with 0.5 µM substrate. A 10 µl aliquot was taken 
immediately upon enzyme addition (final concentration 2 µM) and quenched in 10 µl 2x SDS. 
The rest of the reaction was incubated in a water bath at 37°C. After 1 hour, a second 10 µl 
aliquot was taken and quenched. Both aliquots were stored at -20°C, while the remainder of the 
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reaction was incubated in the water bath overnight. The final aliquot was collected after ~16-18 
hours and quenched similarly.  The samples were boiled in a 90°C heating block and proteins 
were detected with Western blotting. 
 
To test the hypothesis that CLCA1 enzymatic activity depended on divalent cations, 
ethylenediaminetetraacetic acid (EDTA) and 1,10-phenanthroline, as chelators, were added into 
the reaction at a final concentration of 15 mM. Halt protease inhibitor cocktail (78430 Thermo 
Fisher) was used at 1x concentration. Commercially available MMP inhibitors GM6001 (2983 
Tocris), Marimastat (M2699 Sigma) and Batimastat (SML0041 Sigma) (Figure 13b) were added 
into the reaction mixture at a final concentration of 40 µM. 
The MMP inhibitors mentioned above are part of the first-generation MMP inhibitors (3) 
and they all have a peptide-mimetic scaffold with a hydroxamate moiety to chelate the 
catalytically required zinc (4-7). For our custom inhibitor Zeynepstat, we used the same scaffold 
and functionalized the P1’ and P2’ residues to Ala and Leu, respectively, to mimic the CLCA1 
cleavage sequence (Figure 13b). The synthesis was carried out by Dr. Artie Romero at 
Washington University in St. Louis, as described in Yurtsever et al. (2). 
 
3.2.2.3 Results 
Incubation of the enzyme and substrate together resulted in cleavage product formation 
over time, as assayed by Western blot (8D3), while the substrate alone was quite stable over the 
time period observed (~18 hours) (Figure 12b). Addition of EDTA or 1,10-phenanthroline 
blocked cleavage product formation, verifying that the protease activity was dependent on 
divalent cations (most likely zinc) (Figure 12b). 
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HALT protease inhibitor cocktail contains protease inhibitors targeted against serine, 
cysteine proteases, threonine proteases and aspartyl proteases, but not metalloproteases. Addition 
of this cocktail had no effect on CLCA1 activity (Figure 12b), further supporting the hypothesis 
that the CLCA1 enzyme responsible for the self-cleavage reaction is a metalloprotease.  
The MMP inhibitors GM6001, Marimastat and Batimastat had varying efficacies of 
blocking CLCA1 activity, suggesting that the enzyme is indeed a zincin metalloprotease, but 
likely with a novel fold, which cannot be completely blocked by available MMP inhibitors 
(Figure 13a). The custom inhibitor, Zeynepstat, blocked approximately 50% of CLCA1 
enzymatic activity (Figure 13a). 
 
 
 
Figure 12. Cleavage can be reconstituted in vitro. A. CLCA1 enzyme and substrate constructs that were 
recombinantly expressed and purified. B. Western blot monitoring cleavage product formation over time 
under different conditions. Figure modified from Yurtsever et al. (2). 
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Figure 13. Clca1 has a novel metalloprotease fold. A. Western blot monitoring cleavage product 
formation over time in the presence of commercially available MMP inhibitors and our custom inhibitor. 
B. Chemical structures of the commercial MMP inhibitors and the custom inhibitor Zeynepstat. Figure 
modified from Yurtsever et al. (2).   
 
3.2.3 Fluorogenic peptide assay 
3.2.3.1 Experimental design 
We designed a fluorescent substrate, by coupling DABCYL and EDANS FRET pair to 
the termini of the 10-residue CLCA1 cleavage sequence QQSG-ALYIPG (AnaSpec). When the 
substrate is intact, EDANS fluorescence is quenched due to the proximity of DABCYL. Thus, 
fluorescence only increases when the CLCA1 enzyme cleaves the substrate (Figure 14a).  
For the reaction, 10 µM  refolded CLCA1 enzyme (22-478) was mixed with 3.25 µM 
fluorogenic peptide in the digestion buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 10 µM 
ZnCl2,10 mM CaCl2) in a 96-well format. The experiments with inhibitors were carried out at 20 
or 40 µM final inhibitor concentration. Using a BioTek plate reader, end point fluorescence at 
37°C was read continuously for 1 hour at 1-minute intervals (exc=340 nm, emm= 490 nm). 
3.2.3.2 Results 
This assay was used as a more quantitative measurement of CLCA1 enzymatic activity, 
with results similar to those obtained with the in vitro digestion experiment. When mixed with 
the enzyme, increase of fluorescence from the reaction mixture could be observed over time as 
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the functional enzyme cleaved the substrate (Figure 14b). In the presence of a catalytically 
inactive enzyme construct (E157Q), there was no increase in fluorescence above background 
(data not shown), indicating that the increase is solely due to substrate cleavage by functional 
CLCA1 enzyme. Addition of EDTA into the reaction abolished the increase in fluorescence 
(Figure 14b), similar to the metal chelators (Figure 12b). The zinc dependence of the reaction 
was further demonstrated in this assay, where addition of excess Zn over EDTA rescued some of 
the enzymatic activity, leading to increase in fluorescence (Figure 14b).  
 
 
 
Figure 14. Fluorogenic peptide assay shows CLCA1 enzyme is zinc dependent. A. Design of the 
fluorogenic peptide. Fluorescence increases if the substrate is cleaved. B. Graph depicting increase of 
fluorescence over time. Green line, CLCA1 enzyme and peptide. Red line, CLCA1 enzyme, peptide and 
EDTA. Gray line, CLCA1 enzyme, peptide, EDTA and excess Zn. C. Quantification of CLCA1 
inhibition by MMP inhibitors. Green bar indicates 100% CLCA1 activity. Blue bars and red bars indicate 
20 µM and 40 µM of inhibitors, respectively. Figure modified from Yurtsever et al. (2)  
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We were able to quantify CLCA1 activity inhibition with the fluorogenic peptide assay 
using the inhibitors from the digestion assay (Figure 13b). Using a refolded enzyme (instead of 
the purified recombinant protein) and a different substrate (fluorogenic peptide vs. purified 
recombinant CLCA1 substrate protein), we were able to recapitulate the findings qualitatively 
displayed in the Western blot (Figure 13a). While GM-6001, Marimastat and Zeynepstat reduced 
CLCA1 activity by 50%, Batimastat inhibited 80% of CLCA1 activity at the low concentration 
(20 µM) tested (Figure 14c). These quantitative results mirrored the data obtained using 
recombinant purified CLCA1 proteins in the presence of the same inhibitors (Figure 13a) and 
further showed that CLCA1 activity was not fully blocked by these molecules, at concentrations 
sufficient to completely block other MMPs. 
3.3 Features of cleavage 
3.3.1 Cross-cleavage 
3.3.1.1 Experimental design 
In order to determine if CLCA family members could recognize and cleave each other, 
we cloned the full-length CLCA1 constructs with either CLCA2 or CLCA4 cleavage sequence 
(Figure 15a), as well as CLCA2 and CLCA4 protease constructs (Figure 15c), similar to the 
CLCA1 construct in Figure 12a.  
CLCA1 constructs with altered cleavage sequences were transiently transfected into 
HEK293T cells. Cells and supernatants were harvested after 72 hours and cleavage was detected 
via Western blotting against both the N-terminal and the C-terminal cleavage fragments. 
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For the in vitro digestion assay, CLCA2 and CLCA4 protease constructs were refolded 
and incubated with CLCA1 substrate construct. Aliquots were taken at 0, 1 and 18 hour-time 
points and assayed for cleavage product formation via Western blotting. 
3.3.1.2 Results 
Transient transfection of full-length CLCA1 with altered cleavage sequence successfully 
resulted in cleavage product formation in HEK293T cells (Figure 15b), indicating the CLCA1 
enzyme could recognize and cleave slightly different sequences (Figure 15a). Similarly, cleavage 
product was formed over time in vitro, when the CLCA1 substrate (Figure 12a) was incubated 
with CLCA2 or CLCA4 proteases, although the amount of product was significantly less than 
the result of CLCA1 activity (Figure 15d). Thus, the CLCA2 and CLCA4 enzymes could also 
recognize the CLCA1 sequence. These results indicate that cross-cleavage can occur within 
family members. 
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Figure 15. Cross-cleavage between CLCA proteins can occur. A, Full-length CLCA1 protein with altered 
cleavage sequences. B, Western blot monitoring cleavage product formation in HEK293T cells. Right, 
anti-6His blot. Left, anti-N-terminal fragment blot. C, Construct design for CLCA2 and CLCA4 protease. 
D, Western blot monitoring cleavage product formation over time in vitro. Figure modified from 
Yurtsever et al. (2).   
3.3.2 Intermolecular Cleavage 
3.3.2.1 Experimental design 
In order to determine if CLCA1 proteolysis could occur as an intermolecular reaction, I 
used two full-length CLCA1 mutants: E157Q, which is catalytically inactive, and contra, which 
does not have the CLCA1 cleavage sequence. I transiently transfected these constructs into 
HEK293T cells, both separately and together. 24-48 hours after transfection, I harvested cells 
and supernatant and detected proteins via Western blotting.  
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2.3.2.2 Results 
As expected, no cleavage product was formed when either of these constructs were 
transiently transfected (Figure 16, lanes 1 and 2), since the entire population has the same 
cleavage deficiency. However, co-transfection of both constructs resulted in cleavage product 
formation (Figure 16) within the same time frame. This observation suggests that two CLCA1 
molecules can form a functionally active complex and allow the cleavage reaction to take place 
intermolecularly. 
Figure 16. Intermolecular CLCA1 cleavage can occur. Western blot displays cleavage product formation 
in the supernatant of HEK293T cells.  Lane 1, cells transfected with full-length E157Q. Lane 2, cells 
transfected with full-length contra. Lane 3, cells co-transfected with both mutants. Black arrow denotes 
cleavage product formation. 
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3.3.3 Regulation by GAGs 
3.3.3.1 Rationale 
 Glycosaminoglycan (GAG) binding motifs within proteins are described as a cluster of 
basic and hydropathic residues, such as XBBXBX, XBBBXXBX, XBBXXBBBXXBBX, where 
B is a basic residue (mostly Lys, followed by Arg) and X is a hydropathic residue (Ala, Val, Phe 
etc.) (8, 9). There is a predicted GAG binding motif BBXXXB within CLCA1 that is conserved 
within family members (Figure 17). Since there is precedence for binding and regulation of 
metalloprotease activity via GAG interaction (10-16), I wanted to verify if CLCA1 cleavage 
activity could be regulated by the same mechanism. 
!
Figure 17. Sequence alignment of CLCA1-CLCA2-CLCA4 in the N-terminal catalytic region. 
Highlighted in green are all the identical residues. Red arrow at residue 157 denotes the catalytically 
required glutamate residue. Box at residues 70-76 highlights the conserved GAG binding motif 
BBXXXB, where basic residues are colored blue and the hydropathic residues are colored red.  Primary 
sequences were aligned with Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) and annotated 
with ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/index.php). 
! 
 
53 
 
3.3.3.2 Experimental design 
As a cellular assay for GAG dependence of CLCA1 cleavage, I used Chinese hamster 
ovary (CHO) cells, because both WT/K1 and GAG-deficient cell lines were readily available. 
The GAG-deficient CHO cell line, CHO-745, is xylosyltransferase-deficient!(17,$18).!Adherent 
CHO K1 and 745 cells were cultured in RPMI containing 10% serum, 1% pen/strep and 1% 
GlutaMAX at 37°C and 5% CO2. 
To monitor CLCA1 cleavage product formation in these cells, I transfected them with the 
full-length WT CLCA1 plasmid in pHLsec backbone using either 293Fectin or Lipofectamine 
2000. 24 and 48 hours after transfection, I collected the supernatants and the lysates for protein 
detection via Western blotting.  
 
3.3.3.3 Results 
 
Using the same amount of plasmid, transfection efficiency of 293Fectin was higher than 
Lipofectamine 2000 in both CHO cell lines (data not shown). The 8D3 antibody (against N-
terminal CLCA1) detected both the full-length uncleaved protein and the N-terminal cleavage 
fragment in both cell lines and in both the supernatant and the cell lysate fractions. Band 
intensities were not significantly different between the two cell lines, indicating that GAGs are 
not required for CLCA1 cleavage activity (Figure 18a).  
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Figure 18. GAGs are not required for CLCA1 expression, secretion, self-cleavage or cell surface binding. 
A. Western blot of supernatants showing cleavage product formation in native vs. GAG-deficient CHO 
cells. Green box highlights the N-terminal cleavage product. B. Confocal microscopy image showing 
CLCA1 surface staining in native vs. GAG-deficient CHO cells.  
 
3.3.3.4 Confocal 
3.3.3.4.1 Rationale 
 
There have been a number of reports observing cell surface staining of CLCA proteins 
(19, 20). In order to determine if surface exposed GAGs were mediating the cell surface binding 
of CLCA1, I used CHO WT/K1 and GAG-deficient 745 cells (17).  
 
 
 
A B 
! 
 
55 
3.3.3.4.2. Experimental design 
Both cell lines were transiently transfected with full-length WT CLCA1 with 293Fectin. 
Samples were fixed and stained using an anti-CLCA1 antibody 48 hours post-transfection.  
 
At day 0, cells were plated on a 6-well-plate in 2 ml volume. On day 1, cells were 
transiently transfected with 1 µg CLCA1 pHLsec plasmid + 2 µl 293Fectin according to 
manufacturer’s instructions. On day 2, cells were trypsinized and replated on chamber slides 
(Lab-Tek ii chamber slide system / 4 well glass slide) in 400 µl volume and incubated overnight 
for adherence. On day 3, supernatant was aspirated and cells were immediately fixed with 200 µl 
4% formaldehyde for 5 minutes at RT. Then, they were blocked in 200 µl 1% blocking buffer for 
1 hour at RT and stained with primary antibodies (Table 5) in blocking buffer overnight at 4°C. 
Cells were washed twice with PBS and incubated with 200 µl 1:200 WGA-633 in PBS for 30 
minutes at RT. Following two more PBS washes, 200 µl of the secondary antibodies in PBS 
were added for 2 hours at RT. Finally, cells were washed twice with PBS and the media was 
aspirated. Wells were removed from the glass slide. Samples were mounted with DAPI-
containing medium (1 drop/well) and imaged. Confocal microscopy was carried out using a 
Zeiss LSM 880 Confocal Laser Scanning Microscope with Airyscan (Carl Zeiss Microscopy, 
Thornwood, NY). Images were acquired and analyzed using ZEN Blue software (Carl Zeiss 
Microscopy, Thornwood, NY). 
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Table 5. Antibodies used in confocal microscopy. 
Antibody type Name Target Species Dilution Exc/Emm (nm)  
Primary S20 TMEM16A Goat 1:50  
 1228 N-CLCA1 Rabbit 1:100  
 2F4 vWA Mouse 1:100  
 6A4 vWA Mouse 1:100  
Secondary WGA Sialic acid (cell membrane)  1:200 633/647 
  Anti-rabbit IgG donkey 1:200 594/617 
  Anti-goat IgG donkey 1:250 488/525 
  Anti-mouse IgG Donkey 1:200 555/580 
 
3.3.3.4.3 Results 
Comparison of cell surface staining of CLCA1 in WT vs. GAG-deficient CHO cells revealed 
no observable difference, suggesting that cell surface binding of CLCA1 does not depend on 
GAG expression (Figure 18b). 
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3.4 Summary 
 
CLCA proteins have a conserved cleavage sequence and proteolytic processing of family 
members occurs at this very specific site. The cleavage reaction is carried out by an internal N-
terminal zincin metalloprotease. This unique self-cleavage activity likely takes place in the 
extracellular medium, as the full-length, uncleaved CLCA1 can be detected in the supernatant, 
alongside the two cleavage fragments.  
Although the CLCA1 enzyme predicts to have an MMP-like fold, commercially available 
MMP inhibitors can only block up to 50% of CLCA1 activity, suggesting a novel conformation 
for the active site. Unlike MMPs, CLCAs also do not have a Met turn and do not require 
interaction with GAGs to be functionally active.  The data obtained thus far indicate that the 
CLCA zincin metalloprotease has a novel fold, which requires further structural information to 
guide drug design. 
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4 CLCA function as CaCC Regulator 
The bioinformatics and biochemical data shown so far demonstrate that CLCA1 is a fully 
soluble secreted protein, which undergoes a self-cleavage reaction.  In elucidating the 
mechanism, by which CLCA1 regulates calcium-activated chloride currents, we first wanted to 
determine whether CLCA1 cleavage was important to its role as a CaCC regulator. 
4.1 Cleavage is necessary for function 
4.1.1 Whole-cell patch clamp assay 
 
In collaboration with Drs. Colin Nichols and Monica Sala-Rabanal, we set up a whole-
cell patch clamp assay as a functional readout of CLCA1 activity. For the experiments, adherent 
HEK293T cells were cultured as described before. On day zero, cells were plated on a 6-well 
plate (Vtotal = 2 ml). On day one, cells were transfected with 1 µg DNA + 0.2 µg eGFP + 2 µl 
293fectin. On day two, cells were replated onto UV-sterilized glass cover slips in fresh medium. 
On day three, cover slips were removed from the original well and placed into the patch clamp 
rig. Cells that fluoresced under UV light were specifically targeted for whole-cell measurements, 
as the likelihood of co-expressing CLCA1 would be higher in that population. Calcium-sensitive 
chloride currents were measured, which are conducted via a channel endogenously expressed in 
HEK293T cells.    
 
The whole-cell patch clamp experiments were conducted as described in Yurtsever et al. 
(1). Briefly, 2 megaohm pipettes were filled with pipette solution (126 mM choline chloride, 10 
mM HEPES, 10 mM EGTA) with 0 or 10 µM free Ca2+. The bath solution contained 125 mM 
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NaCl, 10 mM HEPES, 30 mM sucrose, 2 mM CaCl2, 2 mM MgCl2. Following seal and break-in, 
cells were voltage clamped at -80 mV. A pulse protocol was applied in which membrane 
potential was held at -80 mV for 500 ms and stepped to a test value for 1000 ms before returning 
to the holding potential for an additional 500 ms. The test potential varied from -100 to +80 mV 
in 20 mV increments.  Membrane capacitance was calculated from the integral of the current 
transient. Data were analyzed with ClampFit 10.1 (Molecular Devices). 
 
4.1.2 Full-length mutants do not activate currents 
As a negative control, cells were transfected with the empty vector backbone, which 
resulted in background currents (~20 pA/pF). Transfection with the full-length, enzymatically 
active protein resulted in a robust increase in slightly outward rectifying currents (~80 pA/pF) 
(Figure 19a). These currents could be blocked by gluconate and were sensitive to the calcium 
concentration in the pipette solution. 
 
Enzymatically inactive full-length constructs, E157Q, H156A, D158A, did not increase 
currents over background levels. The full-length construct with a scrambled cleavage sequence 
(contra) behaved similarly as the enzymatically inactive constructs, and did not increase currents 
(Figure 19a). Since impairment of either of the catalytic sites was detrimental, CLCA1 
enzymatic activity is required for the CaCC activation. 
 
4.1.3 N-terminal fragment is necessary and sufficient for CaCC activation 
In order to determine if the CaCC activation could be attributed to either of the cleavage 
fragments, cells were transfected with the N-terminal and the C-terminal cleavage fragment 
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separately. In the patch clamp assay, cells transfected with the N-terminal cleavage fragment 
displayed high calcium-sensitive chloride currents, at comparable levels to cells transfected with 
the full-length protein. The C-terminal cleavage fragment, on the other hand, did not cause an 
increase in the currents (Figure 19b). 
 
 
 
 
Figure 19. Self-cleavage of CLCA1 is required for CaCC activation. A. Chloride current density 
measured from cells transfected with full-length CLCA1 constructs. B. Chloride current density measured 
from cells transfected with CLCA1 cleavage fragments. C. Model of proposed interaction for CLCA1 and 
CaCC; self-cleavage releases the C-terminal fragment from the N-terminal fragment, which is the 
functional portion of the protein. Figure modified from Yurtsever et al. (1). 
  
! 
 
63 
4.1.4 Enzymatic activity is not required for CaCC activation 
Some channel proteins need to be proteolytically cleaved to become active. For example, 
aerolysin, an Aeromonas toxin that forms pores on the cell membrane, is synthesized as a 
zymogen and is activated via proteolytic removal of the c-terminal peptide. Proteolysis, which 
makes the toxin insertion competent (2), can be carried out by trypsin (3) or furin (4). 
There is another example for proteolytic channel activation, which occurs in the small 
airways where CLCA1 is expressed. The epithelial sodium channel ENaC is expressed in distal 
and proximal airways (5), where it controls ASL volume and mucociliary clearance (6). In both 
in vitro and in in vivo lung models, ENaC activity has been shown to increase following cleavage 
by channel activating protease 1 (CAP1/prostasin) (7-9).  
To determine if the metalloprotease within the N-terminal cleavage fragment was 
important for CaCC activation, the catalytically dead N-terminal fragment (E157Q) was used in 
the whole cell patch clamp assay, side-by-side with the WT N-terminal cleavage fragment. Both 
constructs increased currents to the same extent, thus indicating that CLCA1 enzymatic activity 
does not play a role in CaCC activation (Figure 19b).  
Based on the functional data obtained from the whole-cell patch clamp experiment, self-
cleavage of CLCA1 is necessary for CaCC activation to occur. As the N-terminal cleavage 
fragment is as active as the full-length protein and enzymatic activity is not required to increase 
current, self-cleavage is likely required to release the C-terminal cleavage fragment from the full-
length compact structure of CLCA1. Once the C-terminal tail is released, the N-terminal 
fragment can obtain a conformation that is favorable for interacting with the CaCC (Figure 19c). 
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4.2 Paracrine effect 
4.2.1 GFP co-culture experiment 
4.2.1.1 Experimental design 
As CLCA1 is a secreted protein, the question of where the interaction between CLCA1 and 
TMEM16A occurred was a relevant one. In order to distinguish between an autocrine, i.e. on the 
same cell, and a paracrine, i.e. on neighboring cells, effect, we designed a series of modifications 
on the whole-cell patch clamp experiment described previously. 
For the first experiment, we tested if CLCA1 expressed and secreted from one cell could 
affect cells around it. I transfected one batch of cells with eGFP and another batch of cells with 
full-length WT CLCA1 (or pHLsec as vector control). On day 2, I lifted the cells with trypsin 
and replated both populations together for co-culture. For patching, we only targeted the green 
cells (Figure 20a), which would not be expressing CLCA1, and an increase in currents would 
indicate that CLCA1 from another cell could modulate currents from the green cells.  
 
4.2.1.2 Results 
As shown in Figure 20b, the currents measured from green cells significantly increased 
when the green cells were co-cultured with CLCA1-expressing cells, suggesting that CLCA1 
could modulate currents of neighboring cells. As previously observed, these currents were Ca-
sensitive and could not be activated with 0 µM free Ca2+ in the pipette (Figure 20b). Cells that 
were co-cultured with vector-transfected cells did not display any increase in currents, regardless 
of the calcium concentration in the pipette. 
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Figure 20. CLCA1 can activate CaCC in a paracrine fashion. A. Schematic of the patch-clamp 
experiment. B. Chloride current density measured from GFP-expressing cells co-cultured with vector- or 
CLCA1-expressing cells. Pipette solution had 0 or 10 µM free Ca2+ to determine calcium dependency of 
the currents. Figure modified from  Sala-Rabanal et al. (10). 
 
4.2.2 Conditioned media 
 
4.2.2.1 Experimental design 
In order to verify that it is the secreted CLCA1 protein that activates ICaCC, we took the 
“GFP-coculture” experiment one step further: This time, one batch of cells was transfected with 
full-length WT CLCA1 (or pHLsec), while the other batch was left untreated. On the second day, 
I took the supernatant from CLCA1-transfected cells, “CLCA1-conditioned media”, and 
incubated the untreated cells in it for 24 hours prior to patching. 
B A 
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4.2.2.2 Results 
Similar to the co-culture experiment (Figure 20), CaCC currents were significantly 
increased when cells were grown in CLCA1-conditioned media (Figure 21), indicating that 
CLCA1 could activate these currents in a paracrine fashion. The Ca sensitivity was verified in 
this setup, as well, where 1 µM free Ca2+ in the pipette solution was still insufficient to activate 
currents.  
 Replenishing the media from transfected cells a few hours after the transfection to 
remove residual transfection reagent did not change the results of the patch clamp assay, 
indicating that the leftover transfection complexes in the supernatant, if there were any, were not 
responsible for activating currents.  
Figure 21. CLCA1-conditioned medium increases CaCC currents. A. Schematic of the patch-clamp 
experiment. B. Chloride current density measured from cells conditions with CLCA1. Pipette solution 
had 0, 1 or 10 µM free Ca2+ to determine calcium dependency of the currents. Figure modified from  Sala-
Rabanal et al. (10). 
 
A 
 
 
 
B 
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4.2.3 Purified protein 
4.2.3.1 Rationale 
While the conditioned media format was readily applicable, it did not definitively show 
that CLCA1 was the sole effector of CaCC activity, as the overexpression of a protein by 
transient transfection can result in the expression and secretion of other species. To address this 
concern, we decided to use purified CLCA1 protein. 
4.2.3.2 Protein expression and purification 
CLCA1 construct 22-694 was cloned into Avitag backbone (11), which contains a C-
terminal 6His-tag, followed by a BirA ligase recognition sequence. The plasmid was transiently 
transfected into 293F cells, which grow in suspension in serum-free media. 72 hours after 
transfection, cell culture was spun down and the supernatant was collected. The protein was 
purified using nickel affinity chromatography, exchanged into biotinylation buffer (100 mM tris 
pH 7.5, 200 mM NaCl, 5 mM MgCl2) and concentrated in a centrifugation filter to a final 
volume of 300 µl. Protein concentration was calculated using the Beer-Lambert law from sample 
absorbance at 280 nm: ! = !! ∗ ! ∗ !. The extinction coefficient ! was calculated from the 
primary sequence using ProtParam (http://web.expasy.org/protparam/) from ExPasy (12), which 
uses the number of tyrosines, tryptophans and cysteines in the sequence. The path length b is 1 
cm for the cuvettes used. 
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50 µl of Biomix A (0.5 M bicine pH 8.3) and B (100 mM ATP, 100 mM MgOAc) were 
added. 100 µl 500 µM biotin was added. 20 µl recombinant BirA ligase was added. The solution 
was spun gently overnight at 4°C, then purified using a 0.5 ml ZEBA desalting column (Thermo 
Fisher 89882).  
Purified N-terminal CLCA1 (native or biotinylated) protein was added into the pipette 
solution at 10-50 µg/ml concentration. As a negative control, the exact buffer matches were used 
in the pipette. 
4.2.3.3 Results 
CaCC currents were activated by purified protein to the same level as observed with 
transfection and conditioned media formats, whereas the buffer controls did not induce currents 
above background (Figure 22). This experiment verified that CLCA1 protein is necessary and 
sufficient for CaCC activation. 
 
 
 
 
 
 
 
 
 
Figure 22. Pure N-terminal CLCA1 protein increases CaCC currents. A, Representative traces from cells 
patched with native or biotinylated N-terminal CLCA1. B, Chloride current density measured from cells 
patched with native or biotinylated N-terminal CLCA1 or exact buffer matches (-). Figure modified from  
Sala-Rabanal et al. (10).  
A B 
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4.3 Identification of TMEM16A as Target CaCC 
4.3.1 TMEM16A Structure and Function in the Airways 
The following section is taken from the review “Novel Roles of Chloride Channels, 
Exchangers, and Regulators in Chronic Inflammatory Diseases” authored by Monica Sala-
Rabanal, myself, Kayla N. Berry and Thomas J. Brett (13). Each author contributed one or more 
chapters within the review. While all authors were part of the editing and proofreading process, I 
reviewed the relevant literature and composed the section on TMEM16A. 
While CaCC conductance was a long-observed phenomenon in the airways and could be 
separated from CFTR currents, the molecular identity of the channels responsible for 
these currents remained elusive until the late 2000s. The TMEM16/Anoctamin family 
was identified in 2008 as the first bonafide CaCCs (14-16). However, based on their 
electrical and pharmacological characterization, only two of the ten family members, 
TMEM16A and TMEM16B, displayed properties previously observed for CaCCs in the 
airways (17, 18), whereas most of the other members function as lipid scramblases. Of 
these two, TMEM16A expression has been verified in airway epithelium and airway 
smooth muscle cells (19). 
The predicted topology for TMEM16 family members (Figure 23) is based on the recent 
landmark crystal structure of the fungal Nectria haematococca TMEM16 (nhTMEM16), 
which has 10 transmembrane domains instead of the previously predicted 8 (20). The 
purified and reconstituted protein, which was shown to be a homodimer (21), constitutes 
a channel on its own and does not require other proteins to be active (22). While the Ca2+ 
sensitivity of the channel is well documented (20, 23, 24) and the protein directly binds 
Ca2+, the possible involvement and mechanism of interaction with calmodulin as a 
calcium sensor and binding partner are still controversial (23, 25, 26). 
Similar to CLCA1, expression of TMEM16A is upregulated by IL-4/IL-13 stimulation 
(Figure 2) (27-30).  Upon upregulation, TMEM16A co-localizes to the apical plasma 
membrane of goblet cells (28, 31, 32), along with the mucin MUC5AC. It is expressed in 
airway smooth muscle cells, and has been shown to play a role in AHR (32). 
Additionally, inhibitors of TMEM16A have been shown to block mucus secretion (32, 
33), whereas small molecule activators increase secretion (34). 
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Figure 23. Schematic of TMEM16A. Pink boxes at the N-terminus denote splicing isoforms. The 
extracellular loop in green is the proposed binding site for CLCA1. Figure modified from Sala-Rabanal et 
al. (13). 
 
4.3.2 TMEM16A inhibitors 
4.3.2.1 Experimental design 
T16inh-A01 (27) and MONNA (35) were identified in high-throughput screens as 
TMEM16A-specific blockers. Neither of the compounds block CFTR currents (27, 35) and 
MONNA also does not block Bestrophin1 or CLC2 (35). T16inh-A01 is commercially available 
(4538 Tocris), but MONNA was synthesized in house by Dr. Arthur G. Romero. Stock solutions 
were made by dissolving powder in dimethyl sulfoxide (DMSO) and stored at -20°C. 
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The small molecule inhibitors were used in the whole-cell patch clamp assay to 
determine their effect on CLCA1-activated CaCC currents. For the assay, cells were transfected 
with full-length CLCA1 and replated on cover slips after 24 hours. The inhibitors were added 
onto the culture media at a final concentration of 10 µM and incubated overnight with the cells. 
Equal volume of DMSO was used as a vehicle control. 
 
4.3.2.2 Results 
CaCC currents were activated by CLCA1, as previously described. DMSO treated cells 
did not show any significant changes in the currents measured. However, incubation with either 
of the inhibitors significantly decreased CLCA1-activated currents to levels comparable to 
untransfected cells (Figure 24a). These results suggested that these small molecule inhibitors 
were decreasing CLCA1-activated CaCC currents. 
 
4.3.3 TMEM16A siRNA 
4.3.3.1 Experimental design 
Commercially available TMEM16A siRNA (HSS123904, Life Tech) was dissolved in 
ultra-pure water to yield a 20 mM stock solution. As a transfection control, medium GC content 
RNA (12935300, Life Tech) was also prepared at 20 mM concentration. On the day of 
transfection, siRNA was diluted in OPTI-MEM. The transfection reagent, Lipofectamine 2000 at 
20 pmol siRNA: 2 µl reagent ratio, was diluted separately in OPTI-MEM. The diluted 
transfection reagent was added onto the siRNA solution and incubated for 5 minutes at RT for 
complexation. Then, the solution was added onto the cells dropwise and the cells were returned 
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to the incubator. The final concentration of siRNA in cell culture volume should be 200 nM. The 
format that retains cell viability while maintaining siRNA transfection efficiency is plating 293T 
cells in a 48-well-plate in a volume of 200 µl 24 hours before transfection. The total volume of 
added siRNA-Lipofectamine 2000 complex should be 20 µl, increasing the total volume to 220 
µl.   
 To replate cells 24 hours after transfection, I resuspended them in their own supernatant, 
instead of using trypsin, as the siRNA transfection made cells very fragile and they would not 
survive the trypsin treatment. siRNA- or control RNA-transfected cells were then replated in 
CLCA1-conditioned media and incubated for 24 hours at 37°C prior to patch clamp.  
4.3.3.2 Results 
Cells transfected with siRNA did not respond to CLCA1 treatment. In contrast, cells 
transfected with a control RNA responded to CLCA1 treatment and measured currents were 
significantly higher (Figure 24b). These results showed that TMEM16A siRNA could block the 
currents being activated by CLCA1, definitively showing that CLCA1 was activating 
TMEM16A. 
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Figure 24. CLCA1 increases TMEM16A currents without affecting TMEM16A expression. A. Chloride 
current density measured from cells conditioned in CLCA1-media and incubated with T16inh-A01 (A01 in 
the figure) or MONNA. Chemical structures of inhibitors were drawn with PubChem Sketcher V2.4. B. 
Chloride current density measured from cells transfected with TMEM16A siRNA (or control RNA) and 
conditioned with CLCA1. C. Western blot for TMEM16A expression in HEK293T cells that are 
transfected or conditioned with CLCA1. Figure modified from Sala-Rabanal et al. (10). 
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4.3.4 TMEM16A expression 
4.3.4.1 TMEM16 mRNA levels after CLCA1 treatment 
 
TMEM16A mRNA levels were measured by quantitative PCR (qPCR) using 
commercially available probes (PrimeTime Std qPCR assay, IDT: Hs.PT.58.2239278, 
Hs.PT.56a.3654734, Hs.PT.58.22490791, IDTDNA). The probes were reconstituted in 500 µl 
EB, which makes a 20x stock, and stored at -20°C.   
 
RNA was isolated from 293T cells using TRIzol (15596026 Thermo Fisher) according to 
manufacturer’s instructions and diluted to 100 µg/ml concentration in ultra-pure water. cDNA 
library was constructed with High-capacity cDNA Reverse Transcription Kit (4374966 Thermo 
Fisher)  (4 µl 10x RT buffer + 1.6 µl 25x dNTP + 4 µl 10x random primer + 2 µl multiscribe RT 
+ 0.2 µl RNase inhibitor + 8.2 µl water + 20 µl 100 µg/ml RNA).  For the qPCR reaction, 2 µl of 
the cDNA samples was mixed with 10 µl cocktail, which contained 4.3 µl water, 0.5 µl Std 
qPCR assay, 0.2 µl Rox low and 5 µl KAPA (KK4716 Kapabiosystems).  
 
The reaction was run on an Applied Biosystems 7500 Fast instrument. These assays have 
a FAM reporter and NFQ-MGB quencher. Rox was selected as passive reference. Expression 
levels of TMEM16A were normalized to human GAPDH (4352934-1010033, Applied 
Biosystems) levels from the same sample and all samples were normalized to vector transfected 
HEK293T cells. TMEM16A mRNA levels were not significantly increased after the cells had 
been either transfected or conditioned with full-length WT CLCA1. 
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4.3.4.2 TMEM16A protein levels after CLCA1 treatment 
 
To determine the effect of CLCA1 protein on TMEM16A protein levels, HEK293T cells 
were transfected or conditioned with full-length WT CLCA1. Alongside the treatments with 
CLCA1, some cells were also transfected with TMEM16A siRNA to verify reduced TMEM16A 
protein levels.  
 
After 24 hours of incubation, cells were harvested and lysed. TMEM16A and actin (as 
loading control) proteins were detected via Western blotting. The developed film was scanned 
and the image was converted to an 8-bit tiff file for densitometry quantification. Any 
modifications to the brightness and/or contrast were applied to the entire image. Pixel intensities 
within boxes of equal size were quantified using Imagej 1.48 (http://imagej.nih.gov/ij/). 
 
Compared to untransfected cells, TMEM16A protein levels were unchanged when the 
cells were transfected or conditioned with CLCA1, as expected from the mRNA data. Cells that 
were transfected with TMEM16A siRNA had significantly reduced protein levels, which did not 
increase by additional CLCA1-conditioned media treatment (Figure 24c). 
 
4.3.5 Confocal  
 
In order to visualize cellular localization of TMEM16A and CLCA1, HEK293T cells 
were transfected or conditioned with CLCA1 and then stained for both CLCA1 and endogenous 
TMEM16A. 
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While these HEK293T cells do express TMEM16A, there was no detectable surface 
staining for it in untreated cells (Figure 25- first and third columns), which could be explained by 
the low basal levels or rapid trafficking/shuttling of the channel to and from the cell surface.  
 
Surprisingly, transfecting the cells with CLCA1 increased the surface staining of 
TMEM16A (Figure 25- second column). Results were similar when conditioned medium was 
used instead of transient transfection (Figure 25- fourth column). In both cases, CLCA1 and 
TMEM16A were co-localized on the cell surface. 
 
Figure 25. CLCA1 increases TMEM16A cell surface staining. Confocal microscopy images showing 
cells co-stained for CLCA1 and TMEM16A following CLCA1 treatment by either transfection or 
conditioned media. Figure taken from  Sala-Rabanal et al. (10). 
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4.3.6 Pull-down 
4.3.6.1 Rationale 
Since the images acquired with the confocal microscope suggested a co-localization for 
CLCA1 and TMEM16A on the cell surface, I hypothesized that there would be a direct 
interaction between the two proteins and that I could use a co-immunoprecipitation assay to pull-
down TMEM16A using CLCA1.  
4.3.6.2 Experimental design 
In vitro biotinylated CLCA1 Nterm (22-694) was prepared as described before. On the day of 
the experiment, adherent HEK293T cells were lifted in PBS, resuspended in lysis buffer and 
lysed shaking at 4°C for 30 mins. 
Lysis buffer recipes: 
o 150 mM NaCl, 50 mM HEPES pH 7.4, 1% NP40 
o 1% NP40 in PBS.  
o 1.5 mM KH2PO4, 4.3 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, 1% triton-100 
o 140 mM NaCl, 20 mM tris-HCl, 5% glycerol, 1% triton-100 
The cell lysate was incubated with biotinylated CLCA1 protein, shaking at 4°C for 30 
mins. When using a crosslinker, fresh dithiobis(succinimidyl propionate) (DSP) was added at a 
final concentration of 1 mM, shaking at RT for 1 hour. The reaction was quenched with tris pH 8 
at a final concentration of 100 mM. Then, streptavidin-coated magnetic beads (DynaBeads 
MyOne C1, Thermo Fisher 65001 / Spherotech SVFM-40-5) were added and incubated with the 
protein mixture at 4°C for 1 hour. The beads were isolated from the solution using a magnet 
stand and washed beads with buffer. 
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Wash buffer recipes: 
o 150 mM NaCl, 50 mM HEPES pH 7.4 
o 1.5 mM KH2PO4, 4.3 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, 1% triton-100 
 
Finally, aliquots were mixed with 2x SDS and proteins were detected by Western blotting with 
antibodies against CLCA1 and TMEM16A. 
4.3.6.3 Alterations on the protocol 
• For in vivo biotinylation, 293T cells can be transfected with Nterm Avitag and mammalian 
BirA constructs (1 µg/106 cells) using 293Fectin. After the transfection, add biotin into the 
cell culture at a final concentration of 5 µM. Incubate cells overnight at 37°C, 5% CO2.  
• The order of lysis, CLCA1 incubation and crosslinking can be changed; i.e. intact cells can 
be incubated with protein, cross-linked and then lysed in buffer.  
• Instead of specifically biotinylating CLCA1, antibodies can be non-specifically biotinylated 
in vitro using EZ-Link NHS-PEG4-Biotin (Thermo Fisher 21330). For the protocol, 
biotinylated antibody addition would be after the step with CLCA1 incubation. 
• Instead of directly boiling beads, the proteins can be eluted off the beads in an elution buffer, 
like 10 mM EDTA pH 8.2. 
• Instead of adding biotinylated CLCA1 onto cells and then adding beads into solution, 
biotinylated CLCA1 can be incubated with the beads and then added onto intact or lysed 
cells. 
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4.3.6.4 Results 
TMEM16A is a 10-transmembrane-domain protein and the co-immunoprecipitation of 
the endogenous channel, especially one with low expression, is a challenging experiment. 
Successful pull-down experiments have been conducted only with heterologous expression of 
tagged TMEM16A proteins (21, 36-39). 
Using the methods described above, I was not successful in co-immunoprecipitating 
endogenous TMEM16A using biotinylated CLCA1 protein in a reproducible manner. 
TMEM16A stuck to the DynaBeads non-specifically, which was not observed with the 
Spherotech beads. Although freshly biotinylated CLCA1 could be loaded onto the Spherotech 
beads successfully, there was no detectable enrichment of the TMEM16A band on the Western 
blot.  
4.3.7 Flow cytometry 
4.3.7.1 Experimental design 
As an alternative to the pull-down experiment, we designed a flow cytometry experiment to 
show a physical interaction between CLCA1 and TMEM16A on HEK293T cell surface. For the 
binding assay, biotinylated recombinant CLCA1 protein was used as a staining reagent. 
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Biotinylated N-terminal CLCA1 was prepared as described above. HEK293T cells were 
plated on a Petri dish. On the day of the experiment, cells were lifted and resuspended in ice-cold 
FACS buffer (1% bovine serum albumin (BSA) in PBS) at 2x106/ml density. Cells were sterile 
filtered through 50 µm and aliquoted into 200 µl samples. 2 µl/sample human Fc receptor (FcR) 
block (Miltenyi Biotech 130-059-901) was added and incubated for 10 minutes on ice. In the 
meantime, biotinylated CLCA1 protein was incubated with streptavidin-coated phycoerythrin 
(SA/PE) (Thermo Fisher S-866) for complexation for 15 minutes at RT at 4:1 mole ratio (Figure 
26A).  Blocking antibodies (Table 6) were added onto the cells at 1:10 dilution and incubated for 
20-40 minutes on ice. Then CLCA-SA/PE complexes were added onto the cells at 1:50 dilution 
and incubated for 1-2 hours on ice in the dark. The same volume of SA/PE reagent was added to 
a sample for background staining assessment. Following the incubation, cells were lightly spun 
down, washed with FACS buffer three times and finally resuspended in 400-800 µl of FACS 
buffer. Samples were analyzed by FACScan instrument and data were analyzed with FlowJo 9.  
Table 6. Blocking antibodies used in flow cytometry assay 
 
 
 
 
 
 
  
Name Catalogue number Epitope 
S20 69343 Santa Cruz TMEM16A loop9-10 
C5 377115 Santa Cruz TMEM16A cytosolic N-term 
G19 9890 Santa Cruz Aquaporin5 
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4.3.7.2 Results 
Staining the cells with CLCA1-SA/PE increased the mean fluorescence intensity (mfi) by 
a 10-100 fold over SA/PE background staining (Figure 26b, green line), which indicated the 
binding of CLCA1 to a target on the surface of HEK293T cells. In the follow-up experiment, 
cells were pre-incubated of with an anti-TMEM16A antibody (S20, epitope within the loop 9-
10). When the CLCA1-SA/PE reagent was added onto these cells, the mfi was higher than 
background SA/PE staining, but significantly lower than CLCA1 staining without antibody in a 
reproducible manner (Figure 26b). Neither of the control antibodies (Table 6) blocked CLCA1 
binding to cell surface (Figure 26c) indicating the blocking effect of the loop antibody was 
specific. This finding suggests CLCA1 might be interacting with the 9-10 loop of TMEM16A on 
cell surface. 
 
 
Figure 26. CLCA1 binds TMEM16A on cell surface. A. model of tetrameric CLCA1 staining reagent 
coupled to SA-PE. B. Histograms showing SA-PE background staining (black line), CLCA1 binding 
(green line) and blocking effect of the antibody (red line). C. Histograms showing SA-PE background 
staining (black line) and negative control antibody with CLCA1 (orange and blue lines). Figure modified 
from Sala-Rabanal et al. (10). 
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4.4 Time course of interaction 
 
The two functional assays that we established, the whole-cell patch clamp and the 
confocal imaging, included an overnight incubation step, which means the cells were exposed to 
CLCA1 for approximately 18 hours to affect TMEM16A. However, if the interaction between 
CLCA1 and TMEM16A is direct, the actual time course of activation, in terms of surface 
staining and currents, should be significantly shorter than 18 hours. 
 
4.4.1 Fixed cell imaging 
 
To determine the minimal amount of incubation time required for robust TMEM16A cell 
surface staining, I incubated naïve HEK293T cells with CLCA1-conditioned media and 
immediately fixed cells at distinct time points (0, 5, 10, 20, 30, 60 and 120 minutes). All the 
samples were fixed and blocked for the same amount of time and the timelines matched up for 
the overnight incubation step with the primary antibody. The samples were co-stained for 
TMEM16A and CLCA1.  
 
In the first round of experiments, 30, 60 and 120-minute time points were assayed. The 
staining results indicate that TMEM16A surface staining is robust within 30 minutes of exposure 
to CLCA1-conditioned media. The difference in fluorescence intensity between 30, 60 and 120 
minutes of incubation was negligible, indicating that a half an hour was enough for CLCA1 to 
act on TMEM16A (Figure 27a). 
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Figure 27. CLCA1 increases TMEM16A staining within minutes. A, Images from cells exposed to 
CLCA1 for 0-120 minutes. B, Images from cells exposed to CLCA1 for 0-30 minutes. Note: panels A and 
B are not on the same scale. 
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In the second round of experiments, I assayed a shorter time window and fixed cells at 5, 
10 and 20-minute time points to compare with the 30-minute time point. Increase in TMEM16A 
surface staining was detectable within 5 minutes of exposure to CLCA1 and comparable in 
intensity to the 30-minute time point (Figure 27b), indicating that the interaction between the two 
molecules and the subsequent increase in surface staining are occurring within a few minutes. 
 
4.4.2 Live cell imaging 
 The results from fixed cell immunohistochemistry indicated that exposure to CLCA1 for 
1-5 minutes was long enough to increase TMEM16A surface staining to robust levels. Based on 
these results, combined with the observation that TMEM16A mRNA and protein levels remained 
the same on a whole cell level, I hypothesized CLCA1 was stabilizing TMEM16A on cell 
surface and blocking the recycling of the membrane protein from cell surface. In order to 
monitor TMEM16A recycling, I used the live cell imaging option of the confocal microscope 
and monitored the cellular trafficking of GFP tagged TMEM16A following CLCA1 treatment. I 
used nocodazole in these experiments as a positive control for blocked trafficking. 
4.4.2.1 Experimental design 
Adherent HEK293T cells were cultured as described previously. Cells were plated on a 
6-well plate and transiently transfected with 1 µg mTMEM16A-GFP or 1 µg CLCA1 (for 
conditioned medium) with 293Fectin according to manufacturer’s instructions. Nocodazole 
(1404, Sigma Aldrich) stock was prepared by dissolving the white powder in DMSO for a stock 
concentration of 2 mg/ml. 24 hours after transfection, mTMEM16A-GPF transfected cells were 
trypsinized and replated on imaging dishes (MatTek P35G-0-14-C) and grown overnight for 
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adherence. 1 hour before the experiment, either the medium was replaced with CLCA1-
conditioned media or 1:100 nocodazole stock (or DMSO as vehicle) was added into the media 
and returned to the incubator. Cells were imaged without any further disturbances with 488 nm 
laser for 25 cycles with 5 s intervals at 63x magnification (+2x digital magnification). 
4.4.2.2 Results 
Untreated cells displayed great mobility of bright green dots corresponding to 
TMEM16A channels both inside the cell and on the cell surface (Figure 28a). The movement is 
not as distinct on the graph for the puncta on cell surface, as the background fluorescence for the 
surface is significantly higher than for the cytoplasm. Cells treated with DMSO vehicle looked 
the same as untreated cells (data not shown). 
 
Following application of nocodazole into the supernatant, the green dots were stationary 
and there was no increase or decrease in the fluorescence intensity (Figure 28b). This indicated 
that the transport of GFP-tagged TMEM16A was stopped in both directions, trafficking to and 
from the membrane, as the trafficking machinery was impaired.  
 
Incubating the cells with CLCA1-conditioned medium did not slow down the 
intracellular trafficking of the green dots, as they retained mobility. However the green 
TMEM16A dots on the cell surface remained stationary throughout the experiment (Figure 28c), 
suggesting that CLCA1 was affecting recycling from the cell surface, but not intracellular 
shuttling to the surface. Results were similar between cells conditioned overnight (data not 
shown) and cells conditioned for 1-2 hours. 
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Figure 28. CLCA1 blocks recycling of TMEM16A from cell surface. Live cell images from t=0 and 
graphs showing change of fluorescence within the colored boxes over the course of the experiment (120 
seconds).  A, Untreated cells. B, Cells incubated with nocodazole for 1 hour. C, Cells conditioned with 
CLCA1 for 1 hour. 
 
A 
B 
C 
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4.4.3 Effect of nocodazole 
 In order to ensure that nocodazole was not disrupting the integrity of the cells, the 
application conditions were mimicked for the whole cell patch clamp assay. Cells treated with 
nocodazole displayed increased currents, somewhat higher than cells conditioned with CLCA1 
(Figure 29). Since the small molecule blocks microtubule polymerization/dynein activity (40), 
which is a trafficking mechanism common to most channels, we hypothesized that the treatment 
would increase surface density of multiple channels and result in significantly high currents. 
Surprisingly, the effect of nocodazole on these currents could be completely blocked by 
transfecting the cells with TMEM16A siRNA (Figure 29), indicating that the increase in currents 
is solely due to increased TMEM16A activity. 
Figure 29. Nocodazole affects TMEM16A currents. Chloride current density measured from cells treated 
with nocodazole  ± TMEM16A siRNA or control RNA.  
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4.5 Summary 
Based on the functional data obtained, we have come up with a model of interaction 
between CLCA1 and TMEM16A (Figure 30): CLCA1 gets expressed as a full-length protein, 
gets secreted and the self-cleavage reaction releases the N-terminal fragment as the functionally 
active portion of the protein. This fragment in the extracellular medium interacts with cells and 
binds the cell surface through TMEM16A. The direct interaction between the two molecules has 
rapid consequences of stabilizing TMEM16A on cell surface within minutes and blocking its 
recycling from the surface, which lead to higher channel surface density and thus higher chloride 
currents. 
 
 
 
 
Figure 30. Proposed model of interaction. Secreted full-length CLCA1 undergoes self-cleavage. The 
released N-terminal cleavage fragment interacts with the CaCC TMEM16A on the cell surface. The direct 
interaction stabilizes the channel on cell surface and blocks recycling. Figure modified from Sala-Rabanal 
et al (10). 
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5 Minimal Domains of Interaction 
The N-terminal cleavage fragment of CLCA1 is the fragment that is necessary and 
sufficient to increase TMEM16A currents. This 70 kDa protein is comprised of three distinct 
domains (the metalloprotease domain, the vWA domain and the BSR domain, see Figure 5) and 
the entire N-term as a recombinant protein construct (22-694) is not stable enough to facilitate 
more detailed structural studies required to gain more insight into the interaction mechanism. In 
addition, TMEM16A is also a large protein (~110 kDa), which presents 5 loops to the 
extracellular space (Figure 23) and any of them could be involved in the interaction with 
CLCA1. In order to identify the minimal domain of CLCA1, I cloned each of the domains 
separately and we tested their effect on TMEM16A by whole-cell patch clamp and 
immunohistochemistry. For the minimal domain of TMEM16A, I took a targeted approach and 
focused on the 9-10 loops based on the results from flow cytometry (section 4.3.7). 
5.1 Minimal domain of CLCA1 
5.1.1 Cloning 
 
CLCA1 N-terminal cleavage fragment is an 80 kDa multidomain protein. In order to 
determine the minimal domain necessary, I cloned the three domain constructs (22-293 for 
metalloprotease, 297-478 for vWA , 483-694 for BSR) separately into pHLsec vector using 
AgeI- KpnI restriction sites.  
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5.1.2 Patch clamp 
 
HEK293T cells were transiently transfected with the three short constructs. 24 hours 
later, cells were trypsinized and replated on UV-sterilized cover slips. Following overnight 
incubation, currents were measured using the whole-cell patch clamp assay. Only the vWA 
domain significantly increased endogenous calcium-activated chloride currents; transfection with 
either the catalytic domain or the BSR domain induced currents comparable to vector-transfected 
cells (Figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. CLCA1 vWA is necessary and 
sufficient to increase TMEM16A surface 
staining and currents. Top panel, Chloride 
current density from cells transfected with 
short N-terminal CLCA1 constructs. Bottom 
panel, confocal microscopy images from cells 
transfected with truncated CLCA1 constructs, 
co-stained for TMEM16A (green) and the 
membrane (blue).    
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5.1.3 Fixed cell confocal 
 
HEK293T cells were transfected with either the full-length CLCA1 or truncated N-
terminal fragment constructs (Nterm 22-694, NV 22-478). 24 hours later, cells were trypsinized 
and replated on chamber slides in 400 µl volume. Following overnight incubation, media was 
aspirated from the slides and cells were immediately fixed. Samples were stained for 
TMEM16A. 
 
 Surface staining was detected with constructs that contained the vWA domain, including 
the full-length, N-term and NV construct. The NV construct contains only the catalytic domain 
and the vWA domain; since TMEM16A staining increased following transfection with NV, I 
concluded that the BSR domain was not necessary for this function, as supported by the patch 
clamp data (Figure 31). Hence, the two short constructs of interest were the catalytic domain and 
the vWA domain. Transfection with the catalytic domain did not increase TMEM16A staining 
above vector control levels (Figure 31), confirming that the vWA domain is necessary and 
sufficient to increase TMEM16A staining. 
 
The time course experiment was repeated with the vWA domain alone (data not shown), 
where supernatant was taken from vWA-transfected cells and incubated with untreated cells for 
5, 10, 20 and 30 minutes. Results were comparable with the previous time course observations 
with full-length CLCA1 and TMEM16A surface staining increased within 5 minutes of 
application. 
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5.1.4 Structural motifs of vWA 
 
Since the vWA domain of CLCA1 was determined to be necessary and sufficient to 
directly interact with TMEM16A, I wanted to test structural motifs within the domain and to see 
whether they play a role in stabilizing CLCA1-TMEM16A interaction on cell surface. 
 
5.1.4.1 MIDAS motif 
 
The metal ion dependent adhesion site (MIDAS) motif is highly conserved among vWA 
domains, it coordinates a divalent cation (usually Mg2+) and it is usually engaged in 
substrate/ligand binding (1-6). The ligand also donates an acidic residue, Asp (1, 7) or Glu (2), to 
coordinate the cation in the interface. The vWA domain of CLCA1 has a perfect MIDAS motif, 
which is significant, as it is not a conserved feature of the CLCA family (Figure 32).  
 
Figure 32. Sequence alignment of CLCA1-CLCA2-CLCA4 within the vWA domain. Identical residues 
are highlighted in magenta and similar residues are highlighted in yellow. Black arrows indicate the 
MIDAS residues. Bold residues within the CLCA2 sequence indicate variations from the perfect MIDAS 
motif of CLCA1.    
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Based on previous literature, even a single mutation within this site is sufficient to 
abrogate ligand binding (1, 8-10). In order to determine if this motif was crucial in mediating 
CLCA1-TMEM16A interactions, the cation coordinating residues Asp312 and Ser314 were 
mutated to Ala (Figure 33).  
 
Figure 33. MIDAS motif in the CLCA1 vWA model. Residues highlighted in red in numbered order are 
the MIDAS residues D312, S314, S316, T383 and D412. Figure was drawn in PyMOL.  
 
 
The mutant vWA was used in the two functional assays and compared against the WT 
vWA protein. In the confocal imaging assay, which is a qualitative assay, the mutant behaved 
exactly the same as WT protein. However in the patch clamp assay, the amplitude of currents 
with mutant vWA is decreased from WT protein, but still higher than background currents 
(Figure 34). These results suggest, that maybe the ligand binding site, i.e. the MIDAS, is not in 
the ideal conformation, but it is not fully inactivated by the two mutations either. 
1 
2 
3 
4 
5 
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Figure 34. The double MIDAS mutant does not completely block CLCA1 function on TMEM16A. Left, 
confocal microscopy images from cells transfected with vWA constructs. Right, chloride current density 
from cells transfected with vWA constructs.   
 
 
There are examples when multiple mutations within the site were necessary to block 
ligand binding (11). Looking at the geometry of divalent cation coordination based on the 
homology model built by Phyre2 (Figure 33), the two mutations I have introduced into CLCA1 
vWA may not be sufficient to completely abrogate cation coordination. So, I have also 
introduced the T383A and the D412A mutations onto the D312A + S314A backbone in the 
vWA. After the constructs were verified with sequencing, I transfected HEK293T cells with the 
triple MIDAS mutants and collected both supernatant and cell lysate 48 hours after transfection. 
I did an anti-6His Western blot to detect protein.  
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Figure 35. Triple MIDAS mutants do not behave like WT vWA in heterologous expression system. Left 
panel, 15 second exposure. Right panel, 15 minutes exposure. Lane 1, supernatant from cells transfected 
with vWA D312A+S314A+T383A. Lane 2, lysate from cells transfected with vWA 
D312A+S314A+T383A. Lane 3, supernatant from cells transfected with vWA D312A+S314A+D412A. 
Lane 4, lysate from cells transfected with vWA D312A+S314A+D412A. Green boxes enclose distinct 
species in the lysate fraction. Red box encloses the protein bands detected in the supernatant 
fraction. 
 
 
 
 
 
 
 
Both constructs got expressed, as shown by the bands in the cell lysate. It should be noted 
that there are three distinct bands, one at the corresponding monomeric weight of the protein and 
two higher order sizes. Although the bands in the lysate could be readily detected with 15 
seconds of exposure, the bands in the supernatant only became visible after exposing the films 
for 15 minutes. In this case, only a single band around 60 kDa was detected in the supernatant 
from both types of mutants; this size would roughly correspond to a trimeric complex (Figure 
35). In the absence of a monomeric protein band in the supernatant, it is reasonable to be 
concerned about protein stability and secretion, both of which are required to use these 
constructs in the functional assays (whole-cell patch clamp and confocal microscopy). 
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5.1.4.2 Divalent cation-free patch clamp 
As a complementary experiment to test the requirement of divalent cations in the 
extracellular medium (including the ones coordinated by CLCA1 MIDAS), we modified the 
whole cell patch clamp conditions where the bath solution contained 1 mM EDTA and 1 mM 
EGTA, instead of 1 mM MgCl2 and 1 mM CaCl2.  
 
Native cells were used as negative control. Treated cells were conditioned with either 
full-length WT CLCA1 or the vWA domain. While currents were activated as expected in the 
normal bath solution containing Mg2+ and Ca2+, in the divalent cation-free buffer the activation 
was not significant over background (Figure 36). Overall cell appearance in this experiment was 
unhealthy; the cells started to shrink and round up a while after EDTA/EGTA application, as the 
Mg2+ and Ca2+, which are necessary for cell adhesion and survival, were being depleted.  
 
Figure 36. Extracellular divalent cations are required for CLCA1-activated currents. Chloride current 
density measured from cells conditioned with either full-length or vWA of CLCA1. Standard: 1 mM 
CaCl2 + 1 mM MgCl2. Divalent-free: 1 mM EDTA + 1 mM EGTA.   
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5.1.4.3 Divalent-free confocal 
When I used the conditions of the patch clamp experiment explained above in the context 
of confocal microscopy, I observed that cells exposed to media containing EDTA/EGTA even 
briefly (~15 mins) were starting to round up and showed signs of different morphology. Under 
these conditions, the experiment could not be completed. 
5.1.4.4 S357N mutant 
 
The S357N variant of CLCA1 was identified as a SNP in a clinical CF study. When the 
patients were ranked according to severity of CF, the frequency of this single nucleotide 
polymorphism (SNP) was found directly correlated with severity (12).  
This point mutation falls within the vWA region of CLCA1. Since we knew that the 
vWA domain was the functional part in terms of CaCC activation, I hypothesized that this SNP 
might have a role in blocking the interactions between CLCA1 and TMEM16A.  
The mutation was introduced using Quikchange Lightning Mutagenesis kit according to 
manufacturer’s instructions. S357N mutation within the vWA did not change the effect of the 
recombinant protein on TMEM16A activity as assayed by whole cell patch clamping and 
confocal microscopy (Figure 37). 
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Figure 37. S357N SNP does not affect CLCA1 function on TMEM16A. Left, confocal microscopy 
images from cells transfected with vWA constructs. Right, chloride current density from cells transfected 
with vWA constructs ± TMEM16A siRNA. 
 
 
 
5.2 Minimal domain of TMEM16A 
 
The last extracellular loop of TMEM16A (loop 9-10) is the most likely region of 
extracellular interaction with CLCA1, as it is the largest surface exposed to the extracellular 
matrix by the channel – all the other loops are much shorter, which reduces the likelihood of a 
functional surface. Also, the epitope of the blocking antibody used previously in the flow 
cytometry assay is within this loop (Figure 26b), further strengthening the hypothesis that the 
interaction is localized to this loop. 
 
CLCA 
 
 
TMEM16A 
 
 
MERGE 
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5.2.1 Biolayer interferometry 
 
Proteins were expressed and purified from mammalian cells as described. In vitro 
biotinylation was carried out with recombinant BirA ligase. Running buffer for the biolayer 
interferometry (BLI) experiment contained 20 mM HEPES pH 7.4, 150 mM NaCl, 0.05% 
TWEEN-20 and 1 mg/ml BSA. The detergent was added to wash off substrates more easily and 
BSA was added to reduce non-specific substrate binding to the pins. For a single kinetic assay 
(~1.5 hours), final volume in 96-well plate (655209, Greiner Bio-One) was 250 µl; for longer 
assays (up to three hours), the volume was increased to 300 µl. Both the loading proteins and the 
substrates were diluted in running buffer at the desired concentrations.  
 
Streptavidin (SA) pins (18-5020 ForteBio) were equilibrated in running buffer prior to 
the kinetic assays using SideKick (ForteBio). Biotinylated protein was loaded (loading signal 
should be around 1 nm) and pins were equilibrated in running buffer. Then, pins were dipped 
into substrate containing wells, starting at the lowest concentration. Pins were washed and 
equilibrated between each substrate dilution. To account for non-specific binding to the pin, a 
pin-only control experiment was performed without loading any biotinylated protein. To account 
for buffer-specific effects, a buffer control experiment was performed with the flow-through of 
the substrate. The experiment was carried out on an Octet instrument using Data Acquisition 
software. Data are analyzed with Data Analysis 8.2 software using the double reference mode.  
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5.2.2. Loop binding experiments 
To determine whether the interaction between vWA and the loop can be recapitulated in 
vitro, I designed a biolayer interferometry experiment, where the biotinylated vWA protein is 
loaded onto streptavidin (SA) pins and is incubated in the well containing the purified loop 
peptide as the substrate (at 2 µM, 4 µM, and 10 µM concentrations). While there was some 
observed non-specific binding to the pins, there was also a dose-dependent response, indicating 
binding to the vWA protein on the pin. After the double reference subtraction, there was a net 
binding signal (Figure 38). 
 
Figure 38. CLCA1 vWA domain can bind TMEM16A loop in vitro by BLI. Top panel; raw binding data 
with buffer only and pin only controls. Green line, pin only in buffer. Cyan line, pin only in substrate. 
Red, vWA on the pin in buffer. Blue, vWA on the pin in substrate. Middle panel; net binding data after 
double-reference subtraction. Bottom panel; association curves fit to a global model. Substrate 
concentration: blue 2 µM, red 4 µM, and cyan 10 µM. 
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5.2.3 Small peptide fragmentation 
To further narrow down the region of interaction within the 9-10 loop, we ordered small 
segments (20 aa) of the loop as custom peptides (GenScript) for use in BLI (Table 7). The 
peptides were dissolved in water (+5% DMSO) and used as substrates. Binding of vWA to 
peptides was assayed for all 5 samples, 10-100 µM. Peptides 1-4 interacted with the pin non-
specifically and the double subtracted data indicated no binding was occurring to the vWA 
protein (Figure 39a). Peptide 5 did not interact with the pin or the vWA protein (Figure 39 b).  
TABLE 7. List of small peptide fragments synthesized based on the 9-10 loop sequence of hTMEM16A.  
Peptide+ Sequence+ MW+(g/mol)+ pI+
1! TSDFIPRLVYLYMYSKNGTM! 2399.8! 8.10!
2! KNGTMHGFVNHTLSSFNVSD! 2192.3! 6.92!
3! FNVSDFQNGTAPNDPLDLGY! 2184.3! 3.42!
4! LDLGYEVQICRYKDYREPPW! 2543.8! 4.78!
5! REPWSENKYDISKDFWA! 2268.4! 4.78!
 
As shown in Figure 39, no net binding signal to the vWA protein could be obtained with 
the peptides in the wells, largely due to non-specific binding to the pins themselves. Another way 
of conducting this experiment would be to reverse the initial experiment setup, where 
biotinylated loop peptide would be on the pin and the vWA domain would be in the wells and 
treated as a substrate. In this context, the small peptides could be spiked into the substrate wells, 
where they could compete for vWA binding to the pin.  
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Figure 39. Small peptides do not bind vWA in vitro. Representative raw kinetic data from vWA binding 
to peptides. Top panel, peptide 1 as representative non-specific binder. Bottom panel, peptide 5 as 
representative non-binder. Left column, raw binding data. Middle column, pin-only controls are 
subtracted. Right column, pin-only and buffer-only controls are subtracted. Green line, pin only control in 
buffer. Red line, pin only control in substrate. Cyan line, vWA on the pin in buffer. Blue line, vWA on 
the pin in substrate. 
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5.3 Summary 
The vWA domain of CLCA1 is the necessary and sufficient unit that directly interacts 
with TMEM16A on cell surface. The interaction is likely localized to the last extracellular loop 
of TMEM16A (9-10 loop), which is the largest surface the channel is presenting to the 
extracellular space. The MIDAS motif within the vWA might play a role in mediating the 
protein-protein complex, as mutations within the site decrease TMEM16A currents significantly. 
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6 Implications for airway disease  
6.1 History of CLCA Proteins 
The involvement of CLCAs in airway diseases was first reported by Zhou et al., where 
mCLCA3 and its homologue hCLCA1, which cannot be detected in the lungs under normal 
conditions, were selectively induced by Th2 cytokines (IL-4, IL-9, IL-13) in mouse and human 
cellular models of asthma, respectively (1). Manipulation of gene expression showed that siRNA 
knockdown decreased MCM and AHR (2), while overexpression induced MUC5AC expression 
and MCM (2-5), implying a critical role for CLCA function in inflammatory mucus production. 
Consistent with these observations, DNA vaccines and antibodies targeting CLCA (6-8) have 
displayed some effectiveness in reducing airway inflammation and MUC5AC levels in mouse 
asthma models (9). 
CLCA proteins have been ascribed various functions, starting with lung-specific cell 
adhesion molecules in the early 1990’s (10, 11), followed by calcium-activated chloride channels 
in the late 1990’s (12, 13). While it has been repeatedly confirmed that heterologous expression 
of CLCA results in calcium-activated chloride currents, previous hydropathy algorithm 
predictions of multiple transmembrane domains (TMD) within these proteins (10, 12-15) were 
clearly incorrect. More accurate bioinformatics approaches developed in the 2000’s predicted 
that CLCAs were shown to be not integral membrane proteins, but soluble secreted proteins, and 
these predictions were further supported with biochemical methods (16, 17). The nomenclature 
was revised and CLCAs are now referred to as calcium-activated chloride channel regulator 
proteins. Thus started the mystery of how CLCA as a secreted soluble protein could influence 
calcium-activated chloride currents.  
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An additional mystery surrounding the CLCA family arose from the observation that 
these secreted proteins were recovered from the extracellular medium in two cleavage fragments. 
Analysis of the bronchoalveolar lavage fluid (BALF) from asthmatic patients and ovalbumin-
challenged mice revealed that hCLCA1 and mCLCA3, which were not detected in control 
samples, were abundant in the supernatant at a molecular weight corresponding to a truncated 
protein fragment (~70 kDa), as opposed to the full-length protein (~110 kDa) detected in cell 
lysates (16). The nature of the proteolytic cleavage, the identity of the enzyme responsible and 
how this cleavage affected CLCA function were unknown.  
When CLCAs were first implicated in airway disease, they were thought to carry out the 
function of CaCC in the airways, but as soluble ion channel regulators, it was not clear how 
CLCA signaling could contribute to MCM. It is further possible to hypothesize that CLCAs have 
two distinct functions as signaling molecules that drive MCM and as CaCC regulators. 
6.2 A Brief History of TMEM16A 
The molecular identity of CaCC in the airways remained elusive for a long time, as 
previous candidate genes CLCs, Bestrophins and CLCAs were disproven to be CaCC one after 
the other (summarized in Caputo et al. (18)). The bonafide CaCC TMEM16A was finally 
identified in 2008 by three separate research groups; Schroeder et al. identified xTMEM16A as 
the Xenopus oocyte CaCC using Axolotl oocytes as an expression system (19). Yang et al. 
isolated mTMEM16A cDNA from mouse eye and showed that heterologous expression of this 
gene in HEK293T cells recapitulated previously observed characteristics of the endogenous 
CaCC (20). Caputo et al. identified hTMEM16A as the membrane protein that was differentially 
expressed in bronchial epithelial cells stimulated with IL-4 (18), a Th2 cytokine like IL-13 (21).  
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The name of the family, TMEM16, denotes the family as a group of transmembrane 
proteins with unknown function 16. Based on the prediction that these proteins contained 8 
TMDs (18), together with the observation that family members generated anion channels, the 
family was given the second name of Anoctamins. This name is now controversial, as the CaCC 
activity has only been definitively shown for TMEM16A and TMEM16B, while other members 
function as lipid scramblases and/or non-specific cation channels (22). The predicted 8-TMD 
topology of the channels has also been revised, since the crystal structure of fungal nhTMEM16 
displayed 10 TMDs and this topology appears to be conserved in mammalian orthologues by 
sequence analysis (23). 
Expression of TMEM16A in the airways is regulated by Th2 cytokines IL-4 and IL-13 
(24). This membrane protein is expressed in airway smooth muscle cells and goblet cells in the 
airway epithelium, where it is implicated in AHR (25) and MCM (26). While the purified protein 
can function on its own as a homodimeric channel (27, 28), identification of TMEM16A 
regulators under pathophysiological conditions is an area of active investigation. Various 
proteins and small molecules (Mw < 900 Da) including calmodulin, ezrin, radixin, moezin and 
PIP2 have been proposed to interact with TMEM16A (29-31) , but these interactions are 
localized to the cytoplasm and there had been no reports of an extracellular protein regulator of 
TMEM16A activity until this study. 
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6.3 Contributions of this Study 
The work carried out in this dissertation represents a detailed study of CLCA1 structure 
and function, using biochemistry, biophysics, cell biology, electrophysiology and structural 
biology as tools. The experiments answer questions pertaining to the nature of CLCA proteolytic 
cleavage and the link between this enzymatic reaction and CLCA function as a CaCC regulator. 
In addition, this study directly identifies TMEM16A as the channel regulated by CLCA1, as well 
as giving mechanistic insight into how CLCA1 modulates currents through the channel. 
The first chapter provides an introduction into MCM and how CLCA is involved in 
chronic inflammatory airway diseases as a signaling molecule, while the importance of ion 
currents in mucociliary clearance is highlighted. The second chapter focuses on hCLCA1 
structural organization as predicted by fold recognition servers and describes the protein 
expression and purification system designed for structural studies of CLCA1. These expression 
experiments are significant to the study, as the distinct secreted domains disprove the previous 
hypothesis of multiple TMDs and indicate the presence of a zincin metalloprotease in the unique 
N-terminal domain of CLCA1. 
The third chapter investigates the hypothesis that there is an N-terminal metalloprotease 
using an array of in vivo and in vitro assays, which confirm the presence of a zinc-dependent 
metalloprotease that is responsible for the proteolytic cleavage of CLCA proteins. This 
conserved feature of the family enables cross-reactivity between the human CLCA proteins and 
enables two proteins to interact for the intermolecular cleavage reaction to occur.  
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The fourth chapter elucidates the role of CLCA1 as a CaCC regulator and identifies the 
target CaCC as TMEM16A. Self-cleavage of CLCA1 is required for channel activation, as the 
full-length uncleaved mutant CLCA1 proteins, either with a disabled catalytic site or with an 
unrecognizable cleavage sequence, were unable to increase currents over background levels. 
Following secretion and self-cleavage, the N-terminal cleavage fragment in the extracellular 
medium can directly interact with TMEM16A expressed on neighboring cells. The direct 
interaction between the two molecules stabilizes plasma membrane-associated TMEM16A, 
which otherwise is recycled across the membrane quickly enough that surface levels of 
TMEM16A are too low to be detected by immunohistochemistry. As a result of this stabilization, 
surface density of TMEM16A is increased, which leads to the higher currents induced by 
CLCA1. Two manuscripts resultsing from this work detail CLCA1 self-cleavage and the 
mechanism of TMEM16A activation (32, 33). These results highlight a novel mechanism for ion 
channel regulation, where secreted protein CLCA1 is the first direct protein modifier of 
TMEM16A activity. 
The fifth chapter investigates the minimal interacting domains of CLCA1 and 
TMEM16A. The distinct domains within the N-terminal cleavage fragment were separately used 
in the functional assays, which revealed that the vWA domain of CLCA1 is necessary and 
sufficient to interact with TMEM16A to increase currents. Preliminary direct binding assays 
using biolayer interferometry, supported by the blocking antibody in the flow cytometry 
experiment, suggest that vWA binds the C-terminal loop of TMEM16A (9-10 loop), which is 
roughly 70 residues long. The MIDAS motif within the vWA domain is potentially important for 
mediating CLCA1-TMEM16A interactions. The potential structural features within the loop that 
contribute to the interaction need to be investigated further. 
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6.4 Future Directions 
This is the first study that has linked CLCA and TMEM16 family of proteins, not just by 
physical association, but also by functional association. While further studies will be needed to 
determine whether CLCA1-TMEM16A interaction is involved in airway physiology, or whether 
defective interactions might play any role in disease phenotypes such as like MCM, potential 
functional interactions between other family members should also be investigated. Both CLCA 
and TMEM16 family members display great variability in their tissue expression patterns in 
mammalian organisms (22, 34), which could indicate tissue- and disease-specific CLCA-
TMEM16 pairings, similar to CLCA1-TMEM16A in chronic inflammatory airway diseases.  
Based on the data obtained in this study, CLCA1 seems to carry out two distinct functions 
in the airways: on one hand, CLCA1 is required for MUC5AC expression, and contributes to 
MCM. From this perspective, secreted CLCA1 can be considered an accessible drug target for 
asthma and COPD. Unpublished experiments conducted outside of this thesis suggest that self-
cleavage of CLCA1 is required to induce MUC5AC in cells (Dr. Tom Brett, unpublished 
observations). These results implicate the CLCA1 metalloprotease in the signaling function. 
Further structural studies are needed to determine the geometry of the enzyme and to guide 
structure-based drug design towards MCM therapeutics. On the other hand, CLCA1 is a 
regulator of TMEM16A, which is a chloride/bicarbonate channel, similar in its ionic 
permeability function to CFTR. The direct interaction between CLCA1 and TMEM16A results 
in increased chloride currents, which could be beneficial in a CF setting by rescuing the 
diminished ion gradient to improve mucus hydration and mucociliary clearance. It is specifically 
the vWA domain of CLCA1 that is necessary and sufficient to carry out this particular function. 
This minimal domain can be manipulated separately from the full-length CLCA1 to alleviate CF 
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symptoms in the airways. Judging from these complex functions, the concentration of CLCA1 in 
the airways is likely a major determinant for the fate of airway mucus and pathophysiology, as 
the self-cleaved protein is secreted and can affect airway epithelia in a paracrine fashion once 
disseminated within BALF. 
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APPENDIX 
Self-cleavage of Human CLCA1 Protein by a Novel Internal
Metalloprotease Domain Controls Calcium-activated
Chloride Channel Activation*□S"
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Background: CLCA proteins activate CaCCs; CLCAs have roles in cancer and inflammatory lung diseases, but their
mechanism of action is unknown.
Results: CLCA proteins must undergo self-cleavage via their own novel metalloprotease domain in the N terminus to activate
CaCCs.
Conclusion: Self-cleavage unmasks the N-terminal fragment, which alone activates CaCCs.
Significance: This work identifies a unique ion channel activation mechanism defining framework to understand CLCA
functions in diseases.
The chloride channel calcium-activated (CLCA) family are
secreted proteins that regulate both chloride transport and
mucin expression, thus controlling the production of mucus in
respiratory and other systems. Accordingly, human CLCA1 is a
critical mediator of hypersecretory lung diseases, such as
asthma, chronic obstructive pulmonary disease, and cystic
fibrosis, that manifest mucus obstruction. Despite relevance to
homeostasis and disease, the mechanism of CLCA1 function
remains largely undefined.We address this void by showing that
CLCA proteins contain a consensus proteolytic cleavage site
recognized by a novel zincin metalloprotease domain located
within the N terminus of CLCA itself. CLCA1 mutations that
inhibit self-cleavage prevent activation of calcium-activated
chloride channel (CaCC)-mediated chloride transport. CaCC
activation requires cleavage to unmask theN-terminal fragment
of CLCA1, which can independently gate CaCCs. Gating of
CaCCs mediated by CLCA1 does not appear to involve proteo-
lytic cleavage of the channel because a mutant N-terminal frag-
ment deficient in proteolytic activity is able to induce currents
comparablewith that of the native fragment. These data provide
both a mechanistic basis for CLCA1 self-cleavage and a novel
mechanism for regulationof chloride channel activity specific to
the mucosal interface.
The chloride channel calcium-activated (CLCA)3 proteins
are a complex family targeted for a role in cancer (1, 2) and
inflammatory diseases (3) but are poorly understood in terms of
molecular structure and function. The original annotation of
this family as calcium-activated chloride channels (CaCCs) was
based on the observation that overexpression of several differ-
ent CLCA paralogues from various species all induced chloride
current in response to cytosolic calcium flux (4, 5). However,
bioinformatic (3) and experimental data (6–8) indicate that
CLCA proteins generally lack essential features to form ion
channels by themselves as they either contain only a single
transmembrane anchor or are fully released in soluble form.
Indeed, a recent study provides strong evidence that human
CLCA1 functions as a secreted factor that increases the activity
of other proteins that act as endogenous CaCCs (9).
Significant interest in CLCA proteins stems from their asso-
ciation with human disease. CLCA1 has been linked to the
pathogenesis of human asthma and chronic obstructive pulmo-
nary disease; CLCA1 expression is significantly increased in the
airways of these types of patients (6), and polymorphisms in the
CLCA1 gene have been reported in a subset of patients with
asthma (10) and chronic obstructive pulmonary disease (11). In
animal models of these diseases, the mouse and horse ortho-
logues of CLCA1 were shown to be necessary and sufficient for
driving increased mucus production (12–15). Most impor-
tantly, there is evidence that CLCA1 stimulates an increase in
mucus production by initiating a MAPK signaling pathway to
express mucins (the major protein component of mucus) in
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humans, a pathway that is highly activated in humans with
chronic obstructive pulmonary disease (16). Understanding the
mechanism of CLCA function in signaling for mucus overpro-
duction could lead to effective anti-mucus therapies.
Other studies suggest that CLCAproteins are also associated
with the pathogenesis of cystic fibrosis (CF); mutations in the
cystic fibrosis transmembrane conductance regulator (CFTR),
a chloride channel found in the apical membranes of mucosal
epithelial cells, disrupt normal chloride transport, resulting in
insufficiently salted and hydrated mucus. Fatal intestinal dis-
ease found in CFTR-deficient mice, however, is corrected by
overexpression of native mouse CLCA3 (an orthologue of
human CLCA1) (17). Consistent with this observation, a muta-
tion in the CLCA1 gene is found in a subset of CF patients with
more severe intestinal disease (18). These studies indicate that
CLCA1 may function to alleviate CFTR deficiency symptoms
by increasing endogenous CaCC activity and compensating for
defective CFTR-mediated chloride transport. To that end, an
understanding of the mechanism of activation could also be
exploited to produce effective CF therapies.
In the present study, we aimed to better understand CLCA1
function with an analysis of CLCA processing. We recognized
that proteolytic processing is critical to signaling function for
other proteins (19) and that CLCA proteins are uniformly sub-
jected to proteolytic cleavage within the secretory pathway to
yield N- and C-terminal CLCA fragments of !70 and 38 kDa,
respectively (3). Here, using a combination of sequence analy-
sis, structure prediction, and biochemical, biophysical, and
electrophysiological techniques, we demonstrate that all CLCA
proteins contain a consensus cleavage motif, which is recog-
nized by a novel zincin metalloprotease domain located within
the N terminus of CLCA itself. In addition to self-proteolysis,
we also demonstrate that CLCA paralogues are capable of
cross-proteolysis. Finally, we demonstrate that this self-cleav-
age event is a required step for CLCA1-based activation of
CaCCs, which is mediated solely through the N-terminal frag-
ment. Taken together, these data support a paradigm of CLCA
activation through self-proteolysis to unmask an N-terminal
fragment capable of gating CaCCs.
EXPERIMENTAL PROCEDURES
Expression Constructs—Constructs were generated using
standard PCR andmolecular biology techniques. All constructs
were verified byDNAsequencing. For determination of proteo-
lytic cleavage sites, full-lengthmature-formCLCAproteins (i.e.
without their endogenous signal sequences) were cloned into
the pHLsec vector (20) containing an optimized signal
sequence and C-terminal hexahistidine tag. Soluble CLCAs
were designed by omittingC-terminalmembrane anchors from
those CLCAs that contain them (i.e. human CLCA2, human
CLCA4, mouse CLCA4). Specifically, constructs contained the
following residues: CLCA1 22–914; CLCA2 32–899; CLCA4
22–876;mouseCLCA3 22–913;mouseCLCA4 22–897.Muta-
tions were introduced into the full-length CLCA1 pHLsec con-
struct using Phusion mutagenesis (New England Biolabs) for
mutational analysis of the cleavage site and predicted active site
residues. Full-length CLCA1 and select mutants containing the
optimized signal sequences were subcloned from pHLsec con-
structs into the pCDNA3.1 expression vector (Invitrogen). A
dual-tagged CLCA1 construct in pCDNA3.1 was made by
inserting a FLAG tag directly after the signal sequence and a
hexahistidine tag at the C terminus of the protein. Mammalian
cell expression constructs encompassing the protease and
VWA domain of CLCA1 (22–477), CLCA2 (32–455), and
CLCA4 (22–459) as well as the substrate region (285–915) of
CLCA1 were cloned into pHLsec with C-terminal hexahisti-
dine tags. A tag-free bacterial expression construct composed
of the protease and VWA domain of CLCA1 (22–477) was
cloned into pET23b. Mammalian expression constructs of
CLCA1 N-terminal fragment (22–695) and C-terminal frag-
ment (696–915)were cloned into the pHLsec vector containing
an optimized signal sequence and C-terminal hexahistidine tag
(20).
Protein Expression and Purification—Proteins in mamma-
lian expression vectors were expressed by transient transfec-
tion of FreeStyle 293F cells using 293Fectin cultured in serum-
free FreeStyle 293 media (Invitrogen). Culture supernatants
were collected 72 h after transfection, and proteins were puri-
fied to homogeneity using nickel affinity chromatography.
CLCA1 22–477 was expressed in Escherichia coli as insoluble
protein that was recovered from inclusion bodies, denatured in
6 M guanidine hydrochloride, and refolded by rapid dilution
into buffer consisting of 50mMTris, pH 8.5, 400mM arginine, 5
mM reduced glutathione, 0.5 mM oxidized glutathione, 10 mM
CaCl2, 0.1mMZnCl2. The resulting soluble proteinwas purified
by gel filtration followed by ion exchange chromatography. The
protein was well folded as assessed by circular dichroism.
Determination of Proteolytic Cleavage Sites by Edman
Degradation—Full-length CLCA proteins were expressed by
transient transfection of FreeStyle 293F cells as described
above. Culture supernatants were collected 72 h after transfec-
tion, and C-terminal fragments were captured and purified
using nickel affinity chromatography. C-terminal fragments
were isolated by SDS-PAGE and membrane transfer and then
analyzed by N-terminal sequencing (Edman degradation) to
determine the site of proteolytic cleavage. The first 5 residues
were identified in each case. Additionally, intracellular process-
ing of CLCA1 was assessed by immunoprecipitating the C-ter-
minal fragment from the lysates of washed lung epithelial H292
cells transfected with a CLCA1-expressing adenovirus. Isola-
tion and analysis were performed as described above.
Sequence Analysis—CLCA sequences and naming were
based on recent nomenclature as recently reviewed (3).
Analysis of Proteolytic Processing of Wild-type and Mutant
CLCA1—Mutants were expressed in 293F cells as described
above. Culture supernatants and cell lysates were collected 72 h
after transfection and analyzed byWestern blot using antibod-
ies that recognize either the N-terminal fragment (anti-N-
CLCA1 mAb 8D3; epitope region: 477–695) or the C-terminal
fragment (anti-His6 antibody, Bethyl Laboratories). Processing
of the dual-tagged hCLCA1 construct was analyzed using anti-
FLAG antibody (M2mAb, Sigma) in addition to the other anti-
bodies. To test the CLCA1 tobacco etch virus (TEV)mutant for
cleavage by exogenously added TEV protease, transfection was
carried out as above followedby the addition ofTEVprotease to
the culturemedium (to a concentration of 0.2mg/ml) 48 h after
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transfection. Samples were collected after 72 h after transfec-
tion and analyzed as above.
Proteolytic Digestion Assays—Purified protease (CLCA1
22–477, CLCA2 32–455, and CLCA4 22–459) and substrate
(CLCA1 285–915) were produced as described above. Diges-
tion experiments were carried out by incubating substrate (0.5
!M) and protease (2.0 !M) in 100 !l of digestion buffer (20 mM
Hepes, pH 7.5, 150 mM NaCl, 10 mM CaCl2, 10 !M ZnCl2) at
37 °C for 18 h with samples taken at discrete time points and
analyzed by SDS-PAGE/Western blot using the anti-CLCA1
mAb 8D3. Digestion experiments in the presence of inhibitors
were carried out with GM-6001 (Millipore), Marimastat (Toc-
ris), Batimastat (Tocris), or Zeynepstat001 at 40 !M or Halt
(Thermo) at 1! concentration. All inhibitor stocks were dis-
solved in dimethyl sulfoxide (DMSO).
Fluorogenic CLCA1 Peptide Digestion Assays—A fluorogenic
peptide substrate consisting of a donor-acceptor FRET pair
conjugated to the human CLCA1 cleavage sequence was syn-
thesized by AnaSpec (DABCYL-QQSGALYIPG-EDANS).
Experiments were carried out at 37 °C in the digestion buffer
described above. Reaction progress was monitored using a
BioTek plate fluorometer (excitation, 340 nm; emission, 490
nm). Refolded CLCA1 (22–477) was used as the protease. For
reactions in the presence of inhibitors, [protease] " 10 !M,
[substrate] " 3.25 !M, and [inhibitor] " 20 or 40 !M, respec-
tively. Experiments were conducted in triplicate.
Chemical Synthesis of a Custom MMP Inhibitor—Synthesis
of Zeynepstat001 is described in the supplemental material.
Heterologous Expression for Electrophysiology—Mutations
predicted to interfere with the metalloprotease activity of
CLCA1 (H156A, E157Q) or a disrupted cleavage site (contra)
were generated using the pCDNA3.1 expression vector; cDNAs
encoding the N-terminal or C-terminal fragments of CLCA1
were cloned into pHLsec, as described above. HEK293T cells
were plated in 6-well dishes and cultured in Dulbecco’s modi-
fied Eagle’s medium (Invitrogen) supplemented with 10% fetal
bovine serum, 105 units/liter penicillin, and 100 mg/liter strep-
tomycin. At 80% confluency, cells were transfected with the
relevant plasmids using 293Fectin transfection reagent at a 1!g
of DNA to 2 !l of 293Fectin ratio, and the amount of DNA per
well was kept constant at 2 !g. For identification of expressing
cells, 1% of EGFP-pCDNA3.1 plasmid was added to all trans-
fection mixtures. 24 h after transfection, cells were trypsinized
and replated at low density on glass coverslips. Expression of
wild-type (WT), mutant, and fragment proteins was confirmed
byWestern blot of culture supernatants 48 h after transfection,
as described above.
Whole-cell Patch Clamp Recordings—Experiments were per-
formed at 25 °C, 48–72 h after transfection. Cells that fluo-
resced under ultraviolet light were selected for analysis.
Micropipettes were prepared from nonheparinized hematocrit
glass (Kimble-Chase) on a horizontal puller (Sutter Instrument)
and filled to a typical electrode resistance of 2 megaohms with
pipette solution containing 126 mM choline chloride, 10 mM
Hepes and 10mMEGTA, in the absence or presence of 9.95mM
CaCl2 to attain 10 !M free Ca2#, as calculated by means of the
CaBuf program (available through KU Leuven). The standard
extracellular solution contained 126 mM NaCl, 10 mM Hepes,
30mM sucrose, 2mMCaCl2, and 2mMMgCl2. To determine the
background currents, the cells were superfused with a Cl$-free
solution containing 126mMNa# gluconate, 10 mMHepes, 10.5
mM sucrose, 7 mM Ca2# gluconate, and 3.5 mM Mg2# gluco-
nate. The pH of all solutions was adjusted to 7.4 with Tris. After
formation of a gigaohm seal and establishment of whole-cell
configuration, cells were voltage-clamped at $80 mV. A pulse
protocol was applied in which membrane potential (Vm) was
held at$80 mV for 500 ms and stepped to a test value for 1000
ms before returning to the holding potential for an additional
500 ms. The test potential varied from$100 to#80 mV in 20
mV increments. Currents were measured at the end of the
1000-ms voltage pulse. Membrane capacitance was calculated
from the integral of the current transient in response to 10-mV
depolarizing pulses and wasmonitored for stability throughout
the experiment. Data were filtered at 2 kHz, and signals were
digitized at 5 kHz with a Digidata 1322A (Molecular Devices).
Axoscope and pClamp software (Molecular Devices) were used
for pulse protocol application and data acquisition. Data were
analyzed using Clampfit (version 10.1, Molecular Devices) and
Excel (Microsoft). SigmaPlot 10.0 (Systat Software) and Corel-
DRAWX3 13.0 (Corel Corp.) were used for statistics and figure
preparation. Results are presented as mean % S.E., and
unpaired Student’s t test was used to evaluate statistical differ-
ences between groups.
RESULTS
CLCA Proteins Share a Common Cleavage Site—Proteolytic
processing plays a central role in almost all biological networks,
and dysregulation is implicated in a broad range of diseases
(19). With this in mind, we sought to investigate the role of
proteolytic processing in CLCA protein function. Mammals
express 4–8CLCA familymembers, predominantly atmucosal
surfaces. All CLCAs have been observed to undergo proteolytic
processing when expressed in mammalian cells; the protein
gets cleaved into two fragments of&70 kDa of the N terminus
and 38 kDa of the C terminus (3).We reasoned that elucidation
of the cleavage sitemight allow for identification of the protease
responsible for this activity. To facilitate this analysis, we gen-
erated tagged soluble expression constructs of the three human
CLCA proteins (CLCA1, CLCA2, and CLCA4), as well as two
mouse CLCAs (CLCA3 and CLCA4), and expressed each of
them in mammalian cells (Fig. 1A). Cleavage sites were deter-
mined by amino-terminal sequencing of secreted C-terminal
fragments from media supernatants. All five of the CLCA pro-
teins were cleaved at a common site (Fig. 1B). Because our data
and previous studies indicated that CLCA proteins are pro-
cessed intracellularly (7, 8, 21, 22), we also analyzed CLCA1
retrieved from cell lysates to investigate the possibility of
sequential processing. This sample displayed the same cleavage
site as the fully secreted proteins found in supernatants. Anal-
ysis of all known CLCA sequences from higher mammals
reveals a high degree of conservation in this region (Fig. 1B),
consistent with a consensus cleavage sequence shared among
CLCA family proteins (Fig. 1C) and a common protease, or
family of proteases, responsible for CLCA cleavage.
To verify the location of the cleavage site, we tested the effect
of mutations to the experimentally determined cleavage site
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sequence on proteolytic processing of CLCA1 (Fig. 2A). A point
mutation (A696P) or variations that matched the cleavage
sequence in other CLCAs (CLCA2 and CLCA4) did not affect
proteolytic cleavage of CLCA1; in contrast, variations that sig-
nificantly altered the consensus sequence (contra, TEV) abol-
ished proteolytic processing (Fig. 2B). These mutations did not
grossly affect protein folding as all variant proteins were
robustly secreted into the media supernatants. Furthermore,
TEV protease added to cultures expressing the TEV CLCA1
variant, in which the TEV protease cleavage site replaced the
consensus site, was not cleaved either (Fig. 2C), suggesting that
the cleavage site is not surface-exposed to exogenous proteases
and may only be accessible to the internal metalloprotease
domain in the natively folded full-length protein. Taken
together, these results pinpoint the location of the proteolytic
cleavage site in CLCA proteins and imply that a common pro-
tease with specific access to the site is responsible for cleavage
of all human CLCA proteins.
Proteolytic Processing of CLCARequires Catalytic Residues in
a Predicted Zincin Metalloprotease Domain—Extensive bioin-
formatic searching of the MEROPS protease database (23)
using the CLCA consensus cleavage sequence did not provide
any reasonable candidates for the protease responsible for
cleaving CLCA familymembers. Thus, we decided to revisit the
untested hypothesis that theN-terminal CLCA-Ndomain itself
houses a metalloprotease domain similar to that of matrix met-
alloproteases (MMPs) (24). Indeed, when various CLCA-N
domain sequenceswere submitted to the updated PHYRE2 fold
prediction server (25), most predictions were high-confidence
hits to zincin metalloprotease catalytic domains.
The CLCA-N domain contains 8 cysteine residues that are
invariant across all family members (3). With 2 of these cys-
teines lying in the predicted catalytic region (amino acids
22–199) (Fig. 3C) and 6 in an adjacent cysteine-rich domain
(amino acids 200–283) (26) (Fig. 3A), it is most likely that the
CLCA-N domain is architecturally similar to the ADAM or
ADAMTS family of zinc metalloproteases, rather than MMPs.
Like the CLCA-N domain, ADAM and ADAMTS contain
disulfide bonds in their catalytic regions (Fig. 3A) (27). The
catalytic domains of zinc metalloproteases contain a common
HEXXHXXGXXH motif, which includes the catalytically
required glutamate (bold) and zinc-chelating residues (3 histi-
dine residues) (27). CLCA sequences in the predicted catalytic
region are almost completely invariant and reveal a similar but
unique catalyticmotif: HEXXHXXXGXXDE (Fig. 3C). Previous
studies have reported that mutations of Glu-157 in human
CLCA1 (24), murine CLCA3 (28), and murine CLCA6 (29) to
Gln all produce mutant proteins that are not proteolytically
processed. However, the significance of these results is difficult
to interpret as these studies probed the protein from crude cell
lysates. The observed lack of cleavage could have been due to
loss of the catalytically required residue or to gross misfolding
of the protein caused by the mutation, which would also result
in detecting only full-length proteins in cell lysates. To unam-
biguously assess the catalytic importance of these predicted
FIGURE 1. Identification of a consensus cleavage site in CLCA proteins.
A, schematic of soluble CLCA constructs used to experimentally deter-
mine proteolytic cleavage sites. Dashed line denotes cleavage site with
scissile bond residue number listed underneath. Labels denote the follow-
ing: SS, signal sequence; CLCA-N, N-terminal CLCA domain; FnIII, fibronec-
tin type III domain; 6His, hexahistidine tag. B, comparison of CLCA
sequences in the region of the proteolytic cleavage site. Results of N-ter-
minal sequencing are underlined and highlighted in green text. Sequence
conservation is color-coded as follows: magenta, invariant residues; yel-
low, conservation score of 5 or greater as determined by ALSCRIPT (49).
Lowercase letters preceding CLCA indicate species as follows: h! human,
Homo sapiens; m ! mouse, Mus musculus; r ! rat, Rattus norvegicus; p !
pig, Sus scrofa; b! cow, Bos taurus; e! horse, Equus caballus. C, schematic
of the consensus cleavage site in CLCAs. S and P labels refer to protease
subsite and pocket designations, respectively.
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active site residues, we analyzed proteolytic processing of
CLCA1 point mutants fully secreted into media supernatants,
i.e. proteins that have passed the cellular quality control
machinery and are correctly folded. Mutations to all predicted
active site residues (H156A, E157Q, H160A, D167A, E168A)
produced only uncleaved, full-length proteins, whereas wild
type and a mutation outside the active site (Q150A) displayed
proteolytic processing (Fig. 3B). The data strongly suggest that
theCLCAproteins contain anN-terminal zincmetalloprotease
domain and that they are capable of self-cleavage.
CLCAMetalloprotease Domains Process CLCA Proteins and
Are Blocked by Specific Inhibitors—To definitively confirm the
self-proteolysis activity of CLCA1 by its metalloprotease
domain, we devised a biochemical digestion assay utilizing
purified proteins and monoclonal antibodies. This was carried
outwith separately expressed andpurifiedCLCA1protease and
CLCA1 substrate proteins produced in mammalian cells (Fig.
4A). Substrate consisted of the full CLCA1 protein excluding
the metalloprotease domain. Protease consisted of the CLCA1
metalloprotease andVWAdomains as this construct was stable
and robustly expressed. These proteins were mixed, incubated
at 37 °C, and then analyzed at various time points for accumu-
lation of cleavage product by Western blot with an antibody
that specifically recognized an epitope found only in the sub-
strate. Substrate alone displayed no degradation, whereas the
addition of the CLCA1 protease resulted in the appearance of a
cleavage product of appropriate size over time (Fig. 4B). The
addition of the divalent metal cation chelators EDTA and 1,10-
phenanthroline completely abrogated proteolytic activity as
they sequester the catalytically required zinc. In contrast, the
addition of a commercial mixture containing protease inhibi-
tors to all classes except metalloproteases (Halt, Thermo) had
no effect on proteolysis of the substrate. Taken together with
the previously presented mutational analysis, these data
unambiguously demonstrate that the CLCA proteins con-
tain an N-terminal metalloprotease domain responsible for
self-cleavage.
We next assessed the ability of various commercial and cus-
tomMMP inhibitors to block proteolysis in this assay (Fig. 4C).
These molecules belong to the class of hydroxamate-based
inhibitors, which consist of the moiety attached to a peptide
mimetic chain. These inhibitors act by chelating the zinc
through the hydroxamate group with the peptide mimicking
side chains binding to the S1! and S2! pockets (supplemental
Fig. S1) (30). The inhibitors displayed differing levels of
potency, with Batimastat being most effective, followed by
GM-6001 and Marimastat. In addition, we synthesized a cus-
tom inhibitor consisting of a hydroxamate moiety fused to the
P1! and P2! residues of the CLCA1 cleavage sequence (termed
Zeynepstat001). This inhibitor was also effective in reducing
the activity of the CLCA1 protease.FIGURE2.Mutationsopposing the consensus cleavage sequenceprevent
proteolytic processing of hCLCA1. A, schematic of hCLCA1 displaying the
sequence encompassing the proteolytic site. Sequences are labeled as fol-
lows: SS, signal sequence;WT, wild type sequence; A696P, proline mutant at
the scissile bond; clca2, hCLCA2 cleavage site mutated into hCLCA1; clca4,
hCLCA4 cleavage site mutated into hCLCA1; contra, severe mutations con-
trary to the CLCA consensus cleavage sequence; TEV, tobacco etch virus pro-
tease cleavage site mutated into hCLCA1 site; 6His, hexahistidine tag.
Mutated residues are highlighted in red. B, expression of mutant versions of
hCLCA1 in HEK293T cells. Samples were taken from media supernatants (S)
and lysed cells (C), separated by SDS-PAGE, and analyzed byWestern blot for
either hCLCA1 C terminus (C-term) (His6 antibody, top blot) or hCLCA1 N ter-
minus (N-term) (8D3mAb, bottom blot). Conservativemutations to the cleav-
age site (A696P, clca2, and clca4) do not block proteolytic processing,
whereas radical variations (contra, TEV) block proteolytic processing of
hCLCA1.C, expression of hCLCA1 FL TEVmutant in the absence andpresence
of TEV protease in themedia (0.2 mg/ml). Secreted hCLCA1 FL TEV protein in
the media supernatant was analyzed byWestern blot using same antibodies
as in B.
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Biophysical Characterization of CLCA Protease Activity—
We then developed a quantitative biophysical assay to charac-
terize CLCA1 metalloprotease activity. This assay employed a
fluorogenic peptide consisting of theCLCA1 cleavage sequence
conjugated to a donor-quencher FRET pair for the substrate
and CLCA1 protease refolded from bacterially expressed inclu-
sion bodies. This allowed determination of the kinetics of pro-
tease activity (Km! 1.10" 10#6 M, Vmax! 0.403 fluorescence
units/s) (Fig. 4,D and E). To further address metal dependence,
experiments in the presence of chelators or excess divalent
metal ions were carried out. The addition of EDTA abolished
protease activity, whereas the addition of excess Zn2$ partially
restored activity (Fig. 4D). In contrast, the addition of Ca2$ did
not restore activity (data not shown). We used this assay to
performamore quantitative assessment of theMMP inhibitors.
These experiments indicated that Batimastat was most effective,
almost completely inhibiting protease activity at high concentra-
tions, followed byGM-6001, Zeynepstat001, andMarimastat (Fig.
4F).Wealso tested the inhibitoryactivityof acetohydroxamicacid,
which consists of only the zinc-binding moiety found in this class
FIGURE 3.Mutation of predicted catalytic residues blocks proteolytic processing of hCLCA1. A, schematic of hCLCA1 highlighting the revised view
of the CLCA-N domain as a metalloprotease. Labels denote the following: SS, signal sequence; CAT, metalloprotease catalytic domain; CYS, Cys-rich
domain. Inset displays the predicted catalytic site of hCLCA1 threaded onto the structure of ADAMTS-1 (Protein Data Bank (PDB) ID: 2V4B) (50). Catalytic
and zinc-chelating residues are highlighted. B, Western blot analysis of media supernatants from 293F cells expressing hCLCA1 variants. Blot was
developed with a His6 antibody (anti-6His), which recognizes full-length and hCLCA1 C-terminal fragment. C, sequence alignment of CLCA family
members in the region of the catalytic site. Color coding is as follows: magenta, invariant residues; yellow, conservation score of 5 or greater as
determined by ALSCRIPT (49).
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of inhibitors. It displayed weak inhibitory activity (data not
shown). Taken together, the data definitively show that CLCA1 is
a Zn2!-dependent metalloprotease and that inhibitors of CLCA1
protease activity can be rationally designed.
CLCA Proteases Can Cross-cleave CLCA Substrates—As
multiple CLCA proteins are expressed at mucosal surfaces (3),
we examined the ability of other CLCA proteases to process
CLCA1 substrate. The CLCA1 substrate was incubated with
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proteases, from either CLCA2 or CLCA4. Both proteases
cleaved the CLCA1 substrate, although at a reduced rate (Fig.
4G). Taken together with the data demonstrating that self-
cleavage of CLCA1 is observed in variants where the cleavage
sequence is mutated to that of CLCA2 or CLCA4 (Fig. 2B), this
result suggests that the members of the CLCA family are capa-
ble of self-cleavage as well as cross-cleavage of other family
members. As multiple CLCA proteins are expressed in the
same tissues, this suggests that CLCA proteins might cross-
cleave each other in vivo; however, the physiological relevance
is unknown at this time.
CLCAProteases DoNot Contain N-terminal Prodomains—A
key aspect of zincin metalloproteases is their intrinsic capacity
for self-regulation, and themost commonmode of regulation is
removal of a prodomain. For example, MMPs and ADAM fam-
ily proteases both contain anN-terminal prodomain, consisting
of about 80 amino acids at the N terminus of the protein, that
blocks access to the protease active site. This domain must be
proteolytically removed for substrate access (27, 31). Structure
predictions of the CLCA-N domain metalloprotease region
indicate that the characteristic catalytic fold would begin
around residue 45, which would leave a short stretch of !20
amino acids that may act as a prodomain. To probe whether
CLCA1 contains an N-terminal prodomain that regulates self-
cleavage, we examined the processing of a dual-tagged hCLCA1
construct (Fig. 4H). This construct contains a FLAG tag directly
after the signal sequence so that detection of the FLAG tag on
the fully processed protein would preclude cleavage of any
N-terminal prodomain. The secreted CLCA1 protein was pro-
cessed normally as detected by antibodies that recognized the
CLCA1 N-terminal and C-terminal fragments. In addition,
Western blotting for the FLAG tag revealed an intact N termi-
nus. Collectively, these observations indicate that CLCA1, and
by implication CLCAproteins in general, do not containN-ter-
minal prodomains.
Self-cleavage of CLCA1 Is Required to Modulate CaCC
Currents—To assess the functional role of CLCA1 self-cleavage
in regulating CaCC activity, we designedmutations that gener-
ate either an inactivemetalloprotease catalytic site (H156A and
E157Q) or an impaired cleavage site (contra) (Fig. 5A) and
tested their impact on CaCC currents in HEK293T cells by
means ofwhole-cell patch clamp electrophysiology. In the pres-
ence of 10 !M intracellular Ca2" and physiological concentra-
tions of extracellular Cl#, we observed activation of robust,
slightly outward rectifying currents in HEK293T cells trans-
fected with full-lengthWTCLCA1 that reversed at!0mV and
were significantly reduced by replacement of extracellular Cl#
with gluconate (Fig. 5C). At"80 mV, Cl# current density, cal-
culated as the difference between current density in the pres-
ence (total) and absence (background) of extracellular Cl#, was
31 $ 3 pA/pF in WT cells; individual measurements varied
from 8 to 80 pA/pF but were at least 10-fold larger than in cells
transfectedwith empty pCDNA3.1 vector (2.5$ 0.5 pA/pF; Fig.
5D). When no Ca2" was added to the pipette buffer, Cl# cur-
rent density was 2.7$ 1.5 pA/pF in vector-transfected cells and
3.5 $ 1.2 pA/pF in cells transfected with WT-hCLCA1 (n % 6
cells each) (Fig. 5C). These data are in agreement with reported
biophysical properties of Ca2"-activatedCl# channels in native
cells and heterologous expression systems (4, 32–35) and are
consistent with a previous report that CLCA1 modulates the
activity of endogenous CaCCs in HEK293T cells (9). In cells
transfected with CLCA1 variants, in which themetalloprotease
activity was abolished (H156A, E157Q) or inwhich the cleavage
site was disrupted (contra), the gluconate-sensitive currents
were markedly decreased (Fig. 5C), and on average, the density
of Cl# currents was comparable with that measured in vector-
transfected cells (Fig. 5D). Expression levels of all the variants
were similar to the WT (Fig. 5B), indicating that the observed
effects were due to impaired proteolytic processing, rather than
altered synthesis, trafficking, or secretion. These data demon-
strate that self-processing of CLCA1 by its novel zincin metal-
loprotease domain is required for its activation of CaCCs.
TheN-terminal Fragment of CLCA1 Is Sufficient toModulate
CaCC Currents—To further delineate the role of CLCA self-
cleavage in activation of CaCCs, we assessed the ability of each
of the cleavage fragments to induce Ca2"-activated currents
(Fig. 5E). At"80 mV, Cl# current density was 4.0$ 0.7 pA/pF
in cells transfected with empty pHLsec vector and increased to
35 $ 5 pA/pF in cells expressing full-length CLCA1. Current
density in cells expressing the CLCA1 C terminus was as low as
in cells transfected with empty pHLsec (4.7 $ 0.6 pA/pF). In
contrast, in cells expressing the N-terminal fragment, currents
were similar to those measured in cells transfected with the
full-length construct (32 $ 5 pA/pF). These results demon-
strate that the N-terminal fragment of CLCA1 is necessary and
sufficient to regulate Ca2"-activated Cl# currents and that self-
cleavage is required to release an inhibitory C-terminal frag-
FIGURE 4. Self-cleavage of hCLCA1. A, schematic of protein constructs used in purified protein proteolysis assays. Labels denote the following: SS, signal
sequence; CAT, metalloprotease catalytic domain; CYS, Cys-rich domain; 6His, hexahistidine tag. B, proteolysis of hCLCA1 substrate by hCLCA1 protease.
Sampleswere incubated at 37 °Cwith samples taken at timepoints as noted. Reactions are labeled as follows:A, substrate only;B, substrate (0.5!M)"protease
(2!M); C, substrate"protease" 15mMEDTA;D, substrate"protease" 15mM1,10 phenanthroline; E, protease" substrate; F, protease" substrate"HALT
(1&).C, effect of commercial and customMMP inhibitors onhCLCA1proteolytic cleavage. Conditionswere the same as the abovewith the following inhibitors
added to digestion reactions (at 40 !M): B, GM-6001; C, Marimastat; D, Batimastat; E, Zeynepstat. D, activity of purified refolded hCLCA1 protease on a
fluorogenic peptide corresponding to the hCLCA1 cleavage sequence (DABCYL-QQSGALYIPG-EDANS). Protease and substratewere incubated together for 60
min, and product formationwasmeasured over time. Reactionswere carried out in triplicate and averagedwith standard deviations shown as error bars. Color
coding is as follows:green, protease (10!M)" substrate (3.25!M); red, protease (10!M)" substrate (3.25!M)"15mMEDTA;gray, protease (10!M)" substrate
(3.25!M)" 15mM EDTA" 20mM ZnCl2. E, enzyme velocity versus substrate concentration plot for refolded human CLCA1 protease (22–473) (at 4!M) using
the human CLCA1 fluorogenic reporter peptide as a substrate. Three replicates were performed for each concentration. F, effect of commercial and custom
MMP inhibitors on hCLCA1protease activity in the fluorogenic peptide digestion assay. Reaction conditionswere the same as the abovewith inhibitors added
at 20 and 40!M. Activity was reported as the percentage of reaction velocity in the absence of inhibitors. Reactionswere carried out in triplicate.G, proteolysis
of hCLCA1 substrate by hCLCA2 and hCLCA4 protease. Reactions are labeled as follows: A, substrate only; B, substrate " hCLCA2 protease; C, substrate "
hCLCA4 protease. H, expression of a dual-tagged hCLCA1 protein in 293F cells. Top: schematic of the construct containing an N-terminal FLAG tag and
C-terminal His6 tag. The region containing the 8D3 mAb epitope is highlighted. Bottom: Western of supernatants from 293F cells expressing dual-tagged
hCLCA1. Left: anti-FLAG and 8D3 mAb blot. Right: anti-His6 blot. N-term, N terminus; C-term, C terminus.
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ment and unmask theN-terminal fragment for interactionwith
the channel.
Proteolytic Activity of the CLCA1N-terminal Fragment Is Not
Required to Modulate CaCC Currents—To address whether
the proteolytic activity of the N-terminal fragment was
required for activation of CaCCs, we assessed the ability of the
E157Q variant of this fragment to induce Ca2!-dependent cur-
rents in HEK293T cells. In cells transfected with this variant,
Cl" current density was close to that of the WT N-terminal
fragment (30# 6 pA/pF, Fig. 5E). This demonstrates that gating
of CaCCs by the N-terminal fragment of CLCA1 does not
involve direct proteolytic clipping of the channel and suggests a
direct interaction that induces gating.
DISCUSSION
CLCA1 Is a Self-cleaving Zincin Metalloprotease—Since their
discovery nearly two decades ago (36), there has been much con-
troversy regarding the specific functions of CLCA proteins and
their connection to CaCC activity (9). In the present study, we
demonstrate thatCLCAproteins, specificallyCLCA1,utilize adis-
tinct self-processingmechanism in regulatingCaCC activity. This
discovery is supported by several novel findings.
FIGURE 5.Mutations that disrupt the metalloprotease activity or the cleavage site of hCLCA1 affect Ca2!-activated Cl" currents in HEK293T cells.
A, schematic of hCLCA1 variants used in patch clamp electrophysiology experiments. The table summarizes the biochemical properties of each variant. Labels
denote the following: SS, signal sequence; CAT, metalloprotease catalytic domain; CYS, Cys-rich domain; WT, wild type sequence; contra, severe mutations
contrary to the CLCA consensus cleavage sequence. B, expression levels of hCLCA1 proteins in the same cells used for electrophysiology. S, supernatants;
C, lysed cells. C, whole-cell currents measured in representative cells transfected with empty pCDNA3.1 plasmid, wild-type (WT) hCLCA1, or mutant hCLCA1,
superfused with standard extracellular solution ([Cl"]out, left) and after replacement of external Cl
" with gluconate ([Gluconate"]out, right). For most experi-
ments, the pipette solution contained 10!M free Ca2! ([10!M Ca2!]in), and the pulse protocol is shown at the top left. Selected experiments were performed
in the absence of pipette Ca2! ([0!M Ca2!]in); in those, a simplified pulse protocol was used in which the voltage was held at"80mV and stepped from"80
mVto!80mV in40-mV increments.Outwardcurrents are representedbyupwarddeflections, and thedotted lines indicate zerocurrent.Membranecapacitance
was similar in all cases at$25 pF. D, density of chloride currents at!80 mV. Values represent the difference between current density in presence (total) and
absence (background) of extracellular Cl". Circles represent data from individual patches (n% 10–35); bars indicate themeans# S.E. of all experiments. *, p&
0.001 as compared with the WT (unpaired Student’s t test). E, Cl" current density at !80 mV in cells transfected with empty pHLsec vector or full-length,
C-terminal (C-term) or N-terminal (N-term) hCLCA1, in the absence (N-terminal) or presence of a metalloprotease-disrupting mutation (N-term E157Q). Circles
represent data from individual patches (n% 7–12); bars indicate the means# S.E. of all experiments. *, p& 0.001 as compared with the full-length (unpaired
Student’s t test).
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First, we have demonstrated that CLCA proteins represent a
novel class of zincinmetalloproteases capable of self- and cross-
cleavage. It should be noted that previous studies have
attempted to address the issue of CLCAmetalloprotease activ-
ity (28, 29); however, these studies were based on experiments
utilizing CLCA proteins found in crude membrane fractions.
The authors claimed that purified CLCA proteins could not be
produced. Here, using purified proteins, peptides, and a com-
prehensive functional analysis, we unambiguously demonstrate
that CLCAs are novel zincin metalloproteases that self-cleave.
Up to the present study, the recognized secreted mammalian
zincin endopeptidases consisted of MMP, membrane-bound
MMP (MTMMP), ADAM, and ADAMTS families (26). These
metalloproteases all contain a HEXXHXXGXX(H/D) catalytic
motif, with zinc-binding histidines (the third histidine is some-
times replaced by aspartate) and the catalytically required base/
acid glutamate (bold) (27). Mutational and sequence analysis of
the novel CLCA metalloprotease domain reveals a related
HEXXHXXXGXXDE catalytic motif. Aside from histidine,
aspartate is the most common residue in the third chelating
position. However, aspartate is not strictly conserved at that
position within the CLCA family, whereas the adjacent (and
chemically similar) glutamate is invariant (Fig. 3C). Mutational
analysis indicates that both residues are structurally required
for self-processing, although based on the current data, we can-
not conclude whether the aspartate or glutamate constitutes
the third zinc-binding residue. Regardless of this identity, the
CLCA catalytic motif appears to be unique among secreted
mammalian zincin metalloproteases.
A second key aspect of our findings relates to the regulation
of metalloprotease activity. This is typically controlled at four
levels: expression; compartmentalization; pro-enzyme activa-
tion; and inactivation (usually by inhibitors). MMP and ADAM
proteins are secreted as zymogens that contain an N-terminal
prodomain of around 80–100 amino acids, which folds against
and blocks the catalytic active site (37). Removal of the prodo-
main is required for substratemolecules to access the active site
cleft. However, a similar prodomain arrangement does not
appear to be present in the CLCA proteins as the beginning of
the predictedmetalloprotease catalytic domain is within 10–20
residues of the N terminus of themature protein. Furthermore,
the processing of a dual-tagged CLCA1 protein indicates that
an N-terminal prodomain is not present. Thus, the regulation
of CLCAmetalloproteases has distinct features that suggest the
regulation of specific CLCAproteinswill be unique and specific
to their function. The observation that the addition of a TEV
protease sequence intoCLCA1 in the presence of TEVprotease
indicates that the cleavage site may be buried in the natively
folded full-length protein, suggesting that regulation may be
achieved by conformational change. The trigger for cleavage is
uncertain, but it is possible that the shift in pH that occurs along
the secretory pathway (starting from pH 7.4 in the ER to 5.5 in
secretory endosomes) could control the compartmental loca-
tion of cleavage. Additionally, from the current data, it is
unclear whether self-cleavage predominantly occurs intra- or
intermolecularly. Future studies will be required to define this
mechanism and evaluate the role of endogenous metallopro-
tease inhibitors, such as the tissue inhibitor of metalloprotei-
nase (TIMP) proteins (38), in the regulation of CLCA protease
activity.
A third unique aspect revealed by our analysis of CLCAmet-
alloprotease activity is the distinct nature of the consensus
cleavage site in CLCA proteins. The sequence for this site
shows extreme conservation on the prime (!) side of the scissile
bond (Fig. 1B), suggesting that the substrate-binding cleft in the
CLCAmetalloproteases is similar in feature to others in that its
specificity ismainly built into the prime side,with the unprimed
side being rather flat and featureless (27). Sequence analysis of
the mammalian CLCA proteins suggests the presence of a cys-
teine-rich domain (containing six invariant cysteines) adjacent
to the catalytic domain (Fig. 3A). Cys-rich domains are found in
a number of ADAM and ADAMTS family members; they con-
trol substrate selectivity and access to the catalytic site (26).
MMP (39) andADAMfamily (26, 31) proteases play key roles as
modulators of inflammation and innate immunity through
activation or inactivation of cytokines, chemokines, or other
proteins. The major substrate of the CLCA metalloprotease
domains appears to be the CLCA protein itself, but given the
central involvement of CLCAs in chronic inflammatory airway
diseases, additional CLCA protease substrates should also be
considered.
Self-cleavage Is a Required Feature of CaCC Activation—We
demonstrate that CLCA proteins are distinct in their mode of
modifying ion channel activity. In particular, the observation
that self-cleavage of CLCA1 is required for regulation of CaCC
activity introduces a novelmechanism for controlling ion chan-
nel gating. The CLCA mechanism exhibits some similarity to
the !2" subunit of voltage-gated calcium channels, which are
also secreted, proteolytically cleaved, and contain a VWA
domain (40). Proteolysis cleaves this protein into two pieces
and also relieves the!2 subunit from a transmembrane domain,
and these events are required for enhanced surface expression
of voltage-gated calcium channels (41). However, although !2"
subunits do contain an uncharacterized N-terminal domain,
they do not appear to contain features consistent with being a
metalloprotease, nor do structure prediction algorithms detect
the presence of one.
Our data also indicate details of amechanismof howCLCA1,
and CLCA proteins in general, activate CaCCs. It has been pro-
posed that CLCA1 increases CaCC conductance by directly
affecting the permeation pathway, rather than via enhanced
trafficking or surface expression of endogenous channels (9).
Our results demonstrate that proteolytic cleavage is required
for CLCA1-mediated activation of CaCCs, and the N-terminal
fragment alone is sufficient for activation. Additionally, the fact
that the N-terminal fragment E157Q variant is able to activate
CaCCs just as effectively as WT demonstrates that the proteo-
lytic activity of this fragment is not required to activate the
channel. This suggests that the CLCA1 N-terminal fragment
activates CaCCs by direct interaction with the channel. This
mechanism is thus distinct from the manner by which secreted
proteases activate epithelial sodium channels (ENaCs) in the
airway throughproteolysis of the channel (42).Wepropose that
the C-terminal fragment of CLCAmasks theN-terminal region
in the full-length protein and that self-cleavage is required to
expose the N-terminal fragment, which can then interact with
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the channel (Fig. 6). The precise nature of these interactions
remains to be addressed.
Consequences for AirwayDiseaseMechanisms andTherapies—
Although the precise identity of the CaCC activated by CLCAs
is uncertain, a primary candidate is the anoctamin (also called
TMEM16) family of proteins, which are the only presently
identified CaCC proteins (43). Within this family, only Ano1
and Ano2 have been shown to be surface-expressed and create
Ca2!-activated Cl" currents (44, 45). Studies in Ano1"/"mice
indicate that Ano1-mediated Cl" secretion is necessary for
normal airway surface liquid homeostasis (46), implying a sim-
ilar functional role to CFTR in the airway. Future studies will be
required to determine whether this potential functional associ-
ation between CLCA and anoctamin family members is based
on direct physical association.
The identification of self-processing of CLCA1 as a require-
ment for modulation of CaCC activity has significant implica-
tions for airway disease. In CF, CLCA1 activity appears to pro-
duce improvement of the CF phenotype by activation of
compensating Cl" channels (17, 47). In asthma and chronic
obstructive pulmonary disease, increased CLCA1 activity is
linked to increased mucus production (16), but any connection
to CaCC activity still needs to be defined. Our study is the first
to provide experimental approaches aimed at dissecting these
two seemingly conflicting functional roles of CLCAs by bio-
chemically characterizingmutations that prevent CaCC activa-
tion and identifying the fragment responsible for activation.
Our findings also raise the intriguing possibility of developing
CLCA1 protease inhibitors as research tools and therapeutic
agents. The observed differences in effectiveness amongMMP-
like inhibitors at blocking CLCA1metalloprotease activity pro-
vides useful insights for the design of potent and specific
CLCA1 inhibitors. The main structural difference between
these inhibitors is side chain size for the predicted S2# moiety
(indole, isopropyl, phenyl, and isobutyl forGM-6001,Marimas-
tat, Batimastat, and Zeynepstat001, respectively) (supplemen-
tal Fig. S1). Our results suggest that a larger hydrophobic resi-
due in the S2# pocket produces a more effective inhibitor,
possibly via strengthening noncovalent interactions. These
findingsmay be useful in guiding the design ofmore potent and
specific CLCA metalloprotease inhibitors to prevent excess
CLCA1 activity found in airway disease and perhaps cancer as
well.
A final implication of our findings derives from the differ-
ences in function between human CLCA proteins. Of the three
CLCA proteins expressed at mucosal surfaces (CLCA1,
CLCA2, and CLCA4), only CLCA1 appears to regulate mucin
gene expression and consequent mucus production (16),
although CLCA1 and CLCA2 can both regulate CaCC activity
(9, 48) (CLCA4 has not been tested). A thorough mechanistic
understanding of how CLCA2 (or CLCA4) is able to activate
CaCCs without triggering mucus production could lead to the
development of novel selective CF therapeutics that exploit
these mechanisms.
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Figure S1. Chemical structures of the MMP inhibitors used in this study. Arrows 
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Preparation of Zeynepstat001 (Compound 9): scheme 
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Synthesis: 
 
(4S)-4-Benzyl-3-propanoyloxazolidin-2-one (1)1 
(S)-Benzyl-2-oxazolidinone (5.12 g, 28.8 mmol) was dissolved in THF (35 mL) under a 
nitrogen atmosphere and the reaction was cooled to -20 oC.  A solution of n-buLi (1.6 M 
in hexane) (18 mL, 28.8 mmol) was added and the mixture was stirred for 1 hr at -20 oC.  
Propionyl chloride (2.45 g, 26.5 mmol) was added and the reaction was stirred at room 
temperature for 20 minutes and quenched with saturated aqueous sodium bicarbonate.  
The THF was evaporated and the reaction was partitioned between ethyl acetate and 
aqueous sodium bicarbonate.  The organic layer was evaporated to give 6.62 g of a clear 
oil.  The material was chromatographed on 90 g of silica using a linear gradient from 5%-
40% ethyl acetate/hexane to give 5.38 g of product as a clear oil (87% yield), which 
provided a single peak by LC-MS analysis (M+H = 234.1).  1H NMR (400 MHz, CDCl3) 
δ: 7.36-7.20 (m, 5H), 4.71-4.65 (m, 1H), 4.23-4.15 (m, 2H), 3.31 (dd, J = 13.6, 3.2 Hz, 
1H), 3.05-2.88 (m, 2H), 2.77 (dd, J = 13.2, 9.2 Hz, 1H), 1.21 (t, J = 7.2 Hz, 3H).  
 
Benzyl (3R)-4-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-3-methyl-4-oxo-butanoate (2)1 
LiHMDS (1M in THF) (27.7 mL, 27.7 mmol) was added to a solution of 1 (5.38 g, 23.06 
mmol) in THF (105 mL) at -78 oC and the mixture was stirred at 0 oC for 20 minutes.  
Benzyl bromoacetate (6.87 g, 30 mmol) in THF (70 mL) was added dropwise to this 
solution over 90 minutes.  The reaction was stirred for 30 minutes at 0 oC and then room 
temperature over night.  The reaction was quenched using saturated aqueous sodium 
bicarbonate, the THF was evaporated, and the reaction was partitioned between ethyl 
acetate and aqueous sodium bicarbonate.  The organic layer was evaporated to give 10.57 
g of an orange oil.  The material was chromatographed on 90 g of silica using a linear 
gradient from 5%-40% ethyl acetate/hexane to give 5.33 g of product as a viscous yellow 
oil (60% yield), which provided a single peak by LC-MS analysis (M+H = 382.1).  1H 
NMR (400 MHz, CDCl3) δ: 7.36-7.20 (m, 10H), 5.11 (s, 2H), 4.66-4.60 (m, 1H), 4.27-
4.07 (m, 3H), 3.23 (dd, J = 13.2, 2.8 Hz, 1H), 3.02 (dd,  J = 16.8, 10.4 Hz, 1H), 2.56-2.49 
(m, 2H), 1.23 (d, J = 6.8 Hz, 3H).  
 
(2R)-4-benzyloxy-2-methyl-4-oxo-butanoic acid (3)1 
Solutions of 30% hydrogen peroxide (8.5 mL) and lithium hydroxide-hydrate (0.82 g) in 
water (25 mL) were added to a solution of 2 (5.33 g, 13.97 mmol) in THF/water (100 
mL/25 mL).  The mixture was stirred for 2 h at 0oC and 2 h at room temperature, then 
acidified with 2 N aqueous hydrochloric acid.  The THF was evaporated and the aqueous 
layer was extracted using ethyl acetate and concentrated to give 5.48 g of a clear oil.  The 
material was chromatographed on 80 g of silica using a linear gradient from 0%-60% 
ethyl acetate/hexane to give 1.58 g of product as a clear oil (51% yield), which provided a 
single peak by LC-MS analysis (M+H = 223.1). 1H NMR (400 MHz, CDCl3) δ: 7.38-
7.31 (m, 5H), 5.14 (s, 2H), 3.02-2.94 (m, 1H), 2.80 (dd, J = 16.8, 8.0, 1H), 2.48 (dd, J = 
16.6, 5.6 Hz, 1H), 1.26 (d, J = 6.8 Hz, 3H).  
 
tert-Butyl N-[(1S)-3-methyl-1-(methylcarbamoyl)butyl]carbamate (4)2 
BOC-Leu-OH (5 g, 21.6 mmol) was dissolved in dichoromethane (200 mL).  EDC.HCl 
(4.97 g, 25.9 mmol) and DMAP (cat.) were added to the solution.  Methylamine (2 M in 
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THF) (13 mL, 26 mmol) was then added and the mixture was stirred for 2 h under N2.  
The reaction mixture was washed with 1N aqueous hydrochloric acid (2 x 100 mL), 
saturated sodium bicarbonate (2 x 100 mL) and saturated brine (100 mL).  The organic 
layer was dried over anhydrous sodium sulfate and concentrated to give 4.06 g of product 
as a white solid (77% yield).  This material does not fly in the LC-MS.  1H NMR (400 
MHz, CDCl3) δ: 6.14 (br s, 1H), 4.86 (br s, 1H), 4.07 (br s, 1H), 2.80 (s, 3H), 1.71-1.59 
(m, 3H), 1.41 (s, 9H), 0.94 (s, 6H). 
 
(2S)-2-amino-N,4-dimethyl-pentanamide (5) 
Compound 4 (1 g, 4.09 mmol) was stirred in 4 M hydrochloric acid/dioxane (2 mL, 8 
mmol).  A small quantity of methanol was added to increase solubility.  After 2-1/2 h the 
reaction was evaporated and the resulting solid was triturated in diethyl ether and filtered 
to give 0.68 g of product as the hydrochloride salt.  LC-MS gave a single peak (M+H = 
145.1).  1H NMR (400 MHz, DMSO) δ: 8.52 (br s, 1H), 8.2 (br s, 2H), 3.64 (br s, 1H), 
3.52 (s, 1H), 2.61 (d, J = 4 Hz, 3H), 1.58-1.48 (m, 3H), 0.85 (d, J = 6.4 Hz, 6H). 
 
Benzyl (3R)-3-methyl-4-[[(1S)-3-methyl-1-(methylcarbamoyl)butyl]amino]-4-oxo-
butanoate (6)1  
Compound 5 (1.26 g, 6.97 mmol), HOBt (containing 20% water) (1.08 g, 6.38 mmol), 
EDC.HCl (1.45 g, 7.56 mmol) and DIEA (0.825 g, 6.38 mmol) were add to a solution of 
compound 3 (1.29 g, 5.80 mmol) in dichloromethane (100 mL) and stirred for 2 h at 
room temperature.  The reaction was quenched using excess 0.5 M aqueous hydrochloric 
acid, layers were separated and the organic layer dried over sodium sulfate after which it 
was filtered and evaporated to give 2.06 g of white solid.  The material was 
chromatographed on 24 g of silica using a linear gradient from 20% ethyl acetate/hexane 
to 100% ethyl acetate to give 1.37 g of product as a white solid (68% yield), which 
provided a single peak by LC-MS analysis (M+H = 349.1).  1H NMR (400 MHz, CDCl3) 
δ: 7.38-7.28 (m, 5H), 6.54 (br s, 1H), 6.6.35 (br s, 1H), 5.11 (s, 2H), 4.45-4.39 (m, 1H), 
2.79-2.70 (m, 5H), 2.53-2.46 (m, 1H), 1.72-1.52 (m, 3H), 1.26-1.18 (m, 3H), 0.97-0.89 
(m, 6H).  
 
(3R)-3-methyl-4-[[(1S)-3-methyl-1-(methylcarbamoyl)butyl]amino]-4-oxo-butanoic 
acid (7)1 
Compound 6 (1.54 g, 4.42 mmol) was dissolved in ethyl acetate (65 mL), 10% Pd/C 
(0.200 g) was added and the mixture was stirred under hydrogen (initial pressure 50 
p.s.i.) for 1 h.  The mixture was filtered through diatomaceous earth and evaporated to 
give 1.16 g of product as a white foam (100%).  LC-MS gave a single peak (M+H = 
259.1).  1H NMR (400 MHz, CDCl3) δ: 7.29 (br s, 1H), 6.90 (br s, 1H), 4.52 (d, J = 8.0 
Hz, 2H), 2.84-2.70 (m, 5H), 2.47 (dd, J = 16.4, 4.4 Hz, 1H), 1.66-1.55 (m, 3H), 1.25-1.18 
(m, 3H), 0.93-0.89 m, 6H). 
 
(2R)-N'-benzyloxy-2-methyl-N-[(1S)-3-methyl-1-
(methylcarbamoyl)butyl]butanediamide (8)1  
O-Benzylhydroxylamine hydrochloride (0.84 g, 5.26 mmol), HOBt (containing 20% 
water) (0.82 g, 4.88 mmol), EDC.HCl (1.1 g, 5.74 mmol) and DIEA (0.63 g, 4.88 mmol) 
were added to a solution of compound 7 (1.14 g, 4.41 mmol) in dichloromethane (80 mL) 
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and stirred for 2 h at room temperature.  The reaction was quenched using excess 0.5 M 
aqueous hydrochloric acid and the product precipitated.  The organic and aqueous layers 
were filtered to give 1.16 g of product as a white solid.  The solids were triturated in 
dichloromethane (40 mL) and filtered to give 0.803 g of product as a white solid (50% 
yield), which provided a single peak by LC-MS analysis (M+H = 364.2).  1H NMR (400 
MHz, DMSO) δ: 10.97 (s, 1H), 7.85 (d, J = 8 Hz, 1H), 7.72 (d, J = 4 Hz, 1H), 7.33 (m, 
5H), 4.72 (s, 2H), 4.18-4.12 (m, 1H), 2.74-2.68 (m, 1H), 2.52 (m, 3H), 2.21-2.15 (m, 1H), 
1.96-1.90 (m, 1H), 1.52-1.49 (m, 1H), 1.45-1.32 (m, 2H), 0.98-0.92 (m, 3H), 0.82-0.75 
(m, 6H). 
 
(2S)-2-[[(2R)-4-(hydroxyamino)-2-methyl-4-oxo-butanoyl]amino]-N,4-dimethyl-
pentanamide (9)1  [Zeynepstat001] 
Compound 8 (0.768 g, 2.11 mmol) was dissolved in methanol (80 mL), 10% Pd/C (0.08 
g) was added and the mixture was stirred under hydrogen (initial pressure 56 psi) for 45 
min.  The mixture was filtered through diatomaceous earth and evaporated to give 0.57 g 
of product as a light tan solid.  The material was triturated in dichloromethane (40 mL), 
filtered and dried in a vacuum oven to give 0.513 g of product as a tan solid.  This 
material was re-crystallized from ethanol/ether (10 mL/10 mL) to give 0.264 g of product 
as an off-white solid.  LC-MS gave a single peak (M+H = 274.1).  1H NMR (400 MHz, 
DMSO) δ: 10.34 (s, 1H), 8.68 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 4.4 Hz, 1H), 
4.16-4.10 (m, 1H), 2.70-2.64 (m, 1H), 2.52 (m, 3H), 2.20-2.15 (m, 1H), 1.96-1.90 (m, 
1H), 1.53-1.48 (m, 1H), 1.42-1.37 (m, 2H), 0.94-0.92 (m, 3H), 0.83-0.76 (m, 6H). 
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Abstract Calcium-activated chloride channel regulator 1 (CLCA1) activates calcium-dependent
chloride currents; neither the target, nor mechanism, is known. We demonstrate that secreted
CLCA1 activates calcium-dependent chloride currents in HEK293T cells in a paracrine fashion, and
endogenous TMEM16A/Anoctamin1 conducts the currents. Exposure to exogenous CLCA1
increases cell surface levels of TMEM16A and cellular binding experiments indicate CLCA1 engages
TMEM16A on the surface of these cells. Altogether, our data suggest that CLCA1 stabilizes
TMEM16A on the cell surface, thus increasing surface expression, which results in increased calcium-
dependent chloride currents. Our results identify the first Cl− channel target of the CLCA family of
proteins and establish CLCA1 as the first secreted direct modifier of TMEM16A activity, delineating
a unique mechanism to increase currents. These results suggest cooperative roles for CLCA and
TMEM16 proteins in influencing the physiology of multiple tissues, and the pathology of multiple
diseases, including asthma, COPD, cystic fibrosis, and certain cancers.
DOI: 10.7554/eLife.05875.001
Introduction
The calcium-activated chloride channel regulator (CLCA- previously known as chloride channel
calcium activated) proteins (Cunningham et al., 1995) are a family of secreted self-cleaving
metalloproteases that activate calcium-dependent chloride currents (ICaCC) in mammalian cells
(Yurtsever et al., 2012). CLCA family members are highly expressed in mucosal epithelia where they
play important roles in mucus homeostasis and related diseases (Patel et al., 2009). For example,
human CLCA1 plays a central role in interleukin (IL-) 13-induced mucus cell metaplasia, the main
source of inflammatory mucus overproduction in chronic obstructive airway diseases, such as asthma
and COPD (Alevy et al., 2012). Both clinical and animal model studies suggest a compensatory role
for CLCAs in the context of cystic fibrosis (CF): the fatal intestinal disease, meconium ileus, arising in
CFTR-deficient mice is corrected by overexpression of mCLCA3 (an orthologue of human CLCA1)
(Young et al., 2007) and, correspondingly, mutations in CLCA1 are found in a subset of CF patients
with aggravated intestinal disease (van der Doef et al., 2010). At the cellular level, overexpression of
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CLCA proteins leads to activation of calcium-dependent chloride currents (Gandhi et al., 1998;
Britton et al., 2002; Elble et al., 2002; Greenwood et al., 2002), and this functional observation had
caused CLCAs to be initially misidentified as calcium-activated chloride channels (CaCCs) themselves
(Cunningham et al., 1995). However, further bioinformatic and biochemical studies have
demonstrated that CLCA proteins are secreted, soluble proteins and that they act to modulate
CaCCs that are endogenous to mammalian cells (Gibson et al., 2005; Hamann et al., 2009;
Yurtsever et al., 2012). The molecular identity of these channels, the mechanism of CLCA activation,
and their potential roles in CLCA-mediated diseases, remain unknown.
TMEM16A (also known as Anoctamin1/DOG1) was recently identified as the first genuine CaCC
in mammals by three independent groups (Caputo et al., 2008; Schroeder et al., 2008; Yang
et al., 2008). 10 members of the TMEM16/Anoctamin family have been identified (TMEM16A-K, or
Ano1-10); these proteins, predicted to be transmembrane proteins with eight membrane-spanning
helices, have been found to function predominantly as CaCCs (TMEM16A and B) or as phospholipid
scramblases (TMEM16C, D, F, G, and J) (Pedemonte and Galietta, 2014). TMEM16A, the best-
characterized member of the family to date, is expressed in airway epithelia and smooth muscle,
and its activity recapitulates some of the airway disease traits associated with CLCA1. Not only is
TMEM16A expression significantly increased by IL-13 and IL-4 in primary cell models of chronic
inflammatory airway disease (Caputo et al., 2008; Alevy et al., 2012), but TMEM16A
overexpression is also linked to mucus cell metaplasia and airway hyperreactivity (Huang et al.,
2012; Scudieri et al., 2012). In addition, TMEM16A-specific inhibitors decrease mucus secretion
and airway hyperreactivity in cellular models (Huang et al., 2012). Although experiments with
purified TMEM16A protein reconstituted in liposomes indicate that it can form a functional channel
on its own (Terashima et al., 2013), several cytosolic modulators and interaction partners, such as
calmodulin, phosphatidylinositol 4,5-bisphosphate (PIP2), ezrin, radixin, and moesin, have been
described (Tian et al., 2011; Perez-Cornejo et al., 2012; Pritchard et al., 2014). However, no
eLife digest Many biological processes that are important for our health involve the movement
of ions into, and out of, our cells. For example, the flow of chloride ions out of cells controls the
production of the sticky mucus that lines our windpipe and other airways. This mucus helps trap
pollution and other foreign particles before they reach our lungs, and thus protects the lungs from
harm. However in some diseases—such as cystic fibrosis and asthma—excessive amounts of thick
mucus are produced; this can lead to breathing difficulties and an increased risk of infection.
Proteins belonging to the CLCA protein family were first thought to act as channels that allow
chloride ions to flow through cell membranes. Later studies then revealed that these proteins are not
channels; instead they trigger the movement of chloride ions across cell membranes by activating
other channel proteins. However, the identity of these channel proteins was unknown, and it was
unclear how CLCA proteins might activate these channels.
Sala-Rabanal, Yurtsever et al. have now shown that a member of the CLCA protein family, called
CLCA1, is released from human cells and causes nearby cells to release chloride ions when the
channel detects calcium ions. The movement of chloride ions triggered by CLCA1 looked very similar
to the way chloride ions flow through a channel protein called TMEM16A, and so Sala-Rabanal,
Yurtsever et al. asked whether these two proteins interact.
TMEM16A was discovered several years ago, but remains the only calcium-dependent chloride
channel known in mammals. Sala-Rabanal, Yurtsever et al. showed that adding CLCA1 to cells caused
more TMEM16A channels to appear in the cell surface membrane and thereby increased the flow of
chloride ions. The CLCA protein also physically interacted with the chloride channel in the membrane
to stabilize it; no other protein has been shown to regulate ion channels in this way before.
The findings of Sala-Rabanal, Yurtsever et al. provide a much clearer understanding of how the
CLCA protein and the chloride channel work. Both of these proteins are known to contribute to
excess mucus production in airway diseases; and both have been linked to cardiovascular diseases
and certain cancers. These new findings may therefore also help researchers to target these proteins
and develop treatments for these diseases.
DOI: 10.7554/eLife.05875.002
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secreted regulators of TMEM16A activity have been identified as of yet. Here we report that
secreted CLCA1 modulates TMEM16A-dependent calcium-activated chloride currents, and that this
activation can occur in a paracrine fashion. Furthermore, we show that CLCA1 and TMEM16A co-
localize and physically interact on the surface of mammalian cells, and that CLCA1 increases the
level of TMEM16A protein at the cell surface, representing a novel mechanism of channel regulation
by a secreted protein. We thus demonstrate a first downstream target of CLCA proteins and
provide the first example of a secreted protein modulator of TMEM16A activity. These findings have
significant implications for the roles of CLCA1 and TMEM16A proteins as cooperative partners, not
only in the physiology and pathophysiology of the airways, but also in those of other tissues and
organs.
Results
Secreted CLCA1 can activate Ca2+-dependent chloride currents in
a paracrine fashion
We previously demonstrated that ICaCC are activated in HEK293T (293T) cells overexpressing human
CLCA1 (Yurtsever et al., 2012). Given that CLCA1 proteins are cleaved and secreted from these
cells, we hypothesized that exogenous CLCA1 may activate ICaCC. In a first set of experiments to
test this idea, GFP-expressing cells that had been co-cultured overnight with cells transfected with
CLCA1-pHLsec plasmid (CLCA1) or with empty pHLsec vector (pHLsec) were tested for ICaCC by
means of whole-cell patch clamp electrophysiology (Figure 1A). In the presence of 10 μM
intracellular Ca2+ and physiological concentrations of extracellular Cl−, robust, slightly outward
rectifying currents were activated in cells co-cultured with CLCA1-transfected cells, but only
substantially smaller currents were detected in cells co-cultured with vector-transfected cells
(Figure 1B–D). In a complementary experiment, whole-cell ICaCC were measured in untransfected
cells that had been cultured in medium obtained from CLCA1- or from pHLsec-transfected cells
(Figure 2A). We observed activation of large currents in cells exposed to CLCA1-conditioned
medium that had the same Ca2+- and voltage-dependence properties as those induced in cells co-
cultured with CLCA1-expressing cells (Figure 2B–D). As shown in Figure 2B–C, outward
rectification of the CLCA1-activated current decreases at higher Ca2+ concentrations. In addition,
current reversal potential shifts positive upon lowering extracellular Cl−. These features are in
agreement with the properties of the Ca2+-dependent Cl− conductance observed in CLCA1-
expressing 293T cells (Hamann et al., 2009; Yurtsever et al., 2012), and consistent with those of
CaCCs in native cells and heterologous expression systems (Jeong et al., 2005; Yamazaki et al.,
2005; Xiao et al., 2011). These data indicate that secreted CLCA1 can activate ICaCC in a paracrine
fashion.
CLCA1-dependent ICaCC are carried by TMEM16A
We next focused on identifying the CaCC responsible for carrying the CLCA1-mediated currents. The
CLCA1-modulated ICaCC in 293T cells are Ca
2+-dependent, moderately outward rectifying in the
presence of μM concentrations of intracellular Ca2+, Cl−-selective, and blocked by gluconate (Hamann
et al., 2009; Yurtsever et al., 2012) (Figures 1, 2), closely resembling the biophysical characteristics
of those observed for TMEM16A currents in heterologous expression systems (Schroeder et al.,
2008; Yang et al., 2008; Xiao et al., 2011), proteoliposomes (Terashima et al., 2013), and native
tissues (Caputo et al., 2008).
Given the biophysical and pathophysiological parallels between TMEM16A currents, and those
activated by CLCA1, we hypothesized that CLCA1-activated currents may be carried by TMEM16A.
Consistent with this idea, 293T cells were transfected with either TMEM16A siRNA or with non-
specific, scrambled RNA (siControl), and cultured in CLCA1-conditioned medium. Exposure to
secreted CLCA1 led to the activation of ICaCC in siControl-transfected cells (Figure 3A,B) that were
comparable to the activation recorded in untransfected cells (Figure 2B,D), but these
CLCA1-dependent currents were knocked down to essentially background levels in TMEM16A
siRNA-transfected cells (Figure 3A,B). The TMEM16A siRNA significantly decreased expression
of TMEM16A protein, assessed by Western blot (Figure 3C). These results demonstrate that
CLCA1-dependent ICaCC in 293T cells are indeed carried by TMEM16A.
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CLCA1 colocalizes with and increases cell surface levels of TMEM16A
protein
Next, we used immunohistochemistry and confocal microscopy to examine CLCA1 and TMEM16A
localization in non-permeabilized HEK293T cells. Cells transfected with pHLsec vector alone did not
display noticeable staining for either CLCA1 or TMEM16A (Figure 4A–D), consistent with lack of
endogenous expression of CLCA1 and low endogenous levels of TMEM16A in these cells
(Kunzelmann et al., 2009; Pritchard et al., 2014). However, cells transfected with CLCA1 stained
strongly both for CLCA1 and, surprisingly, for TMEM16A (Figure 4E–H), suggesting that CLCA1
increases TMEM16A protein levels. Furthermore, signal for both proteins clearly overlapped with
Figure 1. Paracrine activation of calcium-dependent chloride currents in HEK293T cells by CLCA1. (A) GFP-expressing
cells were co-cultured with pHLsec- or CLCA1-transfected cells, and assayed for ICaCC by patch clamp electrophysiology.
(B–C) Whole-cell currents measured in GFP-positive cells from experiments as in (A), superfused with standard
extracellular solution, and in the absence or presence of 10 μM free Ca2+ in the pipette (respectively, [0 μM Ca2+]in or
[10 μM Ca2+]in). (B) Representative current traces. The pulse protocol is shown at the top left. Outward currents are
represented by upward deflections, and dotted lines indicate zero current. Membrane capacitance was similar in all
cases at ∼25 pF. (C) Current–voltage relationships at the end of the 600-ms voltage steps. Membrane potential values
were corrected off-line for the calculated liquid junction potentials, respectively −5.5 mV ([0 μM Ca2+]in) and −6.0 mV
([10 μM Ca2+]in). Data are presented as means ± S.E. (n = 5–9). (D) Current density at +100 mV, from the same
experiments as in (C). Symbols represent data from individual patches; bars indicate the means ± S.E. of all experiments.
*p < 0.01 (one-way ANOVA, F = 30.3 and p = 1.2 × 10−7; followed by Tukey test).
DOI: 10.7554/eLife.05875.003
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Figure 2. Activation of calcium-dependent chloride currents by secreted CLCA1. (A) Untransfected cells were
cultured in medium from pHLsec- or CLCA1-expressing cells, and assayed by patch clamp electrophysiology.
(B–D) Whole-cell currents measured in cells from experiments as in (A), superfused with standard ([154 mM Cl−]out) or
reduced Cl− ([14 mM Cl−]out) extracellular solution; and in the absence or presence of 1 μM or 10 μM free Ca2+ in the
pipette (respectively, [0 μM Ca2+]in, [1 μM Ca2+]in or [10 μM Ca2+]in). (B) Representative current traces obtained with
the same pulse protocol and displayed as in Figure 1B. Membrane capacitance was similar in all cases at ∼25 pF.
(C) Current-voltage relationships at the end of the 600-ms voltage steps. Membrane potential values were corrected
off-line for the calculated liquid junction potentials, respectively −5.5 mV ([0 μM Ca2+]in) and −6.0 mV ([1 μM Ca2+]in
and [10 μM Ca2+]in) for the experiments in [154 mM Cl−]out; and −20 mV for the experiments in [14 mM Cl−]out. Data
are presented as means ± S.E. (n = 5–20). Inset, CLCA1-mediated currents right-shifted ∼ +15 mV upon reduction of
extracellular Cl−; symbols have been removed for clarity. (D) Current density at +100 mV, from the same experiments
as in (C). Symbols represent data from individual patches; bars indicate the means ± S.E. of all experiments. *p <
0.01 (one-way ANOVA, F = 10.4 and p = 2.1 × 10−8; followed by Tukey test).
DOI: 10.7554/eLife.05875.004
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the membrane stain (WGA), consistent with a model in which CLCA1 and TMEM16A associate with
and stabilize one another on the cell surface. Since secreted CLCA1 can activate TMEM16A-
mediated ICaCC in a paracrine manner (Figures 1–3), we carried out similar imaging experiments to
determine whether exogenously applied secreted CLCA1 also increased TMEM16A surface
expression. Cells cultured in media from pHLsec-transfected cells again displayed no detectable
staining for either CLCA1 or TMEM16A (Figure 4I–L), but cells exposed to secreted CLCA1
displayed robust staining for TMEM16A. Signal for CLCA1 was also detected in a few cells,
overlapping with TMEM16A and WGA staining (Figure 4M–P). Surprisingly, although TMEM16A
surface levels increased after exposure to CLCA1, total TMEM16A in cells did not change
(Figure 3C). These results indicate that exogenous secreted CLCA1 colocalizes with and enhances
the fraction of TMEM16A located at the cell surface.
CLCA1 associates with cell surface TMEM16A
To investigate whether CLCA1 and TMEM16A associate directly with one another on the cell
surface, we adapted an assay commonly used to identify immunological receptor-ligand pairs
(Altman et al., 1996). We previously demonstrated that CLCA1 is cut into two fragments by self-
cleavage and that the N-terminal fragment is necessary and sufficient to activate CaCCs in
HEK293T cells (Yurtsever et al., 2012). Thus, for these assays we developed a CLCA1 cell-staining
reagent composed of the N-terminal fragment of CLCA1 (N-CLCA1) containing a specific
biotinylation motif on the C-terminus (Figure 5A). Biotinylated N-CLCA1 was coupled to SA-PE
(streptavidin conjugated to phycoerythrin) to produce a tetrameric fluorescent reagent with
enhanced avidity toward its ligand. Cell-binding assays were carried out in the presence or absence
of an anti-TMEM16A antibody raised against epitopes in the last extracellular loop and then
Figure 3. Genetic knockdown of TMEM16A inhibits CLCA1-mediated calcium-dependent chloride currents.
(A–B) HEK293T cells transfected with RNAi negative control (siControl) or TMEM16A siRNA were incubated
in CLCA1-conditioned medium and assayed by patch-clamp electrophysiology, in standard extracellular
solution ([154 mM Cl−]out) and 10 μM free Ca2+ in the pipette ([10 μM Ca2+]in). (A) Representative current traces
obtained with the same pulse protocol and displayed as in Figure 1B. Membrane capacitance was similar in
all cases at ∼25 pF. (B) Current density at +100 mV. Symbols represent data from individual patches (n = 14); bars
indicate the means ± S.E. of all experiments. *p < 0.01 (unpaired Student’s t test). (C) Effect of CLCA1 and/or TMEM16A
siRNA treatment on TMEM16A protein expression. Upper panel: top, TMEM16A; and bottom, actin (loading control)
Western blot from solubilized HEK293T cells. Lanes are labeled as follows: pHLsec-t, pHLsec transfected cells; CLCA1-t,
CLCA1-transfected cells; CLCA1-c, cells treated with CLCA1-conditioned medium; TMEM16A siRNA, cells transfected
with TMEM16A siRNA; TMEM16A siRNA + CLCA1-c, cells transfected with TMEM16A siRNA and treated with CLCA1-
conditioned medium. Bar graph: quantitation of TMEM16A band intensity normalized to actin band intensity using
ImageJ (NIH).
DOI: 10.7554/eLife.05875.005
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analyzed by flow cytometry. The tetramerized N-CLCA1 displayed robust binding to intact
HEK293T cells compared to background, and this binding was significantly reduced by
pre-incubating the cells with the anti-TMEM16A antibody (Figure 5B). Two control antibodies,
one raised against an intracellular epitope of TMEM16A and the other an isotype control, did not
affect N-CLCA1 binding (Figure 5C). In order to validate that the biotinylation of N-CLCA1 did not
adversely affect function, we carried out whole-cell patch clamp experiments where either purified N-
CLCA1 or purified biotinylated N-CLCA1 was exogenously applied to HEK293T cells. We found that both
of these proteins were able to robustly activate the observed currents (Figure 5D,E). These results indicate
that N-CLCA1 engages TMEM16A on the surface of HEK293T cells, and suggests that the enhanced
TMEM16A level is a consequence of stabilization by CLCA1.
Figure 4. CLCA1 colocalizes with TMEM16A and increases TMEM16A surface expression. (A–D) Membrane (WGA) or immunostaining of HEK293T cells
transfected with pHLsec vector; (E–H), or with CLCA1. Surface TMEM16A is greatly increased by expression of CLCA1. (I–L) Membrane (WGA) or
immunostaining of HEK293T cells cultured in conditioned media from cells transfected with pHLsec vector; (M–P) or cells cultured in conditioned media
from cells transfected with CLCA1. TMEM16A surface expression is greatly enhanced after cells are exposed to secreted CLCA1.
DOI: 10.7554/eLife.05875.006
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Discussion
It has been demonstrated that purified TMEM16A protein reconstituted in proteoliposomes
recapitulates the permeation, pharmacological, voltage- and Ca2+-dependence properties of
TMEM16A channels characterized in heterologous expression systems and native cell models
(Terashima et al., 2013), which implies that TMEM16A does not require association with other
proteins for CaCC activity. However, a recent proteomics approach has identified a large number of
endogenous proteins implicated in protein trafficking, surface expression, folding and stability that
interact with TMEM16A, including SNAREs such as syntaxins and syntaxin-binding proteins, and the
ezrin-radixin-moesin (ERM) scaffolding complex (Perez-Cornejo et al., 2012). Our data identify
CLCA1 as the first secreted direct regulator of TMEM16A, and our findings suggest that CLCA1 may
modulate TMEM16A channel activity by stabilizing it at the cell surface, much like the SNARE and
ERM protein networks of the TMEM16A interactome.
So how does CLCA1 modulate TMEM16A currents? We observe that CLCA1 increases
TMEM16A surface expression without increasing expression of the protein (Figure 3C). A model
consistent with our data and the current literature is that CLCA1 engages and stabilizes dimeric
TMEM16A on the surface of the cell. Previous studies have shown that TMEM16A can exist as
a dimer (Fallah et al., 2011; Sheridan et al., 2011), dimerization being mediated by an
Figure 5. N-CLCA1 engages TMEM16A on the cell surface. (A) Schematic of CLCA1 N-terminal fragment (N-CLCA1) construct with specific biotinylation site and
resultant tetrameric cell-staining reagent created after complexation with SA-PE. (B) Flow cytometry of intact HEK293T cells stained with SA-PE alone (black line),
N-CLCA1/SA-PE (green line), or N-CLCA1/SA-PE in the presence of anti-TMEM16A antibody S-20 (red line). (C) Flow cytometry of intact HEK293T cells either
stained with SA-PE alone (black line), N-CLCA1/SA-PE (green line), N-CLCA1/SA-PE in the presence of anti-TMEM16A antibody C-5 (raised against an intracellular
TMEM16A epitope; orange line), or N-CLCA1/SA-PE in the presence of anti-Aquaporin5 antibody G-19 (blue line). (D–E) Cells were incubated in the absence ([−])
or presence ([+]) of purified N-terminal (N-term) CLCA1 protein before (N-CLCA1) or after biotinylation (N-CLCA1biotin), and assayed by patch-clamp
electrophysiology, in standard extracellular solution ([154 mM Cl−]out) and 10 μM free Ca2+ in the pipette ([10 μM Ca2+]in). (D) Representative current traces
obtained with the same pulse protocol and displayed as in Figure 1B. Membrane capacitance was similar in all cases at ∼25 pF. (E) Current density at +100 mV.
Symbols represent data from individual patches (n = 8–11); bars indicate the means ± S.E. of all experiments. *p < 0.05 (unpaired Student’s t test).
DOI: 10.7554/eLife.05875.007
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intracellular region in the N-terminus of TMEM16A (Tien et al., 2013). Mutations to this region
abolish dimerization, prevent protein trafficking to the plasma membrane, and, consequently,
ablate channel activity (Tien et al., 2013). These observations indicate that dimerization regulates
TMEM16A trafficking and channel activity. It is possible that TMEM16A dynamically shuttles
between the cell surface and intracellular compartments. One possibility is that CLCA1 engages
monomeric TMEM16A and drives dimerization; alternatively, CLCA1 may engage and stabilize
dimeric TMEM16A on the cell surface, thereby preventing its removal and, consequently,
increasing calcium-dependent chloride currents (Figure 6). This highlights an unprecedented
mechanism for regulating ion channel currents by a secreted protein.
The identification of CLCA1 as a modulator of TMEM16A activity raises the possibility of
functional associations between other CLCA and TMEM16 family members. Four to eight CLCA
(Patel et al., 2009) and ten TMEM16 family members (Pedemonte and Galietta, 2014) are
expressed in mammalian tissues. A number of these TMEM16 proteins have poorly defined
functions and do not obviously traffic to the cell surface when expressed alone (Duran et al.,
2012). Future studies will be needed to determine whether other CLCA proteins can associate
with other TMEM16 proteins and influence their function. CLCA1 (Yang et al., 2013), CLCA2
(Sasaki et al., 2012; Walia et al., 2012), and CLCA4 (Yu et al., 2013) have all been implicated in
various cancers as have a number of TMEM16 proteins (West et al., 2004; Dutertre et al., 2010;
Duvvuri et al., 2012; Liu et al., 2012; Qu et al., 2014), and such studies could have tremendous
implications for cooperative CLCA/TMEM16 roles in cancer and other diseases.
Here we report that secreted CLCA1 modulates TMEM16A-dependent ICaCC, and that this
activation can occur in a paracrine fashion. Furthermore, we show that CLCA1 and TMEM16A
colocalize and physically interact on the surface of mammalian cells, with CLCA1 increasing the level
of TMEM16A protein at the cell surface. We thus demonstrate a first downstream target of CLCA
proteins, solving the 20-year-old mystery regarding how CLCA proteins activate ICaCC, and provide
the first example of a secreted protein modulator of TMEM16A activity. CLCA1 (Alevy et al., 2012)
and TMEM16A (Huang et al., 2012; Scudieri et al., 2012) have been separately observed to play
critical roles in chronic inflammatory airway disease models. Our findings have significant implications
for the roles of CLCA1 and TMEM16A proteins as cooperative partners, not only in the physiology and
pathophysiology of the airways, but also in those of other tissues and organs.
Figure 6. Model for CLCA1 modulation of TMEM16A-mediated calcium-dependent chloride currents. Following
secretion and self-cleavage of CLCA1, the N-terminal fragment (N-CLCA1) acts in paracrine fashion (1). Dimerization
appears to regulate surface trafficking of TMEM16A. N-CLCA1 engages TMEM16A on the cell surface (2), stabilizing
TMEM16A dimers, preventing internalization (3) and in turn, results in increased TMEM16A surface expression and
calcium-dependent chloride current density.
DOI: 10.7554/eLife.05875.008
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Materials and methods
Reagents
The following commercial antibodies were used according to the manufacturer’s specifications:
mouse-anti-human-TMEM16A monoclonal antibody C-5 (Santa Cruz Biotechnology, Dallas, TX);
goat-anti-human-TMEM16A polyclonal antibody S-20 (Santa Cruz Biotechnology); mouse-anti-actin
monoclonal antibody C4 (Millipore, Billerica, MA), goat-anti-human-Aquaporin5 polyclonal antibody
G-19 (Santa Cruz Biotechnology); rabbit anti-6-His-antibody-HRP conjugate (Bethyl Laboratories,
Montgomery, TX), goat anti-mouse IgG antibody-HRP conjugate (Santa Cruz Biotechnology); wheat
germ agglutinin (WGA)-Alexa Fluor 633 conjugate (Life Technologies, Carlsbad, CA); donkey anti-
goat IgG-Alexa Fluor 488 conjugate (Life Technologies); donkey anti-rabbit IgG-Alexa Fluor 594
conjugate (Life Technologies); and rabbit anti-human CLCA1 polyclonal antibody 1228 (Biosystems,
Rockford, IL). Mouse anti-human CLCA1 monoclonal antibody 8D3 was produced in-house and used
as previously described (Alevy et al., 2012; Yurtsever et al., 2012). Streptavidin conjugated to
phycoerythrin (SA-PE) was purchased from BD Biosciences (San Jose, CA). Hype-5 transfection
reagent was purchased from OZ Biosciences (San Diego, CA).
Heterologous expression of CLCA1
Full length human CLCA1 (22–914) (CLCA1) cloned into pHLsec vector was used throughout
(Yurtsever et al., 2012). HEK293T cells were cultured in 6-well dishes in Dulbecco’s Modified Eagle
Medium (Life Technologies) supplemented with 10% fetal bovine serum, 105 units/l penicillin and
100 mg/l streptomycin, at 37˚C and 5% CO2. Cells were transfected at 80% confluency using 293fectin
transfection reagent (Life Technologies) at a 1:2 ratio (μg DNA: μl 293fectin), using 1 μg of plasmid
DNA per 1 million cells. Experiments were conducted in cells that were transiently transfected with
CLCA1, or in cells that were exposed to exogenous CLCA1 protein via means of two different
experimental approaches: either co-culture with CLCA1 transfected cells; or treatment with
CLCA1-conditioned medium. For co-culture experiments, cells transfected with CLCA1, empty
pHLsec vector (pHLsec), or EGFP-pCDNA3.1 plasmid (GFP) were trypsinized 24 hr post-transfection,
and GFP-expressing cells were mixed at a 1:1 ratio with either CLCA1 or pHLsec-transfected cells, and
replated at low density on UV-sterilized, 8 mm round German glass coverslips (Electron Microscopy
Sciences, Hatfield, PA). Following trypsin treatment, all transfected cells were pelleted by
centrifugation and washed with sterile PBS prior to replating to prevent carry-over of transfection
medium. After 24 hr, the GFP-expressing cells were assayed for Ca2+-dependent Cl− currents by patch
clamp electrophysiology. For conditioned medium experiments, cells were transfected with either
CLCA1 or pHLsec for 6 hr, then transfection medium was removed, cells were washed with sterile PBS,
and fresh medium was applied; following overnight incubation, medium from these cells was
harvested and centrifuged gently (1500×g, 5 min) to remove non-adherent cells. Untransfected cells
were plated onto round coverslips and incubated for 24 hr in 2 ml of cleared CLCA1- or pHLsec-
conditioned medium supernatants.
Recombinant expression of CLCA1 and in vitro biotinylation
The N-terminal fragment of CLCA1 (22–694; N-CLCA1) was cloned into pHL-Avitag3 vector (Aricescu
et al., 2006), which contains a BirA biotin ligase recognition motif and hexahistidine tag at the
C-terminus. This secreted protein was expressed in 293F cells via transient transfection using Hype-5
at 1:1.5 μl ratio (μg DNA: μl Hype-5), using 1 μg of plasmid DNA per 1 million cells. Media
supernatants were harvested after 72 hr. Protein was purified from media supernatant using Ni-NTA
chromatography and eluted in 5 ml buffer A (50 mM K2HPO4 pH 8, 300 mM NaCl and 250 mM
imidazole). Purified N-CLCA1 was concentrated to a final volume of 300 μl in a centrifuge concentrator
and protein concentration was calculated from absorbance at 280 nm. For the experiments reported
in Figure 5D,E, protein was added onto the untransfected cells at 10 μg/ml and incubated for 24 hr
prior to whole-cell patch clamp experiments. The same volume of buffer A was added onto cells as
buffer control. For in vitro biotinylation, N-CLCA1 containing the specific biotinylation tag at the
C-terminus was exchanged into buffer B (100 mM Tris pH 7.5, 200 mM NaCl, and 5 mM MgCl2)
and specifically biotinylated by addition of biotin and Escherichia coli BirA ligase (produced and
purified in-house) at 4˚C overnight. Excess biotin was removed using a 2 ml desalting column.
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Biotinylated N-CLCA1 was added onto the untransfected cells at 10–50 μg/ml and incubated for 24 hr
prior to whole-cell patch clamp experiments. The same volume of buffer B was added onto cells as
buffer control.
siRNA knockdown of TMEM16A
To investigate the molecular identity of CLCA1-modulated CaCCs, a targeted approach was taken
focusing on TMEM16A. For siRNA knockdown of TMEM16A, cells plated in 48-well plates were
transfected with either 200 nM TMEM16A siRNA (HSS123904; 5′-AAG UUA GUG AGG UAG GCU
GGG AAC C-3′, Life Technologies) or 200 nM medium GC-content Stealth RNAi negative control
(12935300; 5′-GGU UCC CAG CCU ACC UCA CUA ACU U-3′, Life Technologies) using Lipofectamine
2000 (Life Technologies) at a 20:2 ratio (pmol siRNA: μl Lipofectamine 2000); 24 hr later, cells were
plated onto round coverslips and incubated for an additional 24 hr in CLCA1- or pHLsec-conditioned
medium as described above. TMEM16A knockdown was estimated at 60–70% as assayed by qPCR.
Whole-cell patch clamp recordings
Experiments were performed at 25˚C, 24 hr after co-culture or incubation in conditioned medium.
Micropipettes were prepared from non-heparinized hematocrit glass (Kimble-Chase, Vineland, NJ)
on a horizontal puller (Sutter Instruments, Novato, CA), and filled to a typical electrode resistance of
2 megaohms with pipette solution containing 150 mM N-methyl-D-glucamine (NMDG) chloride,
10 mM Hepes, 2 mM MgCl2, 8 mM HEDTA, and 5.8 mM CaCl2 to attain 10 μM free Ca2+, as
calculated by means of the CaBuf program (available through Katholieke Universiteit Leuven).
Selected experiments were performed with a pipette solution containing (mM) 150 NMDG chloride,
10 Hepes and 2 MgCl2, in the absence ([0 μM Ca2+]in) or presence of 5 mM EGTA and 4 mM CaCl2 to
attain 1 μM free Ca2+ ([1 μM Ca2+]in). The pH of all pipette solutions was adjusted to 7.1 with Tris. The
bath solution was 10 mM Hepes, 1 mM CaCl2 and 1 mM MgCl2; plus 150 mM NaCl (standard
extracellular, [154 mM Cl−]out), or 140 mM Na-gluconate and 10 mM NaCl (reduced extracellular Cl
−
[14 mM Cl−]out), and adjusted to pH 7.4 with Tris. After formation of a gigaohm seal and
establishment of whole-cell configuration, cells were voltage-clamped at 0 mV. A pulse protocol was
applied in which membrane potential was held at 0 mV for 50 ms and stepped to a test value for
600 ms before returning to the holding potential for an additional 400 ms. The test potential varied
from −100 to +100 mV in 20 mV increments. Membrane capacitance was calculated from the integral
of the current transient in response to 10 mV depolarizing pulses, and was monitored for stability
throughout the experiment. Data were filtered at 2 kHz, and signals were digitized at 5 kHz with
a Digidata 1322A (Molecular Devices, Sunnyvale, CA). MultiClamp 700B Commander and pClamp
software (Molecular Devices) were used for pulse protocol application and data acquisition. Data
were analyzed using Clampfit 10.1 (Molecular Devices). Liquid junction potentials were calculated
using Clampex JPCalc software and command voltages were corrected a posteriori as specified in
the figure legends. Results are presented as mean ± S.E., differences between two groups were
assessed by unpaired Student’s t test with Welch’s correction, and differences between more than
two groups were evaluated by one-way ANOVA and post-hoc Tukey test (Prism 5.0c, GraphPad
Software, San Diego, CA).
Immunohistochemistry
For staining experiments, cells were either transfected or exposed to conditioned medium as
described above. Following 24 hr incubation, cells were fixed on glass slides with 4%
paraformaldehyde (PFA) in PBS for 5 min and washed twice with PBS. Cells were blocked for
1 hr at room temperature with 1% blocking solution in PBS (Life Technologies) and then incubated
with primary antibodies (rabbit anti-human CLCA1 polyclonal antibody 1228 at 1:100 dilution and
goat-anti-human-TMEM16A polyclonal antibody S-20 at 1:50 dilution) overnight at 4˚C. Slides
were washed and incubated with WGA-Alexa Flour 633 conjugate (5 μg/ml) for 30 min at
room temperature, followed by secondary antibodies (donkey anti-rabbit IgG-Alexa Fluor
594 conjugate at 1:250 dilution and donkey anti-goat IgG-Alexa Fluor 488 conjugate at 1:200
dilution) for 2 hr at room temperature. Washed slides were then mounted in VECTASHIELD
H-1200 Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). Confocal
microscopy was carried out using a Zeiss LSM 510 META Confocal Laser Scanning Microscope
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(Carl Zeiss Microscopy, Thornwood, NY). The images were acquired with LSM 4.2 software and
batch processed with AxioVision 4.8.2 (Carl Zeiss Microscopy).
Flow cytometry binding assay
Human CLCA1 was assayed for binding to cell-surface TMEM16A using a flow cytometry-based
binding assay. Prior to staining, intact HEK293T cells were treated with human FcR blocking reagent at
1:100 dilution (Miltenyi Biotec, San Diego, CA) for 15 min. The biotinylated N-CLCA1 was pre-
incubated with SA-PE at a 4:1 molar ratio for 15 min at room temperature to produce fluorescently
labeled tetramers of N-CLCA1 (N-CLCA1/SA-PE). Cells (4 × 105 cells/sample) were either stained with
SA-PE alone (1:50) or N-CLCA1/SA-PE (1:50) diluted in PBS containing 1% BSA (FACS buffer) at 4˚C. In
order to validate specific binding of N-CLCA1/SA-PE to cell surface TMEM16A, goat-anti-human-
TMEM16A polyclonal antibody S-20 (1:10), which was raised against a 15–20 amino acid peptide
within residues 820–870 (corresponding to the last extracellular loop; UniProt Q5XXA6), was added
prior to addition N-CLCA1/SA-PE. A goat polyclonal IgG antibody for human Aquaporin5 was used
(1:10) as an isotype control for the blocking antibody S-20. Mouse-anti-human-TMEM16A monoclonal
antibody C5, which binds a cytosolic epitope, was used as a second control antibody (1:10). Following
staining, cells were washed with FACS buffer, and then analyzed by flow cytometry (BD FACScan).
Data analysis was performed using FlowJo (Tree Star, Ashland, OR).
Western blotting and densitometric quantitation
HEK293T cells were pelleted, lysed in lysis buffer (1.5 mM KH2PO4, 2.7 mM KCl, 4.3 mM Na2HPO4,
137 mM NaCl and 1% Triton X-100 in deionized water), and then diluted 1:2 in 2× SDS containing
2-mercaptoethanol. Samples were boiled for 5 min, and then loaded on a 4–12% bis-tris Nupage gel
(Life Technologies). The proteins were transferred to nitrocellulose membranes using an iBlot Gel
Transfer Device (Life Technologies). Membranes were blocked by 0.5% nonfat milk in PBS with 0.1%
TWEEN. Primary antibodies (mouse α-human CLCA1 8D3, 1:4000; mouse-anti-human-TMEM16A
monoclonal antibody C-5, 1:1000; mouse-anti-actin monoclonal antibody C4, 1:5000) in blocking
buffer were incubated on the membrane for 15 min. Following three washes with PBS-TWEEN,
secondary antibodies (goat-anti-mouse IgG-HRP conjugate 1:5000) in blocking buffer were applied
for 15 min. After three PBS-TWEEN washes, signal was detected using Pierce ECL Western Blotting
Substrate (Thermo Fisher Scientific, Rockford, IL). Developed films were scanned and converted to
8-bit tiff files. Protein bands were processed equally and the pixel intensities were quantified with
ImageJ 1.48 (http://imagej.nih.gov/ij).
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Abstract
Production of secreted mammalian proteins for structural and biophysical studies can be challenging, time intensive, and costly. Here
described is a time and cost efficient protocol for secreted protein expression in mammalian cells and one step purification using nickel affinity
chromatography. The system is based on large scale transient transfection of mammalian cells in suspension, which greatly decreases the time
to produce protein, as it eliminates steps, such as developing expression viruses or generating stable expressing cell lines. This protocol utilizes
cheap transfection agents, which can be easily made by simple chemical modification, or moderately priced transfection agents, which increase
yield through increased transfection efficiency and decreased cytotoxicity. Careful monitoring and maintaining of media glucose levels increases
protein yield. Controlling the maturation of native glycans at the expression step increases the final yield of properly folded and functional
mammalian proteins, which are ideal properties to pursue X-ray crystallography. In some cases, single step purification produces protein of
sufficient purity for crystallization, which is demonstrated here as an example case.
Video Link
The video component of this article can be found at http://www.jove.com/video/53445/
Introduction
Understanding protein structure at an atomic level is key to uncovering the molecular basis of biological pathways and diseases. X-ray protein
crystallography is the most widely used/applicable method for determining macromolecular structures. The main challenge of this method
is obtaining sufficient amounts of properly folded, pure protein. This becomes an issue particularly when working with secreted mammalian
proteins, which undergo specific post-translational modifications.
Bacterially-expressed proteins are the primary source of crystallized proteins deposited in the Protein Data Bank1. Bacterial expression
systems are largely preferred because they are fast, inexpensive and typically produce high yields of protein. However, extracellular domains
of mammalian proteins expressed in bacteria are often not properly folded, in which case refolding and extensive purification steps are required
for obtaining homogeneously folded protein. Additionally, many mammalian proteins require post-translational glycosylation to achieve proper
folding2. Although expression and glycosylation in yeast or insect cells can overcome the folding problem, post-translational modifications,
including glycosylation, differ significantly from those of mammalian cells3, yielding proteins with incorrect or non-homogeneous modifications.
Mammalian cells express all the required molecular machinery to ensure proper post-translational modifications and folding; however,
these expression systems are not typically preferred by most labs, due to limited yields and high costs of reagents and consumables.
Polyethyleneimine (PEI), a standard transfection reagent is relatively cheap but imposes considerable cytotoxicity and low transfection efficiency,
resulting in increased costs in cell media, DNA, and culturing equipment. Many alternatives to PEI are prohibitively expensive. We address these
issues by describing a combination of improved cell culture tools and chemically modified PEI for the quick and relatively inexpensive method for
the expression of secreted mammalian proteins, followed by single-step purification. This robust method gives sufficient yields for functional and
biochemical studies4, and in some cases, results in protein amenable to crystallization without further purification.
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This protocol describes several techniques to maximize expression and yield for secreted mammalian proteins in human embryonic kidney
(HEK) 293F cells grown in suspension. Transfection efficiency (and cost), protein production and purification are all greatly enhanced by
following this protocol. PEI modified by the addition of carbamates through a single-step ring-opening reaction (PEI-TMC-25, synthesis and
properties described in detail in ref 5) greatly improves transfection efficiency, reduces the cytotoxicity from cationic membrane disruption
and accordingly reduces experiment costs. Furthermore, cell viability and protein expression are greatly improved with the addition of culture
supplements to supply glucose and vitamins. Importantly for the production of glycosylated proteins, treatment with kifunensine, a non-toxic
chemical inhibitor of Mannosidase I, produces proteins with defined, immature glycans, which can be removed by the endoglycosidase EndoHf
to yield proteins with a single N-acetylglucosamine in place of a full-length N-linked glycan6. Finally, the secretion of proteins into a serum-free,
chemically defined medium allows rapid and facile purification for structural and biochemical studies. Single-step nickel-nitrilotriacetic acid (Ni-
NTA) resin purification removes the majority of contaminating species in the supernatant and, in some cases, can yield protein of sufficient purity
for crystallization.
Protocol
1. Production of Milligram Quantities of Plasmid DNA for Large-scale Transient
Transfection
1. Clone the protein of interest into a high copy number mammalian expression vector using restriction site cloning, or other appropriate
technique.
1. For optimal results, use pHLsec 7 vector, which has a built-in C-terminal 6His-tag, a strong promoter Kozak sequence and an optimized
secretion signal.
2. Transform the plasmid onto competent cells.
1. Add 20 µl of competent E. coli cells onto 1 µg of plasmid DNA and incubate on ice for 30 minutes.
2. Heat shock cells at 42 °C for 35 sec, then incubate on ice for 2 min.
3. Add 300 µl of microbial growth medium (SOC) and incubate at 37 °C for 45 mins, shaking at 220 rpm.
4. Plate cells on agar plate with appropriate antibiotic selection.
1. Use 100 µg/ml carbenicillin if the plasmid is in the pHLsec vector.
3. Culture colonies in 250 ml of Luria Broth (LB) Media supplemented with 100 µg/ml antibiotic (carbenicillin) overnight at 37 °C, shaking at 220
rpm.
4. Purify DNA from culture using Hi-Speed Plasmid Maxi Kit according to manufacturer's protocol.
1. Elute DNA in buffer EB (10 mM Tris-Cl, pH 8.5), instead of buffer TE.
2. Aliquot the purified plasmid at amount needed for transfection and store at -20 °C.
2. Large-scale Culture and Transient Transfection of 293F Cells
1. Supplement 1 L 293F media with 10 ml of glutamine and 5 ml Pen/Strep (both 100x). Store at 4 °C. 5 ml Pen/Strep is a sufficient strength in
serum-free conditions and the reduced antibiotic concentration improves cell viability during transfection, which improves protein yields.
2. Culture 293F cells in 300 ml media in 1 L polycarbonate baffled Erlenmeyer flasks with vented caps at 37 °C with 8% CO2, while shaking in a
standard tissue culture incubator.
3. Dilute cells to 5 x 105/ml density one day before transfection.
4. On the day of transfection, supplement culture medium by adding 10% volume of 2% w/v Cell Boost in 293F media.
1. Measure glucose concentration using a glucose monitor according to the manufacturer's instructions and use supplements as needed
to achieve a glucose concentration of 500 mg/dL.
5. Add kifunensine (1 µg/ml final concentration) at this step to control protein glycosylation.
6. Calculate volume of DNA required for 1 µg plasmid per 1 x 106 cells. Under sterile conditions, dilute DNA in 5 ml serum-free medium.
7. Calculate volume of transfection reagent required for 1 µg plasmid per 2 µl transfection reagent. Under sterile conditions, dilute transfection
reagent (PEI-TMC-25) in 5 ml serum-free medium.
8. Add transfection reagent into DNA solution in 1 ml increments, mixing gently. Incubate for 30 minutes at room temperature for reagent-DNA
complexes to form. Then add the solution onto the cells in a drop-wise fashion.
9. Allow transfected cells to express protein for 72-96 hr. Supplement with ~10% volume Cell Boost Media daily, or as necessary to keep
glucose reading 400-600 mg/dl.
3. Purification
1. Decant culture into a centrifuge flask, centrifuge for 20 min at 1,300 x g to pellet cells and then collect the supernatant. If necessary, spin a
second time and/or use 0.22 µm filter to clarify supernatant.
2. Add 10% volume 10x Ni-NTA binding buffer (1.5 M NaCl, 0.5 M K2HPO4, 0.1 M Tris pH 8.5, 50 mM imidazole).
3. Prepare a gravity column by adding 2 ml of Ni-NTA slurry in a column and equilibrating with 10 column volumes (CV) of 1x binding buffer.
If possible, do all column steps in a 4 °C room. Alternatively, chill protein and all buffers on ice before column step, and keep protein and
collected flow-through on ice.
Note: Ni-NTA slurry is 50% resin by volume and the manufacture's stated binding capacity is 50 mg/ml. Ni-NTA beads can be re-charged for
multiple uses
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4. Flow the supernatant over the resin and collect flow-through. Repeat this step.
5. Wash with 10 CV of wash buffer (300 mM NaCl, 50 mM K2HPO4, 20 mM imidazole pH 8).
6. Elute the protein in 5 CV of elution buffer (300 mM NaCl, 50 mM K2HPO4, 250 mM imidazole pH 8).
7. If deglycosylation is required:
1. For a final volume of 0.5 ml, concentrate eluate to 0.43 ml using a centrifugation concentrator. If precipitates form, pellet any debris by
centrifugation at 16,000 x g and 4 °C.
2. Add 50 µl of 500 mM Na-Citrate pH 5.5.
3. Add 20 µl of EndoHf (1 x 106 U/ml). Incubate at room temperature for 2 hours.
Note: The enzyme works optimally at 37 °C, which may cause the concentrated protein to aggregate. Extend the room temperature
incubation, if deglycosylation, assessed by SDS-PAGE or immunoblotting, is incomplete. The enzyme does not have activity at 4 °C.
4. To remove EndoHf: Wash Amylose Resin 3x in phosphate buffered saline (PBS) or final storage buffer. Incubate protein with resin for 1
hr at 4 °C. Spin 5 min at 1,000 x g to pellet beads and collect the supernatant.
5. Concentrate protein using appropriate molecular weight cutoff centrifugation filter and buffer exchange into storage buffer (150 mM
NaCl and 20 mM HEPES pH 7.5).
Representative Results
Herein follows the results of this expression system applied to a secreted 13 kDa immunoglobin (Ig) domain from the human protein triggering
receptor expressed on myeloid cells 2 (hTREM2, residues 19-132). TREM2 is a type I transmembrane protein containing a single extracellular
Ig domain that has two disulfide bonds and two N-linked glycosylation sites. Unlike many other Ig domain proteins8, TREM2 was not amenable
to refolding from bacterial inclusion bodies9. Subsequent mutagenesis confirmed N-linked glycans are required for proper expression and
folding. To facilitate structural and functional studies, TREM2 was introduced into the pHLsec vector with a C-terminal 6His-tag7 using standard
molecular biology techniques. Transient expression in HEK293F cells treated with kifunensine yielded protein that was purified by Ni-NTA
chromatography (Figure 1B, lane 2) and the sample was then deglycosylated to produce natively folded, homogenous protein (Figure 1B, lane
3). 293F expression of TREM2 produced 5-10 mg/L (5-10µg/million transfected cells). After buffer exchanging into the storage buffer, this protein
was crystallized (Figure 1C). Despite the final purity of about 80%, these crystals reliably reproduced, diffracted, and were shown by silver-
stain to only contain TREM2 protein (Figure 1D). This observation suggests the biochemical homogeneity of the protein (i.e. folding and post-
translational modifications) can, in some cases, be more critical than overall purity for crystallization success.
In addition to crystallization, this system offers a robust tool for structural and functional studies. It is exploited to produce natively glycosylated
protein and achieve >95% purity by size-exclusion chromatography (Figure 1E, F). This additional purification step, which shows the solution
behavior of the protein, is also an ideal way to monitor protein quality. The purified protein should elute at a volume corresponding to its
molecular weight and should be the most abundant species in the sample. Abnormally large amounts of aggregated protein may indicate
unstable protein and provide clues to optimize protein production and purification. Furthermore, this final purified protein is superior for use in
quantitative biophysical experiments such as circular dichroism spectroscopy, thermal stability, and investigating protein-ligand interactions.
Lastly, controlling the extent of glycosylation provides a robust tool to study glycan-dependent functions.
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Figure 1: Mammalian Expression System: (A) Scheme for mammalian expression of proteins with controlled or native glycosylation in HEK
293F cells. (B) SDS-PAGE of NiNTA-purified hTREM2 expressed under kifunensine shown before (lane 2) and after (lane 3) deglycosylation
with EndoHf. (C) Crystals produced from NiNTA-purified and deglycosylated protein. (D) Silver stain of crystallization input (lane 1) and
harvested crystals (lanes 2 and 3) reveals crystals only contain TREM2. (E) Further purification of TREM2 was achieved using size-exclusion
chromatography of NiNTA-purified TREM2 produced in 293F cells without Kifunensine. Asterisks (*) indicate elution volumes of molecular weight
standards. Proteins eluted in TBS using an analytical S200 column (GE). (F) SDS-PAGE analysis of size exclusion-purified TREM2: input protein
(lane 2) and folded peak (lane 3). Note how full, heterogeneous glycans run at a higher apparent molecular weight with a broad smear by SDS-
PAGE. Please click here to view a larger version of this figure.
Discussion
HEK 293F cells offer robust production of proteins requiring post-translational modifications. This system allows rapid and scalable expression of
natively folded proteins containing disulfides, glycosylation, and phosphorylation that would otherwise be absent using more routine expression
tools. In addition, this system can be used for the expression and purification of multi-protein complexes simply by co-transfection of multiple
plasmids. Besides TREM2, this system has been extensively used for functional studies with other proteins of interest in the lab10,11. Mammalian
cells also offer endotoxin-free protein expression optimal for in vivo experiments or for production of natively folded antigens to generate
conformation-dependent antibodies.
Optimal cell viability and transfection conditions are the most crucial for efficient protein production. For better cell viability, low-passage
cell cultures are boosted with cell culture supplements and the antibiotic concentration in the growth media is reduced. The modified PEI-
TMC-25 has suitable transection efficiency with most proteins; however, there are other options available at moderate price that offer increased
transfection efficiency and reduced cytotoxicity. Hype 5 (Oz Bioscience) increases yields compared to PEI or other reagents, at a considerably
reduced cost compared to more expensive transfection reagents, such as 293fectin. The reagent type and DNA: reagent ratios can be optimized
for individual expressions and the needs of the desired experiment.
The method described here has several advantages over other methods of protein production. Mammalian cells offer native chaperone folding
and post-translational modifications unavailable to bacteria and yeast. The reduced time for plasmid construction and preparation, along the use
of media, the pH of which can be directly modified, make it superior to baculovirus-based production in insect cells; and finally, the serum-free
media offers facile scaling (higher cell density) and purification not attainable to adherent 293T cells. The chief limitation of this system is only the
time and scale the individual researcher is able to commit to protein expression.
Included below are troubleshooting options for the most common issues encountered.
Troubleshooting
If there is low protein expression, avoid passaging 293F cells longer than 2-3 months. Prolonged passaging results in decreased cell health
reflected in slower doubling times and significantly reduced protein expression. Cell growth should be monitored daily and cultures no longer
doubling daily should be discarded. Cell viability can be improved by using culture supplements while passaging cells. Monitor glucose to ensure
a culture concentration of 400-600 mg/dl Cell density should not exceed 2 million/ml and cell viability should be ≥98% by trypan blue exclusion.
Dilute dense cells to 0.5 million/ml and allow to double overnight before transfection. Optimize transfection using different ratios of transfection
reagent: DNA (within the range of 1 µg DNA: 1.5-6 µl reagent). This can be done using 2 ml cultures in a 6-well plate and the output measured
by immunoblotting. Doing 12 hr time points can indicate if the protein is being expressed and degraded rapidly; check the cell lysate if protein is
not observed in the supernatant fraction. Misfolded proteins, which fail to be secreted, will still be apparent in the cell lysate by immunoblotting.
If Ni-NTA retention is low, i.e. protein remains in flow-through after column binding, use fresh resin. Increasing pH of sample to 8.5 will result in
stronger binding to the resin, although this will also increase non-specific binding. Concentrating the sample and batch binding to resin overnight
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at 4 °C before Ni-NTA purification may result in ~5x increase in recovered protein. If the 6His-tag is inaccessible due to tertiary structure of the
protein, try cloning it on the other terminus. Alternatively, use Cobalt resin, which has a higher affinity for His residues.
If the protein aggregates and/or precipitates during purification, increase solubility by adding 10% glycerol into the Ni-NTA wash and elution
buffers. Run the nickel affinity columns at room temperature instead of 4 °C. Use differential scanning fluorimetry12 to screen for pH and salt/
additives that increase stability of the protein in solution.
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Chloride transport proteins play critical roles in inflammatory airway diseases, contributing to the detrimental aspects of mucus
overproduction, mucus secretion, and airway constriction. However, they also play crucial roles in contributing to the innate
immune properties of mucus and mucociliary clearance. In this review, we focus on the emerging novel roles for a chloride
channel regulator (CLCA1), a calcium-activated chloride channel (TMEM16A), and two chloride exchangers (SLC26A4/pendrin
and SLC26A9) in chronic inflammatory airway diseases.
1. Introduction
The chronic inflammatory airway disease, asthma, and chronic
obstructive pulmonary disease (COPD) are significant causes
of morbidity and mortality in children and adults. Asthma
affects over 300million people worldwide, and the prevalence
is increasing among all demographics. COPD is currently
the third leading cause of death in USA. These diseases
are hallmarked by a Th2-mediated inflammatory response
which drives the three pathologies that contribute to airway
obstruction in these diseases: chronic inflammation; airway
muscle constriction due to airway hyperreactivity (AHR);
and mucus overproduction due to mucous cell metaplasia
(MCM). A central feature of these diseases is production
of the inflammatory cytokines IL-4 and IL-13, which drive
MCM and contribute to AHR.
The inflammatory signaling upregulates the expression
of hundreds of proteins in the airway epithelia. A number
of these proteins have roles in anion transport across mem-
branes, including chloride channels, channel regulators, and
transporters. The identity, function, and elucidated mecha-
nism of action of these proteins have lagged behind their
cation channel counterparts. However, recent advances in
several technologies, including high throughput screening,
have made it possible to consider the development of specific
inhibitors and activators for these classes of proteins [1].
The development of such therapeutics, however, requires an
intimate knowledge of the roles these proteins play in airway
homeostasis and mucociliary clearance. Anion channels play
very crucial roles in mucus function. Mucus is composed of
97% water and 3% solids, with the main solid component
being themucin proteins [2]. Mucin proteins are secreted in a
dehydrated form and require anion channel activity to instill
chloride and bicarbonate ions that ensure proper salination,
hydration, and pH of the mucus gel layer. Proper control of
this is crucial as is exemplified by the disease cystic fibrosis
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(CF), which is caused by loss of function mutations to the
chloride channel cystic fibrosis transmembrane conductance
regulator (CFTR) that produces thick, sticky mucus deficient
in mucociliary clearance or innate antimicrobial properties
[3].
Here we discuss what is currently known about the
function of four exciting, new, and emerging proteins affect-
ing anion channel activity in inflammatory airway epithelia:
a chloride channel regulator (CLCA1), a calcium-activated
chloride channel (TMEM16A), and two chloride exchangers
(SLC26A4/pendrin and SLC26A9). In particular, we focus
on recently uncovered contributions to airway diseases and
mucus function, in order to answer whether they can be
targeted by inhibitors or activators and whether they should
be.
2. The CLCA Family of Chloride
Channel Regulators
The CLCA family of proteins was originally misidentified
as calcium-activated chloride channels and has long been
associated with chronic inflammatory airway diseases.Their
evolving functional identity and the possible role they play in
these diseases have only recently been elucidated.
2.1. CLCAs: Association with Chronic Inflammatory Air-
way Diseases. Asthmatic inflammation results from a Th2-
mediated mechanism, where the cytokines IL-4 and IL-13
bind their receptors and activate the transcription factor
STAT6 to drive inflammation and mucus overproduction in
the airways [4, 5]. In mouse models of both allergic and
respiratory virus induced-asthma, CLCA1 (previously known
as mCLCA3 or gob-5) expression has been solidly linked to
IL-13 driven MCM [6, 7] and controversially linked to AHR
[6], both hallmarks of asthma andCOPD. Similar results were
observed in vitro with the human pulmonary mucoepider-
moid cell line NCI-H292, in which expression of the protein
significantly increased mucin geneMUC5AC expression and
subsequent mucus production [8, 9], implying that CLCA1
can drive MCM. Studies using Clca1−/− mice, however, have
failed to show reduced response to IL-13 stimulation, as these
mice showed the same phenotype as wild-type (WT) mice
[7, 10]. Othermembers of the family, particularly CLCA2 and
potentially CLCA4A and CLCA4B, have also been observed
to be upregulated and to induce and colocalize with the
inflammatory mucin protein, MUC5AC [7]. These results
indicate a possible functional redundancy between members
of the mouse CLCA family, which is unlikely to translate to
humanbiology, as there are only three humanCLCAproteins,
compared to the seven mouse CLCA proteins [11] (Figure 1).
Of the three human CLCA proteins, CLCA1 has been
identified as a potential biomarker of inflammation and
MCM in the airways [12] and suggested as a potential drug
target for treatment of asthma and COPD. Similar to mouse
CLCA1, overexpression of human CLCA1 in NCI-H292 cells
increases MUC5AC expression and mucus levels [6, 8, 9].
Its expression is upregulated in primary cell models of IL-
13 driven MCM and siRNA-mediated knockdown of CLCA1
prevents IL-13-driven mucus overproduction [9]. These
experimental observations suggest a central role for CLCA1
function in IL-13-mediated MCM (Figure 2). Additionally, it
is highly overexpressed in the airway epithelia of asthmatic
patients [8] and can be found in the bronchoalveolar lavage
fluid (BALF) at high levels [13]. In contrast, othermembers of
the human CLCA family are not upregulated in response to
IL-13 [8, 9], suggesting that CLCA1 is the sole family member
with an essential role in MCM in human airways.
2.2.The Conceptual Evolution of CLCA Proteins from “Chan-
nels” into “Channel Regulators”. The family of CLCA proteins
were first cloned from bovine and murine samples, where
overexpression of these proteins increased Ca2+-sensitive Cl−
conductance, which led to their initial misannotation as
Ca2+-activated Cl− channels (CaCCs) [14–16]. In addition,
observations that nonspecific chloride channel blockers, such
as niflumic acid and DIDS, seemed to reduce both currents
and the mucus production [17] erroneously supported this
hypothesis. However, modern bioinformatics algorithms and
experimental approaches have definitively demonstrated that
CLCA proteins are soluble, secreted proteins that do not
constitute ion channels themselves [13, 18], and subsequent
studies demonstrated that CLCA proteins activate currents
through an endogenous CaCC [18–20]. As a consequence,
the CLCA nomenclature has been updated and the family
is now recognized as Ca2+-activated Cl− channel regulator
proteins. Allmembers of this family (with the exception of the
likely pseudogenes human CLCA3 and mouse CLCA4C) are
synthesized as full-length proteins and proteolytically cleaved
into two fragments. It has been demonstrated that, for some
of the family members, the cleavage is carried out by a zinc-
dependent matrix metalloprotease-like (MMP-like) domain
located in the N-terminus of the protein [18, 21] (Figure 1).
However, sequence analysis has revealed that all CLCA family
members contain the required MMP active site motif [18];
thus self-cleavage is likely a conserved feature of all CLCAs.
Self-cleavage is required to unmask the N-terminal fragment
ofCLCA1, which then interactswith theCaCC [18] (Figure 2).
The molecular identity of this previously unknown CaCC
has been shown to be TMEM16A and the direct interaction
between the channel and the N-terminal fragment stabilizes
and increases the cell surface expression of the channel,
thereby increasing currents [20].
2.3. CLCA1 as a Potential Regulator of Cytokine Expression.
Upstream of CLCA1 expression, the involvement of Th2-
cytokines IL-4 and IL-13 has been shown in cellular and
animal models as discussed above.The relationship between
CLCA1 and downstream cytokine signaling, however, is still
under investigation. The few articles that do exist report
contradictory observations regarding the role of CLCA1 as
a signaling molecule for cytokine expression. Challenging
Clca1−/− mice with lipopolysaccharide (LPS), Long et al.
observed increasedKC (keratinocyte-chemoattractant) levels
in BALF, but no change inMIP-2 (macrophage inflammatory
protein 2) or IL-17 levels in the knockout mice compared
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Figure 1: Domain architecture schematic for human and mouse CLCA proteins. Each row contains the corresponding human and mouse
homologs. Mouse CLCA proteins are labeled according to the recently updated naming commissioned by the Mouse Gene Nomenclature
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to WT mice [22]. In contrast, Dietert et al. observed sig-
nificantly decreased levels of IL-17 and CXCL-1 in BALF
from the Clca1−/− mice infected with Staphylococcus aureus
[23]. Using a cellular model of inflammation, Ching et al.
showed that CLCA1-conditionedmedia increased proinflam-
matory cytokine (IL-6, IL-8, IL-1훽, and TNF 훼) mRNA
levels in monocyte cell line U-937 and primary porcine
alveolar macrophages. Immunopurified CLCA1 protein only
increased IL-8 and IL-1훽 levels significantly [24]. If such a
regulatory mechanism exists for cytokine expression, modu-
lation of CLCA1 functionwith smallmolecules to treatmucus
cell metaplasia might also alter the inflammatory response in
the airways.
3. TMEM16: The First Family of CaCCs
While CaCC conductance was a long-observed phenomenon
in the airways and could be separated from CFTR cur-
rents, the molecular identity of the channels responsible for
these currents remained elusive until the late 2000s. The
TMEM16/Anoctamin family was identified in 2008 as the
first bona fide CaCCs [25–27]. However, based on their
electrical and pharmacological characterization, only two
of the ten family members, TMEM16A and TMEM16B,
displayed properties previously observed for CaCCs in the
airways [28, 29], whereasmost of the othermembers function
as lipid scramblases. Of these two, TMEM16A expression has
been verified in airway epithelium and airway smoothmuscle
cells [30].
3.1. TMEM16A Is Linked to Chronic Inflammatory AirwayDis-
eases. The predicted topology for TMEM16 family members
is based on the recent landmark crystal structure of the fungal
Nectria haematococca TMEM16 (nhTMEM16) which has 10
transmembrane domains instead of the previously predicted
8 (Figure 3) [31]. The purified and reconstituted protein,
which was shown to be a homodimer [32], constitutes a
channel on its own and does not require other proteins to be
active [33]. While the Ca2+ sensitivity of the channel is well
documented [31, 34, 35] and the protein directly binds Ca2+,
the possible involvement and mechanism of interaction with
calmodulin as a calcium sensor and binding partner are still
controversial [35–37].
Much like CLCA1, expression of TMEM16A is upregu-
lated by IL-4/IL-13 stimulation [38–41]. Upon upregulation,
TMEM16A colocalizes to the apical plasma membrane of
goblet cells along with the mucin MUC5AC [41–43]. It
is expressed in airway smooth muscle cells and has been
shown to play a role in AHR [42]. Additionally, inhibitors
of TMEM16A have been shown to block mucus secretion
[42, 44] whereas small molecule activators increase secretion
[45].
3.2. The Potential for Targeting CLCA1 and TMEM16A in
Chronic Inflammatory Airway Diseases. CLCA1 is a promis-
ing therapeutic target for asthma and COPD, as it is the only
member of its family to be upregulated in models of IL-13
mediated mucus overproduction [9], is a secreted protein
[18], is expressed in goblet cells [7, 9, 16], and associates with
mucin granules [46, 47]. Overexpression of CLCA1 in airway
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epithelium induces MUC5AC expression via a signaling cas-
cade involving the kinase MAPK13, and siRNA-knockdown
of CLCA1 blocks mucus production in these models [9],
implying a critical role for CLCA1 function in inflamma-
tory mucus production. Consistent with these observations,
DNA vaccines [48] and antibodies targeting mouse CLCA1
[49] have displayed some effectiveness in reducing airway
inflammation andMUC5AC levels in mouse asthmamodels.
Similarly, as mentioned above, TMEM16A inhibitors block
ATP-dependentmucus secretion, suggesting a central role for
this pair in inflammatorymucus overproduction. However, it
should be noted that these smallmolecules have relatively low
potency and questionable selectivity and these findings need
to be supported by additional experiments to determine the
role TMEM16A plays in mucus secretion [50]. An important
question that currently remains unanswered is what role this
pair of molecules plays in mucociliary clearance. It is well
known that anion channel activity is required for secreted
mucins (MUC5AC and MUC5B) to function properly in a
mucosal immunity and mucociliary clearance capacity [51].
Mucin proteins are secreted in dense, dehydrated granules
and require anion channel passage of chloride and bicar-
bonate ions to ensure proper hydration, salination, and pH
control [2].Thus, any therapy targeting anion channel activity
in airway diseases should proceed with caution to avoid
any potential detrimental impacts to mucociliary clearance
and innate mucosal immunological properties. Along these
lines, exploiting the mechanism CLCA1-mediated regulation
of TMEM16A action might be a possible therapeutic route
for CF, utilizing a potential compensatory channel to make
up for loss of CFTR activity [52]. Further along these lines,
TMEM16A has been shown to carry not only chloride ions
but also bicarbonate ions [36]; thus activation of TMEM16A
in the setting of CF could be beneficial to adjust mucus
hydration and pH.
4. SLC26: An Ancient Family with
Unexpected New Roles
Over the last decade the anion exchanger pendrin (PDS,
SLC26A4), once thought to be limited mainly to the inner
ear, kidney, and thyroid, has been found to be upregulated by
inflammatory cytokines in the bronchial epithelium, where
it contributes to the pathogenesis of inflammatory airway
diseases [53–55] and also to the host response to bacterial
infections [56, 57]. Another member of the family, SLC26A9,
is prominently expressed in the airway epithelia, where it
interacts with CFTR to modulate mucus production [58].
The discovery of these crucial roles in lung physiology and
pathophysiology makes these anion transporters intriguing
new biomarkers for airway disease and promising novel
pharmacological targets.
4.1. Pendrin: An Anion Exchanger with Critical Roles in Ear,
Kidney, and Lung Physiology. Pendrin (PDS, SLC26A4) is
a member of the SLC26 family of multifunctional anion
transporters and channels [59, 60]. The eleven mammalian
SLC26 genes encode proteins with cytoplasmic N-termini
and C-termini flanking a transmembrane core of unknown
structure, predicted to span the lipid bilayer 10 to 14 times
(Figure 4). Mutagenesis, homology modeling, and molecular
dynamics simulation data are consistent with the hypothesis
that the SLC26 transmembrane fold consists of two nesting,
inverted repeats of 5–7 helices, resembling that of the CLC
Cl−/H+ antiporter channel proteins [61, 62] and the recently
solved three-dimensional structure of SLC26Dg, a bacterial
H+-coupled fumarate symporter, has clarified this [63]. It has
been suggested that SLC26 proteins organize in functional
homodimers or homotetramers [64], though each subunit is
thought to constitute an independent translocation pathway.
The C-terminal cytoplasmic region of all SLC26 proteins
includes a sulfate transporter and antisigma factor antagonist
(STAS) domain (Figure 4), which has been implicated in
nucleotide binding and hydrolysis [65]. SLC26A4, or pen-
drin, functions as an electroneutral exchanger of Cl−, HCO3−,
I−, NO3−, formate, SCN−, and other monovalent anions. It is
expressed in cochlear epithelial cells of the spiral prominence,
in root cells, in spindle cells of the stria vascularis, in
epithelial cells of the endolymphatic sac, and in epithelial
cells surrounding the hair cells of the saccule, utricle, and
ampulla [66]. Additionally, pendrin is expressed in the apical
membrane of thyrocytes [67, 68], renal collecting duct Type
B intercalated cells [69], salivary gland cells [70], and airway
epithelia [53].
Pendrin function is important in several settings. In the
inner ear, pendrin helpsmaintain Cl− andHCO3− homeosta-
sis, which is crucial for normal hearing and for the develop-
ment of bony structures such as the cochlea and the vestibular
aqueduct [71]. In the thyroid gland, pendrin contributes I−
to the follicle for thyroxine biosynthesis [72], and in the
cortical collecting duct the transporter is implicated in Cl−
reabsorption through functional coupling with the epithelial
Na+ channel ENaC and the Na+-dependent Cl−/HCO3−
exchanger NDCBE/SLC4A8 [73]. Most interestingly, it has
been shown that in the bronchial epithelium pendrin medi-
ates an increase in Cl−/SCN− exchange in response to IL-4
stimulation [74] to provide SCN− substrate to lactoperoxidase
for the synthesis of hypothiocyanite (OSCN−), a molecule
with antimicrobial properties [75], and this underscores the
emerging role of pendrin in innate airway defense mecha-
nisms (Figure 5).
4.2. Pendrin and the Pathogenesis of Inflammatory Lung
Disease: Too Much of a Good Thing? Pendrin was first iden-
tified by positional cloning as the disease gene for Pendred
syndrome (OMIM number 247600), an autosomal recessive
condition characterized by deafness with enlargement of
the vestibular aqueduct, complex abnormalities in cochlear
structure, and variably penetrant euthyroid goiter [76–78].
Pendrin is also implicated in DFNB4, an autosomal recessive
form of nonsyndromic deafness [79]. SLC26A4 mutations
that are clinically associated with Pendred syndrome cause
complete loss of transport function when studied in heterol-
ogous expression systems, mostly due to retention in var-
ious intracellular compartments, whereas those exclusively
associated with DFNB4 have residual transport activity [80].
In recent years, pendrin gain of function, mainly due to
increased surface expression, has been linked to respiratory
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diseases including bronchial asthma, COPD, and rhinovirus
infection, rhinitis, and chronic rhinosinusitis [54, 55, 81–86].
The association between pendrin and inflammatory air-
way disease was first proposed in 2005, when it was observed
that pendrin expression was upregulated in three different
murine asthma models, including transgenic overexpression
of IL-13 in lung [83]. Later, it was reported that induction
of asthma or COPD in mice by inhalation of ovalbumin or
elastase, respectively, resulted in increased pendrin expres-
sion; direct overexpression of pendrin in the lung led to
increased mucus production and secretion and neutrophilic
infiltration [86]. In subsequent works, the link between
inflammatory cytokines, in particular IL-4 and IL-13, and
pendrin overexpression has been cemented [81, 85, 87],
and in a recent study SLC26A4 was identified as the most
upregulated gene in human asthmatic bronchi [88]. A major
downstream effect of IL-4 and IL-13 signaling is the activa-
tion of the signal transducer and activator of transcription
6 (STAT6). Following ligand-receptor binding, associated
Janus kinases (JAKs) activate the receptor, allowing STAT6
to then be recruited and activated by phosphorylation. Once
phosphorylated, STAT6 homodimerizes and translocates to
the nucleuswhere it regulates the transcription of target genes
via binding to N4 interferon-훾 activated sequences (N4 GAS)
in the promoter region [89].The pendrin promoter contains
at least one N4 GAS motif, and STAT6 has been shown to
bind this sequence in vitro, thus suggesting that increases in
pendrin promoter activity via STAT6 represent at least one
mechanism bywhich IL-4 and IL-13 increase pendrin activity
[87]. Cytokines other than IL-4 and IL-13may be responsible
for increases in pendrin expression; IL-1훽, a macrophage-
secreted cytokine involved in the immunopathogenesis of
asthma and COPD, has also been shown to increase pendrin
levels in rodent and human bronchial epithelial cells [74, 90].
Signaling through IL-4/IL-13 mediates airway hyperre-
sponsiveness, eosinophilic inflammation, mucus cell meta-
plasia and mucus overproduction, subepithelial fibrosis, and
increased viscosity of the airway surface liquid (ASL), all of
which are common to bronchial asthma and COPD [91].
Pendrin may play a major role in the pathogenesis of asthma
or COPD by regulating some of these responses, in particular
ASL thickness and mucus production (Figure 5). In lung
epithelial cells, reabsorptive Na+ transport through ENaC is
suppressed whereas secretory Cl− transport through CFTR
and CaCCs is stimulated, which collectively results in a
net secretory phenotype whereby water osmotically flows
into the lumen and ASL viscosity decreases. On the other
hand, pendrin imports Cl− in exchange for other anions,
and thus an IL-4/IL-13-mediated increase in pendrin activity
may shift the equilibrium towards a reabsorptive phenotype,
resulting in the osmotic flow of water into the interstitium
and the thinning of the ASL [85]. In asthmatic mice, mucus
overproduction is accompanied by an increased pendrin
expression at the apical surface of bronchial epithelial cells,
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Figure 5: Roles of ion channels in the airway epithelium. In response to allergens and other asthma and COPD exacerbating factors, Th2-
cytokines IL-4 and IL-13 induce a water secretory phenotype by stimulating Cl− secretion via CFTR and Ca2+-activated Cl− channels such
as TMEM16A and by decreasing Na+ and Cl− reabsorption via ENaC and SLC26A9, respectively, which leads to the thickening of the airway
surface liquid (ASL). TMEM16A activity can be increased by secreted CLCA1 protein. In concert, signaling through IL-4/IL-13 increases the
functional expression of pendrin, which results in reabsorption of water and thinning of the ASL. Pendrin can also increase the secretion of
thiocyanate (SCN−), a substrate for the production of the antimicrobial agent hypothiocyanite (OSCN−) by the lactoperoxidase system. Toxins
from B. pertussis and other bacteria trigger an IL-17A-mediated inflammatory host response in the lung epithelium, which is characterized
by a significant upregulation of pendrin activity.
and in pendrin overexpression cell models, production of
MUC5AC, a major mucus protein in asthma and COPD
patients, is increased [86]. In mice, pendrin overexpression
is also accompanied by neutrophil-dominant inflammation,
suggesting that, in this system, mucus production may be
induced not only by a direct effect of pendrin on airway
epithelial cells, but also by an indirect effect of pendrin by
recruiting inflammatory neutrophils [86].
In bronchial epithelial cells, IL-4/IL-13 signaling upregu-
lates the expression of CLCA1 [9], CFTR [92], and pendrin
[87], whereas it downregulates the expression of the 훽
and 훾 subunits of ENaC. Because upregulation of certain
proteins, such as pendrin, might aggravate asthma or COPD
symptoms, whereas the downregulation of ENaC and the
downregulation of CLCA1 might be protective (Figure 5), it
is unsurprising that pharmacological strategies aimed at the
blocking of the IL-4/IL-13 pathway are not as successful as
they were anticipated to be [93]. Selective inhibition of pen-
drin could be an intriguing new strategy for asthma/COPD
therapy, but as noted above, pendrin contributes to the
secretion of SCN−, a substrate of lactoperoxidase for the
production of the protective, antimicrobial OSCN− [74], and
this should be taken into account when exploring novel
treatment avenues.
4.3. The Next Frontier: Pendrin and Infectious Lung Disease.
Most recently, pendrin has been implicated in the IL-17A-
dependent host inflammatory response to bacterial airway
infections (Figure 5) [56, 57]. IL-17A is critical for the
immune response of the lung to infectious bacteria, for exam-
ple,Haemophilus influenzae, Staphylococcus aureus,Klebsiella
pneumoniae, andBordetella pertussis [94].The latter is the eti-
ologic agent of whooping cough, or pertussis disease, which
is a resurgent condition of great clinical concern as it can
progress to pulmonary inflammation anddeath in infants and
for which there is no effective treatment [95]. Pertussis toxin
(PT), the virulence factor of B. pertussis, undermines the host
immune system by inhibiting macrophage and neutrophil
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responses, suppressing the production of antibodies against
the bacteria, and inducing proinflammatory cytokines, in
particular IL-17A [96]. One of the most highly upregulated
genes in association with PT activity is SLC26A4 [97, 98], and
pendrin is upregulated in human bronchial epithelial cells
exposed to IL-17A [56]. In the lungs of B. pertussis-infected
mice there is an increase in pendrin levels that is concomitant
with an increase in IL-17A but not in IL-4/IL-13 levels, and
pendrin upregulation is significantly hampered in Il-17a-
null mice [57]. Other host factors may be involved in PT-
dependent upregulation of pendrin, such as IL-1훽 and IFN-훾,
as both are upregulated during B. pertussis infection and have
been linked with pendrin upregulation [85, 98, 99]. Taken
together, these recent advances suggest that the upregulation
of pendrin, with its associated inflammatory pathology, is a
major mechanism of virulence for the pertussis toxin and
position pendrin as a potential novel therapeutic target for
the treatment of whooping cough.
4.4. SLC26A9: A Novel CFTR Regulator. SLC26A9 is another
member of the SLC26 family of anion exchangers and
channels. It is robustly expressed in apical airway epithelia
[100] and gastric parietal cells [101] and to a lesser extent in
the kidney, brain, and reproductive tracts [59, 102–104]. The
function of SLC26A9 is still unclear: it has been described as
a Cl− channel with a small degree of bicarbonate transport
[104], a Cl− channel or a Cl−/HCO3− exchanger [105, 106].
One group reported increased Cl− conductance particularly
in high bicarbonate conditions [107], and others have found
that SLC26A9 activity is coupled to Na+ transport [58, 103,
108]. Like other members of the family, SLC26A9 is predicted
to span the membrane 14 times, and it contains a STAS
domain followed by a PSD95-Dlg1-Zo-1 (PDZ) domain in
the C-terminal cytoplasmic region (Figure 4) [59, 109]. Two
groups propose that SLC26 proteins, including SLC26A9,
interact with CFTR initially via their PDZ domains [110,
111]. This is followed by a stronger interaction between
the CFTR R domain and the SLC26 STAS domain, which
is enhanced by PKA-dependent phosphorylation of the R
domain [111–113]. The interaction between SLC26A9 and
CFTR has been described in multiple studies. However,
whether the interaction is stimulatory or inhibitory is still
controversial and may be cell type-dependent [108, 114].
Not much is known about the regulation of SLC26A9, but
WNK kinases, also known to regulate other transporters
and channels involved in osmoregulation, have been shown
to inhibit SLC26A9 activity via interaction with the STAS
domain [109]. Though the influence of SLC26A9 on CFTR
has been reported, the reciprocal interaction is less clear.
Multiple groups have describedCFTR regulation of SLC26A9
activity and expression, but the results are not consistent
[58, 114–118]. Evidence of CFTR and SLC26A9 coexpression
has been found in the lung, trachea, stomach, and sweat gland
[119].
Due to its high expression in the lung, numerous studies
have investigated the role of SLC26A9 in lung disease.
Anagnostopoulou and colleagues [120] first reported that
SLC26A9 activity is responsible for increased constitutive
Cl− current under Th2 inflammatory conditions, but not in
normal physiology. The authors also found that SLC26A9
prevents airway mucous obstruction after stimulation with
IL-13. These changes were due to increased SLC26A9 activ-
ity, which may be due to changes in regulation by WNK
kinases [104]. Unlike CFTR and TMEM16A, SLC26A9 is
downregulated in patients with allergic asthma (Figure 4).
Further investigation revealed that a SNP in the 3耠 UTR of
the SLC26A9 gene likely reduced expression levels in these
patients, possibly through enhanced binding of hsa-miR-632
[120].
SLC26A9 has also been implicated in the pathogenesis
of bronchiectasis, the widening of airways frequently due
to mucous obstruction, a condition often seen in patients
with cystic fibrosis. A recent report [119] identified two
patients with diffuse idiopathic bronchiectasis who also had
mutations in the SLC26A9 gene. One patient presented with a
mutation in a transmembrane domain of SLC26A9 (V486I);
the patient’s brother was asymptomatic, though he had the
samemutation.The second patient presentedwith amutation
in the STAS domain of SLC26A9 (R575W) in addition to the
Fdel508mutation in CFTR. Coexpression of both mutants in
Xenopusoocytes provided evidence of a decreased interaction
between the SLC26A9 STAS domain and the R domain of
CFTR. It is thought that wild-type SLC26A9, in conjunction
with CFTR loss, may enhance ion conductance and fluid
secretion [121]. Thus, loss of SLC26A9, in the setting of
CFTR loss, may result in reduced airway surface liquid
hydration, mucous blockage, and consequent bronchiectasis.
The authors of the study further narrow the CFTR-SLC26A9
interaction region to a peptide within the STAS domain but
do not confirm that the R575W mutation in this peptide
disrupts the interaction and activation [119]. In contrast, a
second group did not report changes in Cl− transport with
the R575W mutation [122]. As the second patient’s daughter
only carried the Fdel508mutation andwas asymptomatic, the
authors speculate that one mutation in CFTR is not sufficient
to produce the CF phenotype [119]. However, mutations in
modifier genes, such as SLC26A9, may contribute to CF in
those heterozygous for CFTRmutations.Thus, SLC26A9may
influence phenotypic expression of heterozygous mutations
in ion channels (CFTR, ENaC, and others) involved in airway
surface liquid hydration [119].
Further supporting the modifier gene hypothesis, some
SLC26A9 mutations have been shown to increase the risk
of meconium ileus in patients with CF [123], as well as CF-
related diabetes onset [124] and pancreatic disease severity
[108, 125]. In the case of CFTR and SLC26A9 double muta-
tions, the exact mechanism causing the phenotype must be
further investigated as Cl− transport could be due to altered
CFTR and/or SLC26A9 function or to impaired regulation of
CFTR by SLC26A9 or vice versa [119, 124]. Understanding the
variousmechanisms of SLC26A9mutationswill be important
towards developing therapies that can improve lung diseases
such as asthma, CF, and bronchiectasis.
5. Conclusions
Chloride transport proteins play crucial roles in airway
health and disease. On one hand, they contribute to proper
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mucus function by controlling mucus hydration and pH via
controlling chloride and bicarbonate ion transport. On the
other hand, they may play a direct role in mucus synthesis,
secretion, and AHR. Recent animal model studies have
emphasized the crucial role that mucus and mucin proteins
play in innatemucosal immunology.Deletion ofMUC5B (the
main secreted mucin protein produced in the airway under
homeostatic conditions) results in impaired mucociliary
clearance and increased microbial infection [126]. Knockout
of CFTR in pig results in airway mucus that is more acidic
and deficient in antimicrobial activity due to loss of defensin
function at low pH [3, 127] and is also deficient inmucociliary
clearance as it remains tethered to secreting cells [128]. This
could be due to improper proteolytic processing of mucin
proteins, since loss of CFTR function in the intestine impairs훽-meprin processing and release of secreted mucins in that
setting [129]. Thus a complete understanding of how these
channels contribute to mucus synthesis, secretion, function,
and mucociliary clearance is required to understand the
impact of modulating their activity.
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The p38 MAP kinases (p38 MAPKs) represent an important family centrally
involved in mediating extracellular signaling. Recent studies indicate that family
members such as MAPK13 (p38!) display a selective cellular and tissue
expression and are therefore involved in specific diseases. Detailed structural
studies of all p38 MAPK family members are crucial for the design of specific
inhibitors. In order to facilitate such ventures, the structure of MAPK13 was
determined in both the inactive (unphosphorylated; MAPK13) and active (dual
phosphorylated; MAPK13/pTpY) forms. Here, the first preparation, crystal-
lization and structure determination of MAPK13/pTpY are presented and the
structure is compared with the previously reported structure of MAPK13 in
order to facilitate studies for structure-based drug design. A comprehensive
analysis of inactive versus active structures for the p38 MAPK family is also
presented. It is found that MAPK13 undergoes a larger interlobe configura-
tional rearrangement upon activation compared with MAPK14. Surprisingly,
the analysis of activated p38 MAPK structures (MAP12/pTpY, MAPK13/pTpY
and MAPK14/pTpY) reveals that, despite a high degree of sequence similarity,
different side chains are used to coordinate the phosphorylated residues. There
are also differences in the rearrangement of the hinge region that occur in
MAPK14 compared with MAPK13 which would affect inhibitor binding. A
thorough examination of all of the active (phosphorylated) and inactive
(unphosphorylated) p38 MAPK family member structures was performed to
reveal a common structural basis of activation for the p38 MAP kinase family
and to identify structural differences that may be exploited for developing
family member-specific inhibitors.
1. Introduction
The mitogen-activated protein kinases (MAPKs) are crucially
involved in signal transduction in response to several extra-
cellular stimuli. In mammalian cells, there are four well char-
acterized MAPK families, ERK1/2, ERK5, JNK and p38
MAPK; these are serine/threonine kinases that catalyze the
reversible phosphorylation of proteins. Their central involve-
ment in crucial signaling pathways has made them important
drug targets.
The p38 MAPKs consist of four family members: p38"
(MAPK14), p38# (MAPK11), p38$ (MAPK12) and p38!
(MAPK13). These p38 MAPKs are highly similar in sequence,
and all are activated by dual phosphorylation mediated by
the MAPK kinases MKK3 and MKK6 (Cuenda & Rousseau,
ISSN 1399-0047
2007). Within the family, they can be divided into two
subgroups based on sequence similarity, cellular expression
patterns and substrate specificity: MAPK14 (p38!) and
MAPK11 (p38") represent one subgroup, and MAPK12
(p38#) and MAPK13 (p38$) represent the other. MAPK14
(UniProt ID L7RSM2) and MAPK11 (Q15759) display the
highest sequence identity (75%). MAPK14 was the first family
member to be identified; it is fairly ubiquitously expressed and
is centrally involved in pro-inflammatory signaling, thereby
making it the focus of several drug-development efforts, while
MAPK11 expression is more specific and its function appears
to be redundant with that of MAPK14. In contrast, MAPK12
(P53778) and MAPK13 (O15264) are more divergent in
sequence (62 and 61% identical to MAPK14, respectively),
display more tissue-specific expression patterns and therefore
contribute to more restricted functions (Risco & Cuenda,
2012). This tightly controlled expression pattern suggests that
distinct biological pathways may be targeted by inhibiting
specific isoforms. In this vein, MAPK13 has recently emerged
as a potential disease-specific drug target. MAPK13 regulates
the insulin secretion and survival of pancreatic "-cells,
implying a central role in diabetes (Sumara et al., 2009).
MAPK13 is also pivotal in neutrophil chemotaxis pathways,
contributing to acute respiratory distress syndrome (ARDS;
Ittner et al., 2012). In addition, studies in knockout mice
indicate that MAPK13 contributes to pathways activated in
chronic inflammatory conditions (Risco et al., 2012), is crucial
for the development of arthritis in certain models (Criado et
al., 2014) and is centrally involved in tumorogenesis in colitis-
associated colon cancer models (Del Reino et al., 2014). Along
these lines, we have observed that a signaling pathway
progressing through MAPK13 mediates mucus over-
production in chronic inflammatory lung disease, and that
MAPK13 inhibitors can block inflammatory mucus produc-
tion in cell-culture models (Alevy et al., 2012).
Given the importance of MAPK13 as a potential specific
drug target in chronic inflammatory lung disease (and possibly
in other diseases), we initiated a structure-based drug-design
project targeting this kinase by determining the structure
of the inactive form of the enzyme and comparing it with
two inhibitor-bound complexes (Alevy et al., 2012). In order to
develop a more complete understanding of the structural basis
for activation of MAPK13, we developed methods to produce
activated (dual phosphorylated on Thr180 and Tyr182)
MAPK13 (referred to in the following as MAPK13/pTpY),
determined the X-ray crystal structure of MAPK13/pTpY and
compared it with our previous structure of inactive unphos-
phorylated MAPK13 (MAPK13). In addition, we compared
these with previously determined structures of other inactive
(MAPK14 and MAPK11; Wang et al., 1997; Patel et al., 2009)
and active (dual phosphorylated; MAPK14 and MAPK12;
Bellon et al., 1999, Zhang et al., 2011) p38 MAPKs. These
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Figure 1
Purification and crystallization of unphosphorylated MAPK13 and dual-phosphorylated MAPK13 (MAPK13/pTpY). (a) Representative size-exclusion
chromatogram displaying a single peak for the mixture of MAPK13 and MAPK13/pTpY eluting from a Superdex 75 16/60 column. Peak center elution
volumes for molecular-weight calibration standards are marked as squares. (b) Representative ion-exchange chromatogram displaying peaks for the
MAPK13 and MAPK13/pTpY crystallization constructs. (c) Western blot of the collected ion-exchange fractions from (a) using anti-phospho-p38
antibody. (d) Crystals of unphosphorylated MAPK13. The largest crystals are 0.05 " 0.2 mm in size. (e) Crystals of MAPK13/pTpY. The largest crystals
are 0.15 " 0.15 mm in size.
studies reveal a universal structural basis for activation for the
p38 MAPK family.
2. Materials and methods
2.1. Expression constructs
Full-length human MAPK13 consists of 365 amino acids
and contains several basic residues at the C-terminus (six of
the last 12 residues are either Arg or Lys), and this full-length
protein (1–365) would not readily crystallize in initial trials.
Thus, for crystallization, a slightly truncated MAPK13
construct (1–352) was designed and cloned into pET-28a as an
N-terminally His6-tagged construct using the NdeI and XhoI
restriction-endonuclease sites, as described previously (Alevy
et al., 2012). The construct was confirmed by sequencing.
2.2. Protein expression and purification
The construct was transformed into Escherichia coli
Rosetta2 (DE3) cells (Stratagene) and colonies were grown
on a plate with kanamycin selection. Cultures for protein
expression were grown in LB medium using chloramphenicol
(40 mg ml!1) and kanamycin (50 mg ml!1) selection. Typically,
8 " 1 l cultures were grown at 37#C until the OD600 reached
0.8–1.0. Protein expression was then induced at 30#C by the
addition of 0.5 mM IPTG, and each 1 l of medium was enri-
ched with 10 ml saturated glucose solution during protein
expression. Protein expression was carried out at 30#C for 4 h.
Cell pellets were harvested by centrifugation (typically
yielding 5–10 g cell paste per litre of culture) and suspended in
lysis buffer suitable for nickel–nitrilotriacetic acid (Ni–NTA)
chromatography (50 mM K2HPO4 pH 8.0, 300 mM NaCl,
10 mM imidazole, 10% glycerol, 10 mM !-mercaptoethanol).
The cells were lysed by the addition of 0.5 mg ml!1 lysozyme
and DNAse I followed by sonication. The clarified lysate was
passed over Ni–NTA, which was washed with lysis buffer
containing 20 mM imidazole and the proteins were then eluted
with 250 mM imidazole. The protein was further purified
by gel-filtration chromatography on an A¨KTA FPLC. The
protein was run over a Superdex 75 16/60 prep-grade column
in a buffer consisting of 20 mMHEPES pH 7.5, 150 mM NaCl,
0.001% NaN3, 5 mM dithiothreitol, 10% glycerol. The protein
(at this point still a mixture of MAPK13 and MAPK13/pTpY)
eluted as a single peak correlating to a monomeric molecular
weight (Fig. 1a). This peak was harvested and then dialyzed
against a buffer consisting of 20 mM Tris pH 8.0, 10 mM NaCl,
1 mM DTT, 10% glycerol (buffer A). The protein was then
subjected to anion-exchange chromatography using a Mono Q
5/50 GL column (GE Life Sciences). The protein was bound
onto the column using buffer A and then eluted off using a
gradient of 0–60% buffer B (20 mM Tris pH 8.0, 1M NaCl,
1 mM DTT, 10% glycerol) over 40 column volumes. This
resulted in the separation of MAPK13 and MAPK13/pTpY
(Fig. 1b). The eluted fractions were analyzed by Western blot
using anti-phospho-p38 antibody (AF869), which was raised
against a dual-phosphorylated p38 activation-loop peptide
(Millipore; Fig. 1c). These preparations yielded an average of
6 mg MAPK13 and 4 mg MAPK13/pTpY per litre of culture
(i.e. roughly a 3:2 ratio of MAPK13:MAPK13/pTpY).
2.3. Crystallization of MAPK13/pTpY and MAPK13
MAPK13/pTpY was exchanged into buffer consisting of
20 mM HEPES pH 7.5, 150 mM NaCl, 0.001% NaN3, 1 mM
dithiothreitol, 10% glycerol and concentrated using an
Amicon spin concentrator (Millipore). MAPK13/pTpY would
not crystallize under similar conditions to MAPK13. There-
fore, we initiated crystallization trials using broad commercial
screens including The JCSG Core I–IV Suites (Qiagen), The
PEGs I and II Suites (Qiagen), Crystal Screen (Hampton
Research) and Index (Hampton Research), followed by
optimization. Crystals were grown at 17#C using the hanging-
drop vapour-diffusion method. Hexagonal crystals of
MAPK13/pTpY were grown by mixing protein solution (at
10 mg ml!1) with reservoir solution (100 mM bis-tris pH 6.2–
6.6, 21% PEG 3350, 200 mM NaCl) in a 1:1 ratio (Fig. 1e). The
total drop volume was 2 ml. Orthorhombic crystals of non-
phosphorylated MAPK13 (Fig. 1d) have been described
previously (Alevy et al., 2012).
2.4. Data collection, processing and structure determination
X-ray diffraction data were collected on beamline 4.2.2 at
the Advanced Light Source (ALS) using a NOIR-1 CCD
detector and an 85 " 120 mm beam size. Data were indexed
and processed with HKL-2000 (Otwinowski & Minor, 1997).
A molecular-replacement solution was obtained using
BALBES (Long et al., 2008). The best solution utilized
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Table 1
Data-collection and refinement statistics for MAPK13/pTpY.
Values in parentheses are for the highest resolution shell.
Data-collection statistics
Space group P65
Unit-cell parameters (A˚) a = 107.23, b = 107.23, c = 125.53
X-ray source ALS 4.2.2
Wavelength (A˚) 1.0070
Resolution (A˚) 50.0–2.60 (2.69–2.60)
Rmerge (%) 0.088 (0.590)
Completeness (%) 97.9 (91.5)
Multiplicity 8.9 (5.5)
hI/"(I )i 19.8 (2.0)
Wilson B factor (A˚2) 48.61
Refinement statistics
Rwork 0.205 (0.265)
Rfree 0.255 (0.318)
No. of amino-acid residues 674
No. of waters 186
R.m.s.d., bond lengths (A˚) 0.005
R.m.s.d., angles (#) 1.015
Average B factor (A˚2)
Protein (chain A/chain B) 57.2 (51.2/63.2)
Water 47.8
Ramachandran plot
Favored (%) 93.0
Allowed (%) 6.1
Outliers (%) 0.9
Poor rotamers (No./%) 5/0.84
Clashscore (score/percentile) 7.79/99th
MolProbity score (score/percentile) 1.87/98th
Luzzati error 0.3067
PDB code 4myg
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Figure 2
Structure of MAPK13/pTpYand comparison with MAPK13. (a) Ribbon diagram of MAPK13/pTpY color-coded as follows: N-lobe, green; C-lobe, blue;
hinge, red; activation loop, red. Simulated-annealing OMIT Fobs" Fcalc electron density contoured at 3.0! for pThr180 and pTyr182 is shown in the inset.
(b) Superposition of MAPK13pTpY (green with red activation loop and hinge) and MAPK13 (orange with blue activation loop and hinge). MAPK13/
pTpY was superposed using the C-lobes. (c, d) Coordination of pThr180 and pTyr182 and comparison of structure of the activation loop between the
active and inactive forms. Hydrogen bonds are shown as yellow dashed lines. ‘Warhead’ arginines involved in direct interactions with pThr180 and
pTyr182 are shown with grey C atoms. Hydrogen bonds are shown as yellow dashed lines. Note that a major portion of the MAPK13 activation loop is
disordered, displays no visible electron density and therefore could not be placed in the inactive structure.
phosphorylated MAPK12 (p38!/pTpY; PDB entry 1cm8;
Bellon et al., 1999) as a probe. Solutions were not obtained
using unphosphorylated full-length MAPK13 (PDB entry
4exu; Alevy et al., 2012) and could only be obtained by
searching separately with the N- and C-lobe domains. This is
owing to the large degree of relative motion between the N-
and C-lobes that occurs upon phosphorylation. The solution
had a Q-factor of 0.829 and a final Rwork and Rfree of 0.267 and
0.328, respectively. The model was completed in Coot (Emsley
et al., 2010) using "A-weighted 2Fobs ! Fcalc maps, and
refinement was carried out in PHENIX (Adams et al., 2010).
Because of the moderate resolution, torsion-angle NCS
restraints were used throughout. Data-collection and refine-
ment statistics are summarized in Table 1. Following all
refinements, model bias in electron-density maps was reduced
using the kicked-map feature in PHENIX. The final model for
both chains included residues 15–351 (residues 1–14 and 352
could not be located in electron-density maps and were not
built). The average error in the coordinates from the Luzzati
plot was calculated using SFCHECK (Vaguine et al., 1999) in
the CCP4i interface (Potterton et al., 2003; Winn et al., 2011).
LSQ was used within Coot to perform and calculate r.m.s.d.s
of C# superpositions. Motion between domains upon phos-
phorylation was analyzed using DynDom using the domain-
select mode (Hayward & Berendsen, 1998). All molecular-
graphics figures were produced using PyMOL (Schro¨dinger).
All crystallographic software was provided from the latest
distributions of the SBGrid (Morin et al., 2013).
3. Results and discussion
3.1. Production, purification and crystallization of active
MAPK13/pTpY
Large amounts of pure, active (phosphorylated) forms of
MAPKs are required for structural, biophysical and enzymatic
studies. For other p38 MAPKs, this has previously been
accomplished either by using eukaryotic expression systems
capable of post-translational modifications such as insect cells
(Pargellis et al., 2002) or by overexpression and purification
from bacteria followed by directed phosphorylation by treat-
ment with a constitutively active MKK6 mutant (Bellon et al.,
1999). Here, we demonstrate that MAPK13/pTpY is produced
by autophosphorylation during expression in E. coli and that
the unphosphorylated and phosphorylated MAPK13 can be
separated using ion-exchange chromatography (Figs. 1b and
1c), producing protein of sufficient purity for the crystal-
lization of both forms (Figs. 1d and 1e). We have reported
previously that $-phosphatase can be used to dephosphorylate
MAPK13 (Alevy et al., 2012); however, this treatment is not
very efficient (only increasing the yield of MAPK13 by about
10%) and is unnecessary to produce either MAPK13 or
MAPK13/pTpY suitable for crystallization. The expression
and purification scheme outlined here is sufficient for these
purposes. Previous studies have indicated that activated
MAPKs may dimerize and that this dimerization contributes
to kinase activity. We observe that MAPK13/pTpY co-elutes
with MAPK13 in the context of a gel-filtration chromato-
graphy experiment, eluting at a roughly monomeric weight
(Fig. 1a). Thus, within the context of a gel-filtration chroma-
tography experiment, MAPK13 appears to be monomeric in
both the active and the inactive forms.
3.2. Structure of MAPK13/pTpY and comparison with
MAPK13
To gain an understanding of the structural basis for the
activation of MAPK13, and a more complete understanding
of p38 MAPK family activation in general, we determined
the structure of MAPK13/pTpY and compared it with our
previously determined structure of inactive MAPK13 (Alevy
et al., 2012). In our previously determined MAPK13 structure
(PDB entry 4exu) there is one molecule in the asymmetric
unit. There are two molecules in the asymmetric unit of the
MAPK13/pTpY structure that are nearly identical (the same
residues are built; r.m.s.d. on C# atoms of 0.94 A˚); thus, only
the A chain will be discussed and used in structural compar-
isons throughout this manuscript. While the crystals of
MAPK13 diffracted to high resolution (1.70 A˚), the crystals of
MAPK13/pTpY diffracted to moderate resolution (2.60 A˚; see
Table 1); however, the phosphorylation sites and covalently
bound phosphates, as well as the entire activation loop, were
well resolved in the electron-density maps (Fig. 2a). The
structures display the standard MAPK topology consisting of
N- and C-lobes encompassing a catalytic groove between
them. Nearly the entire protein could be placed in electron-
density maps for both MAPK13 (2–172 and 181–351) and
MAPK13/pTpY (15–351). The main difference between the
two structures occurs in the relative orientation of the N- and
C-lobes and also in the activation loop (Fig. 2b). The two
phosphorylated residues in the activation loop are coordi-
nated by basic side chains from both lobes of the kinase, and
this results in a more compact catalytic site and overall
structure. The largest difference between the two structures
occurs in the activation loop; much of this region is notably
absent from electron-density maps and is therefore likely to
be disordered in the MAPK13 structure, but it is very well
ordered in the MAPK13/pTpY structure (Figs. 2c and 2d).
This is in contrast to MAPK14, where the activation loop is
clearly observed in both the inactive MAPK14 and activated
(MAPK14/pTpY) structures (see, for example, Fig. 5b). We
have previously demonstrated that these crystals of inactive
MAPK13 are useful for the determination of MAPK13–
inhibitor complexes via soaking for the purposes of structure-
based drug-design studies (Alevy et al., 2012), since the acti-
vation loop is disordered and is not involved in crucial crystal
contacts, and therefore is amenable to the conformational
adjustments required for inhibitor binding.
3.3. Comparison of activation phosphate coordination in p38
MAPK/pTpY structures
The activation loop is the nexus of conformational differ-
ences between unphosphorylated and phosphorylated
structures. Phosphorylation of Thr180 and Tyr182 induces
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conformational changes in the activation loop in order to
stabilize the large negative charges introduced by the phos-
phate groups. Packing analysis suggests that this conforma-
tional change is not greatly influenced by crystal packing. This
coordination involves basic residues from both the N- and
C-lobes, which in turn drives reorientation of catalytic site
residues and, ultimately, closure between the two lobes,
producing a conformation that is compatible with substrate
binding and/or catalysis. Given the crucial importance of
phosphate coordination in producing the catalytically active
form, we examined the known p38 MAPK/pTpY structures
in order to compare their activation-loop conformations and
coordination of phosphate groups. Using superpositions of
the C-lobes, MAPK13/pTpY and MAPK12/pTpY displayed
nearly identical activation-loop conformations (r.m.s.d. on C!
of 0.23 A˚ for activation-loop residues), while MAPK14/pTpY
displayed a very different activation-loop conformation
(r.m.s.d. on C! of 2.24 A˚ for activation-loop residues) (Fig. 3).
Surprisingly, the basic residues utilized to coordinate the
phosphates were not invariant in the structures of the p38
MAPK family, even though nearly all of the residues used are
sequence-invariant throughout the family and in proximity
(Figs. 3 and 4b). For coordination of the pThr moiety, two
invariant arginines (Arg71 and Arg173 in MAPK13) are used
in all three structures, while a third (Arg149 in MAPK13) was
utilized in two of the structures (Figs. 3b, 3c, 3d and 4b).
Additionally, this moiety is coordinated by two unique
residues in both MAPK14/pTpY (Arg67; Fig. 3c) and
MAPK12/pTpY (Lys69; Fig. 3d). For coordination of the pTyr
moiety, one invariant arginine was used by all three of the
kinases (Arg186 in MAPK13) as well as an additional invar-
iant arginine in MAPK13/pTpY and MAPK12/pTpY only
(Arg189 in MAPK13). A unique histidine (His228), which is
not conserved in MAPK13 or MAPK12, was also utilized to
coordinate the pTyr phosphate in MAPK14/pTpY (Fig. 3c).
Taken altogether, these observations are surprising in that the
p38 MAPK family display a high degree of sequence identity
(e.g. 61% identity between MAPK13 and MAPK14, the most
divergent pair; Fig. 4a) yet achieve stabilization of the active
form of the kinase using different structural elements. This
is owing to a redundancy of basic residues available in this
region and is also likely to be contributed to by the different
configurations of N-lobes in the structures. These observations
suggest that despite the high degree of sequence identity,
structural differences can exist between the active forms of the
kinases, and this could contribute to selective activation and
possibly be exploited to design specific inhibitor strategies.
3.4. Comparison of structural transition upon activation in
MAPK13 versus MAPK14
The only other p38 MAPK family member for which crystal
structures of both the inactive unphosphorylated and activate
pTpY forms have been determined is MAPK14, which is also
the least homologous to MAPK13. Thus, we performed a
comparison of the structural changes that occur between the
research papers
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Figure 3
Comparison of activation-loop phosphate-group coordination in p38 MAPK/pTpY crystal structures. (a) Overlay of MAP13/pTpY (PDB entry 4myg;
blue with red activation loop), MAP14/pTpY (PDB entry 3py3; orange with magenta activation loop) and MAP12/pTpY (PDB entry 1cm8; green with
cyan activation loop) superposed using the C-lobes. Note the similarity in activation-loop conformations in MAPK13/pTpYand MAPK12/pTpY. (b, c, d)
Coordination of pThr and pTyr phosphate groups. ‘Warhead’ basic residues involved in direct interactions with phosphate groups are colored according
to their conserved use in the three structures (black, used in all three; grey, used in two; white, used in one). Hydrogen bonds are shown as yellow dashed
lines.
two forms for these family members. Overall, the structural
differences between the inactive and active forms of the
kinases are not major; however, slightly larger changes occur
upon activation of MAPK14. The r.m.s.d. for superposition of
MAPK13 compared with MAPK13/pTpY was 2.38 A˚ (for 329
C! atoms in common excluding the activation loop) versus
2.55 A˚ on comparing MAPK14 and MAPK14/pTpY (with the
same 329 C! atoms in common excluding the activation loop).
The largest difference between the inactive and activated
structures is the conformational rearrangement of the activa-
tion loop. This loop is disordered in
MAPK13 (residues 172–180 are
missing) and thus not built in the
MAPK13 structure (see Fig. 2c) and
only becomes ordered in the active
MAPK13/pTpY structure; however, this
loop is ordered in both the MAPK14
and MAPK14/pTpY structures. The
coordination of the activation-loop
phosphates is carried out by basic resi-
dues from both lobes and leads to a
more closed and compact structure in
the activated state. We compared the
relative movement of the two domains
in the MAPK13 versus MAPK13/pTpY
and MAPK14 versus MAPK14/pTpY
structures using DynDom (Hayward &
Berendsen, 1998). The difference
observed in MAPK13 versus MAPK13/
pTpY is most dramatic (25! relative
rotation between the N- and C-lobes)
compared with the MAPK14 and
MAPK14/pTpY pair (only 8! relative
rotation) (Figs. 5a and 5b).
The activation-loop reconfiguration
also induces a large rotation of about
100! in the side chain of Asp168 in the
conserved DFG motif in both MAPK13
and MAPK14, which locks the crucial
Phe169 side chain into a hydrophobic
pocket (Figs. 5c and 5d). Interestingly,
there are differences in the ATP-
binding site that occur in MAPK14
activation that are not present in
MAPK13. In MAPK14, Met109 in the
hinge region blocks the ATP-binding
site; however, in MAPK14/pTpY
Met109 occupies a new pocket and this
conformational rearrangement allows
a flip of the peptide bond owing to the
presence of the adjacent Gly110
(Fig. 5d). The hinge region of MAPK13
does not contain a glycine residue and
correspondingly does not undergo large
backbone changes in going from the
inactive to the active form (Fig. 5c). The
arrangement of having a glycine at this
position in the hinge region is not
frequent, occurring in only about 9% of
the human kinome. These observations
suggest that targeting this structural
transition could be an effective strategy
research papers
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Figure 4
Sequence comparison of p38 MAP kinases. (a) Table of percentage sequence identity of MAPK13
compared with other p38 MAPK family members. (b) Sequence alignment of human p38 MAPKs.
Invariant and conserved residues are highlighted with magenta and yellow backgrounds,
respectively. The secondary structure of phosphorylated human MAPK13 is shown above the
alignment. The hinge region, DFG motif, gatekeeper (G), dual phosphorylation site (P), activation
loop, R-spine residues (R) and C-spine (C) are shown. Warhead basic residues (W) are colored
according to their conserved use to coordinate activation-loop phosphates in the p38 MAPK/pTpY
structures compared here (black, used in all three; grey, used in two; white, used in one). This figure
was generated using ESPript3.0 (Gouet et al., 2003).
to specifically target MAPK14, as has recently been demon-
strated with skepinone-L (Koeberle et al., 2012).
3.5. Comparison of conserved ‘spine’ structures in p38
MAPKs
Kornev and Taylor recently performed an analysis of the
conservation of spatial motifs found in activated but not
in inactivated protein kinase structures and uncovered the
presence of two crucial hydrophobic elements in activated
kinases that they termed ‘spines’ (Taylor & Kornev, 2011).
They concluded that all protein kinases contain two contig-
uous hydrophobic structures that link the N- and C-lobes of
the protein in the activated form, that breaking these spines
results in an inactive kinase structure, that many kinases
research papers
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Figure 5
Comparison of MAPK13 and MAPK14 conformational change upon phosphorylation. (a) MAPK13/pTpY, blue; MAPK13, light blue. (b) MAPK14/
pTpY, orange (PDB entry 3py3; Zhang et al., 2011); MAPK14, light orange (PDB entry 1p38; Wang et al., 1997). Note that the activation loop of
MAPK14 is ordered in both the inactive and active forms, whereas the MAPK13 activation loop is disordered in the inactive form. (c, d) Comparison of
the hinge and ATP-binding pocket region in (c) MAP13/pTpY and (d) MAPK14/pTpY.
display discontiguous spine structures in their inactive form,
and that activation drives the assembly of contiguous spines.
These two spines were termed the regulatory spine (R-spine),
which consisted of four residues (two from the N-lobe, one
from the C-lobe and one from the activation loop), and the
catalytic spine (C-spine) consisting of seven residues (two
from the N-lobe and five from the C-lobe). The R-spine is
usually dynamically assembled upon reconfiguration of the
activation loop after phosphorylation, whereas assembly of
the R-spine is only completed upon binding of ATP, with the
adenine ring docking into and completing the spine structure.
Given that structures have now been determined for three p38
MAPK family members in both the activated (MAPK12/
pTpY, MAPK13/pTpY and MAPK14/pTpY) and inactivated
(MAPK11, MAPK13 and MAPK14) forms, we undertook the
first comprehensive comparison of spine structures within this
family. All of the R-spine residues are invariant within the
p38 MAPK family, as are all of the C-spine residues, with
the exception of conservative substitutions at two positions
(Fig. 4b). All display a discontiguous R-spine in the inactive
forms (Figs. 6b, 6d and 6f), which becomes contiguous after
configuration of the activation loop (Figs. 6a, 6c and 6e). This
largely comes from the repositioning of Phe169, which takes
on varied conformations in the inactive forms (Fig. 6h) but
locks into a hydrophobic pocket in the active forms (Fig. 6g).
Dislodging of this Phe side chain from this pocket, thereby
breaking the C-spine, is the mechanism exploited by so-called
type II and III kinase inhibitors (Karcher & Laufer, 2009).
Most of the structural transitioning of the C-spine residues
comes from pure translation as the kinases take on a more
compact structure in the activated form. Thus, the p38 MAPKs
display a dynamic assembly of spines in going from the in-
active to the active state (similar to that observed in other
kinases) and the largest structural change within these spines
comes from reconfiguration of the Phe side chain from the
DFG motif which completes the R-spine.
4. Conclusion
Here, we report the first production and purification of
MAPK13/pTpY suitable for structural and biophysical studies.
This allowed us to determine the first structure of the activated
form MAPK13/pTpY, to compare it with our previously
determined structure of inactive MAPK13 and to perform the
first comprehensive analysis of inactive versus active forms of
p38 MAPK family members. Including the structure reported
in this manuscript, there are currently structures of three p38
MAPK family members in both the inactive state, MAPK11
research papers
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Figure 6
Comparison of the assembly of ‘spine’ residues in inactive versus active p38 MAPK structures. Catalytic spine residues (C-spine) are shown as yellow
CPK spheres and regulatory spine residues (R-spine) are shown as red CPK spheres. (a, b) Comparison of MAPK13/pTpY and MAPK13. (c, d)
Comparison of MAPK14/pTpY and MAPK14. (e, f ) Comparison of MAPK12/pTpY (PDB entry 1cm8; Bellon et al., 1999) and MAPK11 (PDB entry
3gc9; Patel et al., 2009). (g) Multiple alignment of residues comprising the two spines in p38 MAPK/pTpY structures. Alignment is based on
superposition of the C-lobes. (h) Multiple alignment of residues comprising the two spines in p38 MAPK structures. Residue labeling is shown for
MAPK13 in both (g) and (h).
(Patel et al., 2009), MAPK13 and MAPK14 (Wang et al., 1997),
and in the active (pTpY) state, MAPK12 (Bellon et al., 1999),
MAPK13 and MAPK14 (Zhang et al., 2011). This makes this
subfamily of MAP kinases the most comprehensively studied
structurally, as the only other structure of an activated family
member is that of ERK2 (Canagarajah et al., 1997). The major
structural changes that occur in comparing the inactive with
the active form of MAPK13 occur to stabilize the negative
charge introduced by the two phosphates at pThr180 and
pTyr182. This coordination is achieved using residues from
both the N- and C-lobes of the kinase, which give the active
form a more compact structure. This is consistent with what
is observed on comparing MAPK14 and MAPK14/pTpY,
although the interlobe rotation is more dramatic for MAPK13
(25! for MAPK13 versus 8! for MAPK14) and is closer to that
observed for ERK2 (Canagarajah et al., 1997). Another major
difference is in the hinge region, in which major backbone
rearrangements occur in MAPK14 that are required to allow it
to engage the catalytically required ATP. This rearrangement
does not occur in MAPK13. This structural transition repre-
sents a possible unique feature to target for the development
of specific inhibitors.
Stabilization of the major negative charges introduced by
dual phosphorylation is achieved using basic residues from
both lobes within the p38 MAPK family. A surprising obser-
vation from our analysis is that, despite a high degree of
sequence similarity in the p38 MAPK family, different resi-
dues are utilized to carry out the coordination of the phos-
phate groups in the different p38 MAPKs. This suggests that
the inhibition of specific p38 MAPKs may be accomplished
by targeting the nonconserved residues that are critical for
stabilizing the active form of the kinase.
Among the p38 MAPKs, MAPK13 appears to have a more
restricted expression pattern and correspondingly has been
linked to specific disease pathways. For example, we have
observed that MAPK13 activity is crucial in a model of IL-13-
induced mucus overproduction which upregulates the self-
cleaving metalloprotease CLCA1 (Alevy et al., 2012), where
self-cleavage is required to activate the CLCA1 protein
(Yurtsever et al., 2012). These studies detail the first compre-
hensive analysis of p38 MAPK structures in the inactive and
active (pTpY) forms, thus providing a framework for under-
standing the structural basis for activation of p38 MAPKs that
could be useful in the design of specific inhibitors.
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Abstract 
The p38 MAP kinases are an important family centrally involved in mediating extracellular signaling 
in various diseases. While much attention has previously been focused on the ubiquitously expressed 
family member MAPK14 (p38α), recent studies indicate that family members such as MAPK13 
(p38δ) display a more selective cellular and tissue expression and might therefore represent a specific 
kinase to target in certain diseases. In order to facilitate the design of potent and specific inhibitors, we 
present here the structural, biophysical, and functional characterization of two new MAPK13-inhibitor 
complexes, as well as the first comprehensive structural, biophysical, and functional analysis of 
MAPK13 complexes with four different inhibitor compounds of greatly varying potency. These 
inhibitors display IC50 values either in the nanomolar range or micromolar range (1000 fold range). 
The nanomolar inhibitors exhibit much longer ligand-enzyme complex half-lives compared to the 
micromolar inhibitors as measured by biolayer interferometry. Crystal structures of the MAPK13 
inhibitor complexes reveal that the nanomolar inhibitors engage MAPK13 in the DFG-out binding 
mode, while the micromolar inhibitors are in the DFG-in mode. Detailed structural and computational 
docking analyses suggest that this difference in binding mode engagement is driven by conformational 
restraints imposed by the chemical structure of the inhibitors, and may be fortified by an additional 
hydrogen bond to MAPK13 in the nanomolar inhibitors. These studies provide a structural basis for 
understanding the differences in potency exhibited by these inhibitors and provide the groundwork for 
future studies to improve specificity, potency, pharmacodynamics, and pharmacokinetic properties. 
 
  
1. Introduction 
The mitogen activated protein kinase (MAPK) p38α (MAPK14) is the founding and most studied 
member of the p38 MAPK family. MAPK14 is ubiquitously expressed and centrally involved in pro-
inflammatory signaling; it has thus been the focus of numerous drug-development projects for several 
diseases involving chronic inflammation, including rheumatoid arthritis and inflammatory bowel 
disease (Feng & Li, 2011, Schieven, 2009, Muller & Knapp, 2010, Schnieders et al., 2012). Recent 
breakthroughs in structure-based drug design have resulted in highly specific and potent inhibitors to 
MAPK14 (Koeberle et al., 2012, Azevedo et al., 2012, Millan et al., 2011), but there are remaining 
concerns as to the practicality of targeting this enzyme, since knockout of this gene in mice results in 
embryonic lethality (Adams et al., 2000, Mudgett et al., 2000, Tamura et al., 2000), and efforts to 
develop MAPK14 inhibitors have ended in failed drug trials, usually due to toxicity (Goldstein & 
Gabriel, 2005). In contrast to MAPK14, other members of the p38 MAPK family display restricted 
tissue and cellular expression, and therefore may represent viable targets for specific diseases. Along 
these lines, MAPK11 (p38β) is highly similar to MAPK14 (75% sequence identity), whereas MAPK12 
(p38γ) and MAPK13 (p38δ) are more sequence diverse (62% and 61% identical to MAPK14, 
respectively). Also, the MAPK12/MAPK13 double knockout mouse displays no detrimental 
phenotypes, only reduced innate inflammatory responses induced by lipopolysaccharide (LPS) (Risco 
et al., 2012). 
MAPK13 has recently emerged as a disease specific p38 MAPK drug target. Compared to MAPK14, 
MAPK13 displays more tissue-specific expression patterns, and therefore contributes to more 
restricted functions (Risco & Cuenda, 2012, O'Callaghan et al., 2014). This restricted expression 
pattern suggests that this kinase may be targeted in specific biological pathways. For example, 
MAPK13 regulates insulin secretion and survival of pancreatic β-cells, and MAPK13-deficient mice 
are protected against insulin resistance induced by a high-fat diet and oxidative stress-mediated β-cell 
failure, suggesting a role in diabetes (Sumara et al., 2009). MAPK13 is also pivotal in neutrophil 
chemotaxis pathways, where it contributes to acute respiratory distress syndrome (ARDS) (Ittner et al., 
2012). In addition, studies in knockout mice indicate that MAPK13 contributes to pathways activated 
in chronic inflammatory conditions (Risco et al., 2012), is centrally involved in tumorogenesis in both 
colitis-associated colon cancer (Del Reino et al., 2014) and squamous cell carcinoma models (Zur et 
al., 2015), and is crucial for development of arthritis in certain models (Criado et al., 2014). Finally, 
MAPK13 activation is required for IL-13-dependent airway mucus overproduction which is a 
characteristic feature of chronic inflammatory lung disease (Alevy et al., 2012). 
Given the role of MAPK13 in chronic lung disease (and possibly other diseases), we initiated the first 
structure-based drug project to develop inhibitors targeting MAPK13 (Alevy et al., 2012). This work 
also presented the first structures of MAPK13 complexes with inhibitors, which are the only 
complexes for any p38 MAPK family member other than MAPK14. As noted above, MAPK14 has 
been the subject of intense structure-based drug design efforts, and numerous structural and 
biophysical studies of MAPK14-inhibitor complexes have been reported (>170 structures in the PDB 
as of October 2015). Thus, much is known about the structural requirements for MAPK14 inhibition 
(Lee & Dominguez, 2005). To develop a more complete understanding of the structural basis for 
activation of MAPK13, we developed methods to produce both unphosphorylated (inactive) and 
dually-phosphorylated (active) MAPK13 in quantities for structural and biophysical studies and used 
these proteins to study complexes with inhibitors for the purposes of targeting this kinase through 
structure-based drug design (Alevy et al., 2012) (Yurtsever et al., 2015). Here we present a complete 
functional, biophysical, and structural characterization of two new MAPK13-inhibitor complexes, new 
biophysical data on two previously reported complexes, and the first comprehensive analysis of 
MAPK13 in complex with all four structurally characterized inhibitors, which display greatly varying 
potency. These studies reveal the structural basis for differences in potency for this set of inhibitors.  
 
2. Materials and Methods 
2.1. Materials 
All inhibitors were synthesized at Washington University as described previously (Alevy et al., 2012). 
2.2. Expression constructs 
Full-length human MAPK13 is 365 amino acids and contains several basic residues at the C-terminus. 
For crystallization, a slightly truncated MAPK13 construct (1-352) was designed and cloned into 
pET28a as a N-terminal 6-His-tagged construct using the NdeI and XhoI restriction endonuclease sites. 
A full-length human MAPK13 construct was prepared similarly to produce protein for enzyme 
inhibition and biophysical studies (Alevy et al., 2012).  The construct was confirmed by sequencing. A 
pET28a construct of N-terminal-6-His-tagged lambda-phosphatase was a kind gift from Dima 
Klenchin (University of Wisconsin, Madison, WI). 
2.3. Protein Expression and Purification  
Constructs were transformed into Rosetta2 (DE3) E. coli (Stratagene) and colonies were grown on a 
plate with kanamycin selection (50 µg/mL). Cultures for protein expression were grown in Luria broth 
(LB) media using chloramphenicol (40 µg/mL) and kanamycin (50 µg/mL) selection. Both the 
MAPK13 crystallization construct (1-352) and full-length protein (1-365) were expressed and purified 
in a similar manner, as outlined here. Protein expression was induced at 30° C by addition of 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and each 1L of media was enriched with 10 ml of 
saturated glucose solution during protein expression.  Protein expression was carried out at 30° C for 4 
hours. 
Cell pellets were harvested by centrifugation and suspended in lysis buffer suitable for nickel-
nitrilotriacetic acid (Ni-NTA) gravity chromatography (50 mM K2HPO4 pH 8.0, 300 mM NaCl, 10 
mM imidazole, 10% glycerol, 10 mM 2-mercaptoethanol). Cells were lysed by addition of 0.5 mg/ml 
lysozyme and DNAse I followed by sonication. Clarified lysate was passed over Ni-NTA superflow 
resin (Qiagen), which was then washed with lysis buffer containing 20 mM imidazole and then 
proteins were eluted with 250 mM imidazole. The protein was further purified by gel filtration 
chromatography (Superdex 200) in a buffer consisting of 20 mM HEPES pH 7.5, 150 mM NaCl, 
0.001% NaN3, 5 mM dithiotreitol (DTT), and 10% glycerol. The protein eluted as a single peak 
correlating to a monomeric molecular weight (Yurtsever et al., 2015).  This peak was harvested and 
then dephosphorylated in vitro by addition of lambda phosphatase (0.1 mg/ml) and 5 mM MnCl2 at 
room temperature for 30 minutes, which was then quenched with 5 mM EDTA.  This treatment was 
not very efficient and only increased the amount of dephosphorylated MAPK13 by about 10%. 
Following dialysis against a buffer consisting of 20 mM Tris pH 8.0, 10 mM NaCl, 1 mM DTT, and 
10% glycerol (buffer A) at 4° C overnight, the protein was then subjected to anion exchange 
chromatography using a MonoQ column (GE Lifesciences). Protein was injected onto the column 
using buffer A and then eluted off using a gradient from 0-60% of buffer B (20 mM Tris pH 8.0, 1 M 
NaCl, 1 mM DTT, and 10% glycerol) over 40 column volumes. This resulted in separation of 
unphosphorylated and phosphorylated MAPK13 (Yurtsever et al., 2015). The unphosphorylated 
MAPK13 peak was harvested and used for structural studies with inhibitors. Full-length MAPK13 for 
enzyme inhibition and biophysical assays was expressed and purified similarly. 
2.3. Preparation of MAPK13-inhibitor co-crystals 
Crystals of non-phosphorylated MAPK13 were obtained by mixing protein solution (at 10 mg/ml) with 
reservoir solution (50 mM ammonium tartrate, 18% PEG 3350) in a 4:1 (protein: reservoir) ratio, 
similar to those previously described by us (Alevy et al., 2012). Co-crystal complexes with inhibitor 
compounds 58 and 117 were prepared by soaking, similar to our previous work. Inhibitor compound 
stocks were prepared in DMSO at 100 mM and then added to crystal-containing drops at 1:10 volume, 
for a final inhibitor concentration of 10 mM in the drop. Crystals were allowed to soak for 10 minutes 
to 4 hours before cryoprotection in mother liquor supplemented with 25% ethylene glycol, followed by 
flash-freezing at -160° C in a chilled nitrogen stream.   
2.4. Data collection, reduction and structure determination  
X-ray diffraction data were collected at either the Advanced Photon Source (beamline 19-ID) or the 
Advanced Light Source (beamline 4.2.2). Data were indexed and processed with HKL2000 
(Otwinowski & Minor, 1997). The phase problem was solved by isostructural replacement using the 
apo form of MAPK13 (PDB ID: 4YNO) (Alevy et al., 2012) in an initial round of rigid body 
refinement. Compounds were clearly visible in FO – FC difference maps following rigid body 
refinement (see Fig. 3). Model rebuilding and compound fitting to electron density maps was 
performed manually using Coot (Emsley & Cowtan, 2004) and refinement was carried out in PHENIX 
(Adams et al., 2002). Structural analysis of MAPK13-inhibitor contacts was performed in LigPlot+ 
(Laskowski & Swindells, 2011). All molecular graphics figures were produced using PyMOL 
(Schrodinger, 2010). All crystallographic software were obtained and maintained by the SBGrid 
distribution (Morin et al., 2013). Diffraction images were deposited with the Structural Biology Data 
Grid (Meyer et al., 2016). Data collection and refinement statistics are summarized in Table 1. 
2.5. Differential Scanning Fluorimetry 
Melting temperature of MAPK13 and MAPK14 was measured in the presence of inhibitors (58, 61, 
117, 124) using a Protein Thermal Shift Dye Kit (Life Technologies, CA) according to manufacturer’s 
specifications. This assay used both the unphosphorylated and the phosphorylated forms of MAPK13 
and unphosphorylated MAPK14 at a final concentration of 0.15 mg/ml in the reaction mixture. A 
titration experiment was carried out first to demonstrate specificity and establish dynamic range. Based 
on this, single point experiments were carried out on all kinases using a final inhibitor concentration of 
25 µM. Each condition was replicated five times. The experiment was carried out on a 7500 Fast Real-
Time PCR System (Life Technologies, CA) using the melt curve template.  The initial incubation step 
at 25 °C was modified to be 30 minutes to ensure complex formation between the inhibitors and the 
proteins. Data were analyzed using Protein Thermal Shift Software v1.1 (Life Technologies). 
Additional statistical analysis was carried out in Prism v5.0c. Results are summarized in Figure 6 and 
Table 3 and presented as mean ± S.E.M. 
2.6. MAPK13 Inhibition Assay 
Compounds were assayed for inhibition of MAPK13 kinase activity using an immobilized metal 
affinity polarization (IMAP) as previously described (Alevy et al., 2012). Briefly, the assay contained 
activated (phosphorylated) MAPK13, a FITC-labeled substrate, and the test compound. Experiments 
were carried out at concentrations in the linear phase of the rate kinetics. Assay reactions contained 0-
100 µM test compound, 5-35 nM (EC80) activated MAPK13, 3 µM (Km,app) ATP, and 100 nM FITC-
labeled EGFR peptide substrate (FITC-KRELVERLTPSGEAPNQALLR-NH2). The IC50 values for 
each compound were determined from the compound concentration versus fluorescence polarization 
(mP) plot using nonlinear curve fitting. 
2.7. Inhibitor binding kinetics measured by biolayer interferometry 
Kinetics of MAPK13 binding to small molecules was assessed using bio-layer interferometry with an 
Octet (ForteBio, Menlo Park, CA) as described previously (Alevy et al., 2012). MAPK13 was 
randomly biotinylated in vitro using EZ-link NHS-PEG4-Biotin (Thermo Scientific) at a 1:2 molar 
ratio (protein: reagent). Super-streptavidin-coated biosensors from ForteBio were used to capture 
biotinylated MAPK13 onto the surface of the sensor. After reaching baseline, sensors were moved to 
association step for 300 s and then dissociation for 300 s. Curves were corrected by a double-
referencing technique using both biotin-coated pins dipped into the experimental wells and a buffer-
only reference. The binding buffer consisted of 20 mM HEPES pH 7.5, 150 mM NaCl, 0.005% Tween 
20, and 5% DMSO. MAPK13-inhibitor complex half-lives were calculated from dissociation constants 
determined from global kinetic analysis (t1/2 = ln2/kdissociation). 
2.8. Computational docking 
In silico docking studies were carried out in GLIDE from the Schrodinger Suite (Halgren et al., 2004, 
Friesner et al., 2004). All inhibitors were treated as ligands and prepared from their SMILES strings 
using LigPrep without changing ionization states.  Protein coordinates were imported from pdb files 
and processed using the Protein Preparation Wizard (PDB ID 4MP9 for MAPK13 DFG-out; 4MP5 for 
MAPK13 DFG-in; 1KV2 for MAPK14 DFG-out; 1P38 for MAPK14 DFG-in). A rigid grid of 36 Å 
was generated centered on the DFG residues. Ligands were docked flexibly into the grid in Standard 
Precision (SP) mode. After the docking simulation was completed, the protein was overlapped with the 
coordinates from the co-crystal structures. RMSD between the docked coordinates and the crystal 
coordinates for the inhibitor was calculated using a command-line script, rmsd.py (available from 
http://www.schrodinger.com/scriptcenter/14). Results are summarized in Table 4. 
 
3. Results and discussion 
3.1. A series of inhibitors with greatly varied potencies for MAPK13. 
Here we report the steady-state, biophysical, and structural evaluation of a set of MAPK13 inhibitors. 
The inhibitor design was inspired by analyzing potent MAPK14-inhibitor complex structures, 
superposing on our unphosphorylated (apo) MAPK13 structure, and realizing smaller substituents in 
the ATP-binding pocket would be required for optimal binding (Alevy et al., 2012).  Specifically, we 
focused on BIRB-796, which binds to MAPK14 in DFG-out mode and exhibits an IC50 of 4 nM, and 
inhibits other p38 isoforms, but at much lower potencies (IC50 = 520 nM for MAPK13) (Kuma et al., 
2005). Superposition of BIRB-796 into MAPK13 indicated it could sterically clash with the gatekeeper 
residue, so we designed inhibitors with smaller substituents at this position that we hypothesized would 
bind in DFG-out mode (Alevy et al., 2012). We began by determining the IC50 values in a steady-state 
enzyme inhibition assay. These values for 1-(3-tert-butyl-1-methyl-1H-pryzol-5-yl)-3-[4-(pyridin-4-
yloxy)phenyl]urea (compound 61) and  2-(morpholin-4-yl)-N-[4-pyridin-4-yloxy)phenyl]pyridine-4-
carboxamide (compound 124)  were reported previously (Alevy et al., 2012). Here we determine the 
IC50 values for 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-[4-(pyridin-4-ylsulfanyl)phenyl]urea 
(compound 58) and 3-(4-methyl-1H-imidazol-1-yl)-N-[4-(pyridin-4-xyloxy) phenyl] benzamide 
(compound 117) (Fig. 1a). Surprisingly, the IC50 values varied over a wide range; while compounds 58 
and 61 displayed IC50 values in the nanomolar range, compounds 117 and 124 displayed IC50 values in 
the micromolar range, over a thousand fold less potent (Figs. 1b and 1c).  
3.2. Kinetic and binding analysis of inhibitors with MAPK13. 
Inhibitor binding kinetics has become an important drug design criteria. In particular, slow dissociation 
rates have been associated with improved inhibitor activities due to prolonged target engagement in 
vivo (Wood et al., 2004). To understand whether inhibitor binding kinetics correlated with potency, we 
analyzed this property using biolayer interferometry (BLI), in a manner similar to that for compounds 
61 and 124 reported previously (Alevy et al., 2012). In these assays, biotinylated MAPK13 was 
immobilized on the streptavidin-coated BLI pin and association and dissociation kinetics were 
analyzed. The two compounds that displayed IC50 values in the nanomolar range displayed slower 
association and dissociation rates with around 100-fold longer complex half-lives (t1/2 = 111 to 137 
sec) as compared to inhibitor compounds with micromolar IC50 values (t1/2 = 1 to 3 sec) (Fig. 2 a-c). 
These kinetic constants are of similar magnitude as those for MAPK14 complexes with inhibitors 
measured by surface plasmon resonance (SPR) (Angell et al., 2008). We hypothesized that this 
difference could correlate with different binding modes or binding pockets utilized by the inhibitors. 
3.3. MAPK13 inhibitors display two different binding modes. 
In order to elucidate how our novel inhibitors bound to MAPK13, we determined the X-ray crystal 
structures of the complexes (Table 1). We had noticed during our structural analysis of the inactive 
(MAPK13) and dually-phosphorylated active (MAPK13/pTpY) forms of the protein (Yurtsever et al., 
2015) that a significant portion of the activation loop (residues 173-180), which is ordered in the dual-
phosphorylated protein, is not visible in our high resolution electron density maps of the 
unphosphorylated form. We therefore reasoned that we should be able to obtain inhibitor complexes 
with MAPK13 via soaking inhibitors into crystals of the unphosphorylated form, and indeed we were 
able to demonstrate the validity of this method previously with the crystal structures of MAPK13 in 
complex with compounds 61 (PDB ID: 4EYJ) and 124 (4EYM). We observed a strong difference 
electron density for the two new compounds using this method (Fig. 3c & e). We found that the 
compounds displaying nanomolar IC50 values all bound similarly and occupied the ATP binding 
pocket, as well as an adjacent pocket usually occupied by Phe169 (of the DFG motif), displacing it 
from this pocket (Fig. 3a, c-d, and Table 2). This mode of binding has been termed as “DFG-out” and 
was first observed in the complexes of c-Abl with Gleevac (Schindler et al., 2000) and MAPK14 with 
BIRB-796 (Pargellis et al., 2002). In contrast, compounds displaying micromolar IC50 values bound in 
a similar manner, but did not displace Phe169 from the pocket (Fig. 3b,e,f), binding to MAPK13 in 
what is known as “DFG-in” mode (Table 2). Thus, in the case of the MAPK13 inhibitors presented 
here, it appears that binding mode creates a marked difference in potency. However, it should be noted 
that highly potent inhibitors that bind to MAPK14 in DFG-in mode have been identified (e.g, 
skepinone-L (Koeberle et al., 2012) and SB203580 (Wang et al., 1998)), so binding mode does not 
always dictate efficacy. 
3.4. Analysis of binding pocket interactions of inhibitors in complex with MAPK13. 
To understand the structural basis for the observed binding modes exhibited by the different MAPK13-
inhibitor complexes, we performed a comprehensive analysis of the binding pockets occupied by each 
inhibitor. The inhibitors analyzed here have similar designs, consisting of a heterocyclic ring that 
interacts with the hinge region of MAPK13, a central aromatic that occupies the ATP-binding site, and 
a bulky (mostly hydrophobic) group, with these units spanned with by various polar linkers (Fig. 1a). 
The binding pockets were very similar, with similar numbers of van Der Waals contacts and hydrogen 
bonds to MAPK13. We found that, compared to the micromolar inhibitors, the nanomolar inhibitors 
engaged in one additional hydrogen bond with MAPK13 (3 versus 4) (Fig. 4c). All inhibitors engaged 
in hydrogen bonds with the backbone amide nitrogens of Met110 (in the hinge) and Asp168 (in the 
DFG motif) (Fig. 4a,b,d,e). The main difference was seen in interactions involving the side-chain 
carboxylic acid of Glu72. This side-chain engages in a hydrogen bond with the linker between central 
aromatic and bulky hydrophobic groups in these inhibitors. The nanomolar inhibitors all contain urea 
linkers whereas the micromolar inhibitors both contain amide linkers. The second hydrogen bond made 
possible with the urea linkages (red arrow, Fig. 4a,b) assists to lock the bulky hydrophobic groups in 
relative conformations that require the moieties to bind to the Phe pocket, thus making these inhibitors 
selective for the DFG-out conformation of the kinase. Biphenyl amide inhibitors similar to compounds 
117 and 124 have previously been observed to bind to both DFG-in and DFG-out conformations of 
MAPK14 and bind in similar modes to those observed in our MAPK13 structures (Angell et al., 2008), 
thus the inclusion of such groups does not dictate that these inhibitors can only bind in DFG-in modes.   
3.5. Sequence comparison of inhibitor binding pockets in mammalian MAPK13 proteins. 
Given that numerous animal systems are used for in vitro studies, we carried out analysis of MAPK13 
sequences from higher mammals to examine whether there were any gross differences in the MAPK13 
binding pockets for the inhibitors characterized here. The MAPK13 sequences for the species analyzed 
here averaged greater than 90% identity (Fig. 5). Of the numerous residues lining the binding pocket 
for the inhibitors, only one displayed a very conservative variation. Residue Phe109 (in the hinge 
region) is a Tyr in chicken MAPK13 (Fig. 5). Structure-based analysis of the inhibitor binding pocket 
sequence conservation would suggest that the inhibitors analyzed here should bind similarly to 
MAPK13 proteins in common animal models. 
3.6. Thermodynamic stability of MAPK13 complexes with inhibitors. 
Previous studies have demonstrated the use of differential scanning fluorimetry as a method for 
identifying potential kinase inhibitors based on the enhanced thermal stability upon complexation 
(Niesen et al., 2007, Vedadi et al., 2006). A general observation has been that more potent kinase 
inhibitors lend greater thermal stability to the protein (Fedorov et al., 2012).  We decided to analyze 
our diverse potency inhibitors using this method. We carried out experiments with both the inactive 
(unphosphorylated) MAPK13 and active (dually-phosphorylated) MAPK13/pTpY, as well as with 
MAPK14. First, we carried out a titration on MAPK13 to establish a dynamic range for the inhibitors 
(Fig. 6). Based on this result, we carried out subsequent experiments with 25 µM inhibitor. The 
differences in melting temperatures using the two forms of MAPK13 were similar, indicating that the 
inhibitors effectively bound both forms of the protein (Table 3). The melting point shifts were about a 
degree higher for MAPK13/pTpY, likely due to the fact that this form is stabilized by contacts 
involving the phosphorylated activation loop, (Yurtsever et al., 2015) which would be dislodged by the 
DFG-out inhibitors. We found that the micromolar inhibitors (compounds 117 and 124) induced small 
increases in melting temperatures of MAPK13 (1-2° C). In contrast, the nanomolar inhibitors all 
induced large shifts in melting temperatures of MAPK13 (7-8° C). In addition, we found that our 
inhibitors induced larger Tm shifts in MAPK13 than MAPK14 (by a difference of 2-3 °C). For 
comparison, we also ran the DSF experiments with the potent MAPK14 inhibitor BIRB-796, which is 
optimized for MAPK14 (IC50 [MAPK14] = 4 nM; IC50 [MAPK13] = 520 nM) (Kuma et al., 2005). We 
found that the melting point shifts corresponded with the known differences in potencies (DTm 
[MAPK14] = 13.7 °C; [MAPK13] = 5.9 °C). Taken together, these results suggest our best inhibitors 
characterized here display slight selectivity for MAPK13 versus MAPK14, which should improve with 
optimization. Thus, the inhibitors which displayed the greatest potency and longest complex half-lives 
induced the greatest shift in thermal stability, indicating that this could be a robust screening method to 
presage inhibitor potency for MAPK13, and selectivity versus MAPK14.  
3.7. Computational analysis of inhibitor complexes. 
We carried out computational docking studies to gain further insight into why subsets of inhibitors 
bind to the DFG-in conformation versus the DFG-out conformation of MAPK13. In these calculations, 
the inhibitors were introduced as SMILES strings (with no predefined conformation) and were flexible 
during docking. The inhibitors were docked to MAPK13 coordinates in both the DFG-in and DFG-out 
mode. For compounds 58 and 61, which bind in the DFG-out mode, the calculations reproduced the 
crystal structures extremely accurately when docked to the MAPK13 DFG-out coordinates (Table 4). 
However, they showed high variation and poor docking scores when docked to MAPK13 in DFG-in 
coordinates. In contrast, for compounds 117 and 124, which bind in DFG-in mode, the calculations 
accurately reproduced the crystal structure coordinates for the inhibitors regardless of whether 
MAPK13 was in DFG-in or DFG-out mode (Table 4). In other words, regardless of whether or not the 
Phe pocket was available for inhibitor moiety binding, the DFG-in inhibitors preferred to bind to the 
same pockets as observed in the crystal structure. These calculations indicate that this set of inhibitor 
structures can be predicted fairly accurately using GLIDE, and imply that part of the selective driving 
force is goodness of fit to the available pockets and the inherent structure preferred by inhibitor. To 
analyze this further, we carried out the same calculation using MAPK14 in both DFG-in and DFG-out 
mode as the receptor for these inhibitors. With the MAPK14 structures, we obtained similar results as 
with MAPK13, and the simulations reproduced inhibitors binding configurations observed in the 
MAPK13 co-crystal structures. Thus, regardless of the receiver kinase, the inhibitors take on 
configurations observed in the crystal structures, indicating that the major driving forces for this set of 
inhibitors is chemically-encoded structural constraints of the compound and shape complementarity to 
available pockets.  
 
4. Conclusions 
Here we present the functional, biophysical, and structural characterization of two new inhibitor 
complexes with MAPK13, as well as a comprehensive functional, biophysical, and structural analysis 
of all four of our inhibitor complexes. These represent the only four MAPK13 inhibitor complexes 
structurally characterized to date. The inhibitors examined here displayed widely varying potencies, 
with IC50 values in either the nanomolar range, or, greater than 1000-fold less potent, in the micromolar 
range. These potencies correlated well with small-molecule binding kinetics measured by BLI. The 
nanomolar-potency inhibitors displayed complex half-lives about 100  times longer than those of the 
micromolar inhibitors. It should be noted that the half-lives measured here using BLI are comparable 
to those of MAPK14-inhibitor interactions measured by the comparable flow-based method of SPR 
(Angell et al., 2008). Co-crystal structures of MAPK13 in complex with each of the four inhibitors 
revealed that the high potency inhibitors all bound to the kinase in DFG-out configuration, whereas the 
lower potency inhibitors both bound in DFG-in configuration. This is worth noting, since high potency 
inhibitors can be developed for either mode, for example skepinone-L (Koeberle et al., 2012) and 
SB203580 (Wang et al., 1998) are highly potent MAPK14 inhibitors that bind in DFG-in mode. Slow 
inhibitor dissociation rates have emerged as an important parameter for sustained efficacy of kinase 
inhibitors. In general, slower kinetics have been observed for inhibitors binding to the DFG-out mode 
of kinases, possibly due to kinetic constraints caused by the necessary structural reconfiguration 
(Gruenbaum et al., 2009, Pargellis et al., 2002). However, the structural mechanisms that influence 
inhibitor binding kinetics are poorly understood, thus comprehensive structural and kinetic studies 
such as those presented here are quite valuable in creating these correlations.   
Detailed analysis of the binding pockets for the inhibitors revealed that all inhibitors, regardless of 
potency, interacted with MAPK13 in a very similar fashion, forming hydrogen bonds with the same 
residues in all four structures. The high potency inhibitors all engaged in one additional hydrogen 
bond, but computational docking and chemical reasoning indicate that this is mostly driven by the 
preferred lowest energy configuration of the inhibitor, which is intrinsic to its structure, and the 
goodness of fit of that conformation to the available pockets. It is worth noting that one of the 
development points of the GLIDE software has been to predict accurate kinase complexes with 
inhibitors (Lyne et al., 2006). The complexes with MAPK13 characterized here were readily predicted 
and suggest that this software approach could be used effectively for in silico screening to identify new 
chemical families with the potential to bind MAPK13.   
DSF has been shown previously to be an effective method for screening for potential binders and 
inhibitors of kinases, and the thermal melting shifts usually correlate well with affinity (Fedorov et al., 
2012). We found this to be the case with the set of inhibitors here, with the thermal shifts also 
correlating with binding mode (DFG-in versus DFG-out). These thermal shifts appear to correlate with 
binding affinities of the inhibitors, as observed in our titration experiments. These experiments do 
suggest, however, that this method could be utilized effectively to identify new inhibitors for MAPK13 
by screening and to prioritize ranking based on magnitude of melting point stabilization. These 
experiments also suggest this method could be used to screen for inhibitors that selectively target 
MAPK13 versus MAPK14. The inhibitors analyzed here have not been optimized yet for potency or 
selectivity, yet they do display some preference for binding MAPK13 in our DSF experiments. 
Combining our structural studies of inhibitor binding done here with sequence comparison of MAP13 
versus MAPK14 (Yurtsever et al., 2015), the most sequence divergent area that contacts the inhibitors 
is in the hinge region, thus this will be focus of our future iterations of inhibitor design. 
 Altogether, the functional, structural, and biophysical characterizations presented here provide the first 
comprehensive analysis of this type for inhibitor complexes with MAPK13, elucidating the structural 
basis for their mechanism of action, thus providing a knowledge base for the structure-based 
development of potent, and eventually specific, inhibitors. 
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PDB References: mitogen-activated protein kinase 13 (p38δ), complex with compound 58 5ekn; 
complex with compound 117, 5eko. 
 
Figure 1 
Schematic of MAPK13 inhibitors and their IC50 values. (a) Schematic of MAPK13 inhibitor 
compounds characterized in this manuscript. (b) Data and curve fit used to determine IC50 values for 
compounds 58 and 117. (c) IC50 values, 95% confidence range, and coefficients of determination (R2). 
* denotes values were previously reported (Alevy et al., 2012). 
 
Figure 2 
Biolayer interferometry analysis of MAPK13 binding to inhibitors. (a-b) Biolayer interferometry 
sensorgrams for (a) compound 58 and (b) compound 117. Processed data are shown as black lines with 
global kinetic fits overlaid as red lines. (c) Table of MAPK13-inhibitor complex half-lives derived 
from the global kinetic fits of kassociation and kdissociation (t1/2 = ln2/kdissociation). * denotes values were 
previously reported (Alevy et al., 2012). 
 
Figure 3 
Structures of MAPK13 complexes with inhibitors. (a) Ribbon diagram of MAPK13 (grey) with DFG-
out inhibitors 58 and 61. Hinge and activation loop are both colored red. (b) Ribbon diagram of 
MAPK13 (grey) with DFG-in inhibitors 117 and 124. Hinge and activation loop are both colored red. 
(c) Crystal structure of compound 58 (green) in complex with MAPK13 in DFG-out mode. Omit Fo – 
Fc electron density contoured at 3.0 σ is shown for the compound and 2Fo – Fc electron density 
contoured at 2.0 σ is shown for Phe169. (d) Our previously reported crystal structure of compound 61 
(cyan) in complex with MAPK13 in DFG-out mode for comparison (4EYJ). (e) Crystal structure of 
compound 117 (yellow) in complex with MAPK13 in DFG-in mode. Omit Fo – Fc electron density 
contoured at 3.0 σ is shown for the compound and 2Fo – Fc electron density contoured at 2.0 σ is 
shown for Phe169. (f) Our previously reported crystal structure of compound 124 (magenta) in 
complex with MAPK13 in DFG-in mode for comparison (4EYM). The dynamic positioning of Phe169 
of the DFG motif is shown in all complexes.  
 
Figure 4 
MAPK13 binding pockets for inhibitor compounds. Binding pockets for (a) compound 58, (b) 
compound 61, (d) compound 117, and (e) compound 124. All residues that make van der Waals or 
polar contacts are shown. Hydrogen bonds are shown as thin black lines. One hydrogen bond that is 
unique to compounds 58 and 61 as compared to 117 and 124 is highlighted with the red arrow. (c) 
Table of polar and non-polar contacts each compound makes with MAPK13. 
 
Figure 5 
Sequence alignment of MAPK13 from relevant disease model mammals. Invariant and conserved 
residues are highlighted with magenta and yellow backgrounds, respectively. Secondary structure of 
human MAPK13 is shown above the alignment. The hinge region, DFG motif, gatekeeper (G), dual 
phosphorylation site (P), and activation loop are shown. Residues that form the binding pockets for 
inhibitor compounds are marked (black I). Figure was generated using ESPript3.0 (Gouet et al., 2003). 
 
Figure 6 
Changes in MAPK13 melting temperatures (ΔTm) induced by binding inhibitors as measured by DSF. 
Titration of inhibitors is shown while MAPK13 concentration was held at 0.15 mg/ml. The point at 
each concentration is an average of three measurements. Error bars are SEM. Curve fitting done in 
PRISM 5 using the one site total binding equation for nonlinear regression. Calculated Kd’s listed in 
Table 3.  
 
Table 1. Crystallographic statistics for MAPK13 complexes with inhibitor compounds 
Compound 58 117 
Data collection statistics 
Space Group P212121 P212121 
Unit Cell (Å) a=61.0 
b=70.2 
c=92.9 
a=61.3 
b=69.7 
c=93.1 
Source ALS 4.2.2 APS 19-ID 
Wavelength(Å) 1.0000 0.9790 
Resolution(Å) 50.0-2.60 (2.69-) 50.0-2.00 (2.07-) 
Rsym(%) 0.091(0.508) 0.055(0.369) 
Completeness(%) 88.5 (100) 81.2(87.8) 
Redundancy 7.0(7.3) 4.6(4.4) 
I/σ(I) 20.6(3.6) 21.6(2.5) 
Refinement statistics 
Rwork 0.218 0.200 
Rfree 0.273 0.241 
Amino Acid Residues(#) 340 340 
Waters (#) 23 213 
RMSD bond length (Å)/angles(°) 0.003/0.667 0.004/0.904 
Wilson B (Å2) 48.4 31.3 
Ave  B. protein 52.2 37.0 
Ave. B inhibitor 40.5 31.3 
Ave. B water 48.1 42.7 
Ramachandran   
     %Favored 87.4 95.3 
     %Allowed 12.0 4.4 
     %Outliers 0.6 0.3 
Poor rotamers (no. / %) 12 / 3.99% 5 / 1.6% 
Clashscore (score / percentile) 6.72 / 99th 6.10 / 95th 
Molprobity (score / percentile) 2.16 / 94th 1.83 / 85th 
Luzzati Error 0.35 0.24 
PDB ID 5EKN 5EKO 
Values in parenthesis are for the highest-resolution shell. 
  
 
 
Table 2. Backbone torsion angles that define the conformation of the MAPK13 DFG motif 
  Leu 167 Asp 168 Phe 169 
Compound DFG conformation ϕ (°) ψ (°) ϕ (°) ψ (°) ϕ (°) ψ (°) 
58 DFG-out -124.5 170.8 -154.0 150.4   
61 DFG-out -119.6 169.4 -144.7 93.6 -66.0 -22.9 
117 DFG-in -107.8 156.4 62.5 37.1 -82.5 150.0 
124 DFG-in -111.3 160.9 55.5 39.7 -81.9 162.6 
 
 
 Table 3. Inhibitor-induced thermal stability shifts measured by differential scanning fluorimetry (DSF) 
Compound ΔTm-MAPK13 (°C)* ΔTm-MAPK13/pTpY (°C)* ΔTm-MAPK14 (°C)* Kd  (µM)** 
58 8.1 ± 0.3 9.0 ± 0.4 5.2 ± 0.3 1.9 ± 0.3 
61 7.2 ± 0.3 7.8 ± 0.4 5.1 ± 0.3 2.6 ± 0.5 
117 1.8 ± 0.4 2.0 ± 0.5 -1.4± 0.4 N.D.*** 
124 1.1 ± 0.3 1.2 ± 0.5 -0.8± 0.3 N.D 
BIRB-796 5.9± 0.2  13.7± 0.3.  
*DTm are reported at inhibitor concentrations of  25 µM and kinase concentrations at 2.5 µM 
** Derived from titrations shown in Fig. 6 
***Not determined 
 
 
Table 4. GLIDE in silico docking results compared to co-crystal structures 
Compound 58 61 117 124 
 Score* RMSD** Score RMSD Score RMSD Score RMSD 
MAPK13 DFG-out -9.91 1.26 -8.88 1.23 -8.85 1.42 -8.24 1.62 
MAPK13 DFG-in -5.34 10.15 -5.21 9.99 -9.81 1.07 -6.14 2.00 
MAPK14 DFG-out -9.25 1.34 -8.70 1.10 -7.96 1.92 -4.20 12.71 
MAPK14 DFG-in -4.10 11.92 -4.16 12.25 -5.26 9.71 -8.15 3.57 
* Glide Score in kcal/mol 
** RMSD of compound heavy atom positions compared to crystal structure (Å) 
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